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Protein therapeutics offer numerous advantages over small molecule drugs and 
are rapidly becoming one of the most prominent classes of therapeutics.  Unfortunately, 
they are delivered almost exclusively by injection due to biological obstacles preventing 
high bioavailability via the oral route.  In this work, numerous approaches to overcoming 
these barriers are explored. 
pH-Responsive poly(itaconic acid-co-N-vinylpyrrolidone) (P(IA-co-NVP)) 
hydrogels were synthesized, and the effects of monomer ratios, crosslinking density, 
microparticle size, protein size, and loading conditions were systematically evaluated 
using in vitro tests.  P(IA-co-NVP) hydrogels demonstrated up to 69% greater 
equilibrium swelling at neutral conditions than previously-studied poly(methacrylic acid-
co-N-vinylpyrrolidone) hydrogels and a 10-fold improvement in time-sensitive swelling 
experiments.  Furthermore, P(IA-co-NVP) hydrogel microparticles demonstrated up to a 
2.7-fold improvement in delivery of salmon calcitonin (sCT) compared to methacrylic 
acid-based systems, with a formulation comprised of a 1:2 ratio of itaconic acid to N-
vinylpyrrolidone demonstrating the greatest delivery capability. 
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Vast improvement in delivery capability was achieved using reduced ionic 
strength conditions during drug loading.  Use of a 1.50 mM PBS buffer during loading 
yielded an 83-fold improvement in delivery of sCT compared to a standard 150 mM 
buffer.  With this improvement, a daily dose of sCT could be provided using P(IA-co-
NVP) microparticles in one standard-sized gel capsule.  P(IA-co-NVP) was also tested 
with larger proteins urokinase and Rituxan.  Crosslinking density provided a facile 
method for tuning hydrogels to accommodate a wide range of protein sizes. 
The effects of protein PEGylation were also explored.  PEGylated sCT displayed 
lower release from P(IA-co-NVP) microparticles, but displayed increased apparent 
permeability across a Caco-2 monolayer by two orders of magnitude.  Therefore, PEG-
containing systems could yield high bioavailability of orally delivered proteins. 
Finally, a modified SELEX protocol for cellular selection of transcellular 
transport-initiating aptamers was developed and used to identify aptamer sequences 
showing enhanced intestinal perfusion.  Over three selection cycles, the selected aptamer 
library showed significant increases in absorption, and from an initial library of 1.1 
trillion sequences, 5-10 sequences were selected that demonstrated up to 10-fold 
amplification compared to the naïve library.  These sequences could provide a means of 
overcoming the significant final barrier of intestinal absorption. 
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Chapter 1:  Introduction 
Protein therapy offers a number of advantages in disease treatment that cannot be 
matched by traditional therapy with small molecule drugs.  The complex structure of 
proteins enables complex and effective therapeutic functions with unmatched specificity, 
equating to more effective medications with fewer side effects.  As such, protein therapy 
is the most rapidly expanding area of modern medicine, already treating scores of 
diseases with the potential to treat thousands more. 
Unfortunately, therapeutic proteins are almost universally administered via 
injections, which can be painful, inconvenient, and embarrassing.  Protein therapeutics 
generally require repeated administration, so the cumulative frustration with a painful and 
inconvenient administration method often causes patients to intentionally skip injections, 
leading to dangerous lapses in treatment. 
Oral delivery of therapeutics is generally considered the most desirable of drug 
administration routes.  It is easy to self-administer, highly familiar to all patients, 
generally less expensive, and completely free of biohazard sharps waste, chronic 
irritation, and scarring.  With the protein therapeutics market expanding rapidly to meet 
the needs of millions of patients, the time to develop improvements to the basic delivery 
strategy is now.  Development of an oral delivery strategy for protein therapeutics would 
be a boon to both patients and the pharmaceutical industry by offering improved patient 
quality of life and reduced cost as this young class of therapeutics expands. 
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Unfortunately, despite significant interest, the oral route has not yet been adopted 
with protein-based drugs due to significant biological obstacles, including:  the acidic, 
proteolytic environment of the stomach, which denatures proteins before reaching the 
bloodstream; proteolytic enzymes in the small intestine; the mucosal and epithelial cell 
linings of the small intestine, which have evolved to keep large macromolecules and 
organisms from entering the bloodstream; and longevity in the body once present in the 
bloodstream.  All of these issues lead to negligible bioavailability of protein therapeutics 
via the oral route without a well-designed delivery system that overcomes these 
obstacles. 
Numerous such delivery systems have been proposed and studied, although none 
have reached use on the market as a result of insufficient bioavailability to make the final 
product financially feasible.  One promising delivery strategy has been to use the large 
and rapid shift in pH from the stomach to the small intestine to trigger the release of 
protein therapeutics from pH-responsive hydrogels.  Much work has been performed with 
such systems for insulin, but charge interactions have limited the use of these systems 
with proteins exhibiting a high isoelectric point. 
In this thesis, multiple strategies for overcoming the numerous barriers blocking 
the path to oral delivery of high isoelectric point therapeutic proteins are explored.  pH-
Responsive and enzymatically-degradable hydrogel microparticles are evaluated as 
protein delivery vehicles.  The effects of numerous hydrogel design variables on oral 
protein delivery capability are evaluated.  Bioconjugation strategies to improve protein 
bioavailability are also explored, and the effects of bioconjugation on drug delivery and 
 3 
intestinal transport are assessed.  Finally, an aptamer-based strategy for enhancing the 
intestinal absorption of macromolecules is proposed, and the results of the aptamer 
discovery process are presented. 
  
 4 
Chapter 2:  Background 
2.1 PROTEIN THERAPEUTICS 
Protein therapeutics has become the cornerstone of modern medicine, and now 
represents the most rapidly expanding class of new therapeutics.  Protein-based drugs 
have remained one of the most common classes of newly FDA-approved drugs for the 
past few years, accounting for 23% of new drugs in 2012
1
 and 20% of new drugs in 
2011.
2
  Since the first recombinant protein therapeutic, insulin, was approved three 
decades ago in 1982, over 150 different protein-based drugs have received FDA approval 
to treat an impressive array of diseases.  Protein therapeutics have accordingly grown into 
a large global market, with sales of over $108 billion in 2010, and projected sales of $165 
billion by 2018.
3–5
  As of the end of 2013, 9 of the 20 best-selling drug products in the 
world are protein therapeutics, as listed in Table 2-1.
6
 
Protein therapy has enjoyed such rapid expansion because it offers several distinct 
advantages over traditional small molecule-based pharmaceutics.  The advantages 
primarily stem from the additional complexity offered by a large molecule made of many 
individual units, allowing function to be determined by both structure and functional 
groups, not solely the functional groups as with small molecule drugs.  As a result, 
proteins have significantly fewer systemic side effects because their complex structure 
enables them to act with high activity specifically for one function, rather than acting in 
different ways at many different sites throughout the body.  Additionally, the molecular 
intricacy allows for significantly more complex functions that simply cannot be 
replicated with small molecule drugs—the main reason missing or misfolded proteins 
cause diseases that cannot be easily treated without protein or gene therapy (which is not 
currently available as a treatment option).  Finally, because proteins are often found 
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naturally throughout the body, proteins are generally well-tolerated and display low 
immunogenicity.
7
  In short, the field of protein therapeutics has grown so rapidly because 
proteins are nearly ideal therapeutics:  they perform their specific function, they perform 
it very well, and they do almost nothing else until they are degraded and removed from 
the body. 
Despite already staggering sales, the technology is still in its infancy.  The human 
genome contains genes encoding for 25,000 to 40,000 different proteins, and post-
translational modifications allow for multiple functionally different proteins to result 
from the same gene.
7
  Thus, compared to the many tens of thousands of proteins present 
in the human proteome, 150 drugs is but a small drop in the bucket.  As a result, there are 
many thousands of proteins native to the human proteome remaining to be utilized in 
treatment of many different diseases, as well as a nearly unlimited number of synthetic 
proteins.  Although advancement in synthetic protein synthesis would undoubtedly usher 
in a boom era in protein research and new drugs, much like what has occurred with 
nucleic acid research following the invention of PCR, the current potential for 
advancement with novel drugs is still pushing protein therapy forward at an impressive 
pace:  the market is projected to grow by 10-30% per year for at least the next decade.
8
  
This expansion is aided by the fact that pharmaceutical companies have strong incentive 
to develop new protein therapeutics.  Due to the reduced number of systemic side effects 
and low immunogenicity, protein drugs have on average a much shorter FDA-approval 
process than small molecule drugs—3 years on average compared to roughly 7.7  Patent 
protection of recombinant protein drugs is also quite extensive, allowing companies to 
avoid having generic competitors on new drugs for many years.  With all of the benefits 
associated with protein therapy, the rapid expansion of the market is expected to 
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continue, making now the best time to develop not only new drugs, but also better 
systems for delivering the protein therapeutics into the body. 
2.2 ADMINISTRATION OF PROTEIN THERAPEUTICS 
Currently, nearly all protein therapeutics are delivered by intravenous, 
subcutaneous, or intramuscular injection.  Although comparatively simple and 
straightforward, injections have major drawbacks.  Injections are often painful and/or 
frightening to the user, embarrassing to administer in public, and relatively costly.  
Injections require highly sterile, clean-room manufacturing facilities and sterile syringes, 
and intravenous injections must be administered by a healthcare professional, all of 
which adds greatly to the cost of the treatment and requires significantly more time from 
the patient’s day.  All of these drawbacks have been shown to adversely affect patient 
compliance with prescribed treatment.  In one study, it was reported that over half of 
insulin users have intentionally skipped injections at some point, and 20% regularly do so 
to avoid the pain and embarrassment of the injection.
9
  Skipping injections greatly 
reduces the efficacy of the treatment plan and can be quite dangerous.  As a result, a more 
amenable delivery option would not only improve patient quality of life, but would also 
improve treatment efficacy if users do not feel inclined to skip injections. 
Delivery via the oral route is a more preferred method of administration.  It offers 
a much more convenient pathway that is very familiar to all users and eliminates the fear, 
pain, and embarrassment that is associated with injections.  Additionally, delivery via the 
oral pathway in a pill form typically helps reduce the cost of the treatment.  Orally-
delivered drugs need not be produced in such a highly sterile cleanroom environment as 
required for injections because potential contaminants are unlikely to survive through the 
proteolytic environment of the stomach.
10
  This significantly reduces the production cost 
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of the drug and eliminates costs of sterile syringes and professional application (for 
intravenous injection).  Protein therapy can be cost-prohibitive, with the average 
treatment cost being around $100,000 per year,
7
 so even a slight reduction in cost can be 
significant in allowing wider access to highly effective treatments. 
2.2.1 Obstacles to Oral Delivery 
Unfortunately, there are significant obstacles that have prevented oral delivery of 
protein therapeutics thus far.  The path that a drug must take when delivered orally is 
fraught with peril.  When ingested, a drug first passes down the esophagus into the 
stomach.  There, it encounters an environment that is highly acidic and contains many 
proteolytic enzymes seeking to degrade the protein.  This environment of course allows 
for humans to ingest animal or plant proteins, break them down into their substituent 
amino acids, and absorb these building blocks as nutrients for constructing our own 
proteins as needed.  However, this function also prevents therapeutic proteins from 
reaching the bloodstream intact, as naked proteins exhibit almost negligible 
bioavailability without some means of protection.
11–13
 
The average residence time in the human stomach is approximately 3.5 hours.
14
  
Within this time, the protein is digested by the digestive system’s primary proteolytic 
enzyme, pepsin.  Pepsin comes from an inactive precursor molecule, pepsinogen, a 44-
amino acid zymogen that is secreted by chief cells in the stomach.  Pepsinogen is then 
activated by the hydrochloric acid released from parietal cells in the stomach through an 
autocatalytic cleavage, yielding the active enzyme pepsin.  Pepsin remains active in 
acidic conditions (pH < 6.5), with maximal activity at pH 2.0.  It typically cleaves 
approximately 20% of amide bonds in ingested proteins, with preference for cleaving the 
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N-terminal side of aromatic amino acid residues such as phenylalanine, tryptophan, and 
tyrosine.
15,16
   
In addition to cleavage by pepsin, the hydrochloric acid responsible for activating 
pepsin also acts to denature proteins.  A study on the effects of acid on protein 
denaturation by Fink et al.
17
 revealed three classes of responses depending on the strength 
of the acid, the temperature, and the presence of salts or other denaturants.  Proteins may: 
1) initially unfold at pH 3-4 and then refold into a molten, globule-like state at lower pH; 
2) not fully unfold, but directly transition to the molten, globule-like state; 3) show no 
significant unfolding with pH as low as 1.  However, the presence of salts or denaturants 
such as urea can significantly affect such behavior.  Therefore, although some proteins 
will naturally be resistant to denaturation by acid, many will deform and lose tertiary 
structure, at least to some degree. 
The median gastric pH for healthy people in the fasted state has been found to be 
1.7; after a meal, the pH briefly raises to a median peak of 6.7 and declines back to the 
fasted state pH over 2 h.
18
  This means that the drug will most likely spend roughly 1.5 h 
in highly acidic conditions (pH 1.7) and another 2 h in harsh to mild acidic conditions 
(pH 1.7 - 6.7).  Thus, a functioning drug delivery system for enabling oral delivery of 
protein therapeutics requires that it both protect the protein from pepsin and provide some 
sort of support for secondary and tertiary structure so that the drug is not denatured in the 
highly acidic environment.  Of course, all of this is needed to overcome the obstacles in 
just the stomach! 
After the stomach, the drug the passes on to the small intestine, where nutrient 
absorption into the bloodstream occurs.  This is the ideal site for transport of an orally-
delivered protein into the bloodstream where it can be active as though it were injected.  
The pH of the small intestine is decidedly more neutral than that of the stomach:  in the 
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fasted state, the median duodenal pH is 6.1; after a meal, the pH decreases to pH 5.4 and 
then fluctuates between 5 and 6.2 for over 4 h.
18
  Thus, the primary concern in the small 
intestine is not acidic denaturation, although significant obstacles do remain. 
One obstacle presented by the small intestine is the presence of additional 
proteolytic enzymes, primarily trypsin and chymotrypsin.  Together with pepsin, these 
enzymes comprise the primary proteolytic enzymes of the gastrointestinal tract.  Trypsin 
predominantly degrades proteins at the carboxyl side of lysine or arginine residues.
19
  
Chymotrypsin has similar cleavage sites as pepsin, preferentially cleaving on the N-
terminal side of tyrosine, tryptophan, and phenylalanine residues, with slower cleavage of 
leucine and methionine residues, and therefore acts as a second screen for ensuring 
protein degradation.
20
  
In addition to surviving potential degradation by these additional enzymes, the 
protein must cross the intestinal mucosa and epithelial cell layer to reach the bloodstream 
and enter systemic circulation.  As shown graphically in Figure 2-1, there are two 
primary means of crossing the epithelium: paracellular transport, as the protein diffuses 
through the tight junctions between cells, or transcellular transport through the cells by 
active or passive means.  Many small molecules such as amino acids are readily absorbed 
across the intestine, but the intestine has evolved to keep foreign proteins, viruses, and 
bacteria (i.e., large molecules or organisms) out of the bloodstream in an effort to prevent 
invasion by foreign parasites.  Therefore, although there are some naturally occurring 
proteins that readily cross by active transcellular transport, such as transferrin
21
 and IgG 
antibodies,
22
 the primary means of transport for macromolecules is through paracellular 
transport,
23
 which limits most proteins to 0-10% absorption.
24,25
  As a result, even a 
hypothetical delivery system capable of delivering 100% of encapsulated drug to the 
small intestine would still fail to achieve high bioavailability without promoting intestinal 
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absorption through some mechanism.  Thus, the problem of intestinal permeability is a 
highly significant obstacle to overcome in terms of achieving high bioavailability of 
orally delivered proteins.  As such, in addition to offering protection throughout the 
gastric environment, an ideal oral protein drug delivery system would also offer some 
protection from trypsin and chymotrypsin as well as promote intestinal absorption. 
2.3 HYDROGELS FOR DRUG DELIVERY 
The numerous obstacles presented by human physiology have kept orally-
delivered protein therapeutics from entering the market thus far.  However, recent 
research has led to promising advances for enabling oral delivery.  Peppas and 
collaborators have previously studied pH-responsive hydrogels based on methacrylic acid 
that show promise as protein delivery vehicles.
21,27–31
  In these systems, methacrylic acid 
is copolymerized with poly(ethylene glycol) monomethyl ether monomethacrylate 
(PEGMMA) or N-vinyl pyrrolidone (NVP)—two hydrophilic and biocompatible 
monomers—and a crosslinking agent such as tetra(ethylene glycol) dimethacrylate 
(TEGDMA) to form a pH-responsive hydrogel.  The structure of these molecules and a 
resulting gel network are shown in Figure 2-2. 
The carboxylic acid group on methacrylic acid provides the pH-responsive 
activity.  The pKa of methacrylic acid is 4.65, which leads to the acid group being 
protonated (-COOH) at highly acidic pH below the pKa, as found in the stomach, and 
deprotonated (-COO
-
) at neutral or basic pH above the pKa, as found in the small 
intestine.  When protonated, the hydrogen groups are available for hydrogen bonding 
with the oxygen atoms in the poly(ethylene glycol) chains or on the N-vinyl pyrrolidone 
side group.  This complexation causes the hydrogel to adopt a smaller, collapsed state, 
reducing the pore sizes of the hydrogel network and allowing the gel to effectively 
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encapsulate a protein drug for protection throughout the stomach.  When entering the 
neutral pH of the small intestine, the acid groups deprotonate and lose their hydrogen 
bonding abilities, causing swelling throughout the hydrogel network due to a combination 
of entropic interactions, favorable water imbibition by osmotic pressure, and anionic 
repulsion of the –COO- groups.32  The increased pore size allows for diffusive release of 
an encapsulated drug within the small intestine. 
Methacrylic acid-based gels copolymerized with poly(ethylene glycol) 
monomethyl ether monomethacrylate or N-vinyl pyrrolidone, designated P(MAA-g-EG) 
or P(MAA-co-NVP) respectively, have been synthesized and studied as potential protein 
delivery vehicles.  pH-Responsive swelling has been shown to cause up to a 30-fold 
increase in weight when comparing the collapsed and swollen states of the polymers.
33
  
Both polymers have also shown ability to effectively encapsulate and release insulin in in 
vitro loading and release experiments and in vivo, closed-loop animal models.
27,31,33–35
 
While this system has been promising for insulin, proteins represent an extremely 
broad class of molecules.  Importantly for polymer-based delivery, proteins differ widely 
in terms of size, shape, chemical stability, hydrophilicity or hydrophobicity, and 
isoelectric point.  For example, proteins range in size from a few kDa to several hundred 
kDa, which may require pore sizes to accommodate different diameters spanning over an 
order of magnitude.  As a result, the polymer system used to deliver the protein needs to 
be tailored to meet the demands of the specific therapeutic being delivered. 
One of the properties that must be accommodated is the isoelectric point.  The 
isoelectric point (pI) is the pH at which the protein has no net charge.  Above a protein’s 
pI, the protein will have a net negative charge; below the pI, the protein will have a net 
positive charge.  Insulin has a pI of 5.39,
 
meaning that it will be cationic in the low pH 
environment of the stomach and anionic in the neutral environment of the small 
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intestine.
36
  Because the P(MAA-g-EG) swells based on an anionic functional group (-
COO
-
), the charge on insulin works advantageously, repelling insulin from the hydrogel 
mesh by anionic interactions when in the desired release site of the small intestine and 
assisting with diffusive release. 
Unfortunately, the human proteome is split approximately evenly between 
proteins with low isoelectric points (pI < 7.4), like insulin, and proteins with high 
isoelectric points (pI > 7.4).
37
  For high isoelectric point-exhibiting proteins, the charge 
interaction works disadvantageously.  In the small intestine, the environmental pH 
remains below the pI of the protein, making the protein cationically charged while the 
hydrogel is anionically charged.  This leads to coulombic charge interactions that bind the 
protein to the hydrogel mesh, hampering diffusive release.  Therefore, the P(MAA-g-EG) 
and P(MAA-co-NVP) systems developed previously are not as ideally suited for 
achieving high bioavailability when delivering high isoelectric point-exhibiting proteins 
via the oral route.  Studies have shown that a high isoelectric point-exhibiting protein 
used for treating osteoporosis called salmon calcitonin can achieve complete release from 
the hydrogel over the time span of days;
38 
unfortunately, the average residence time in the 
small intestine is only 4 hours,
39
 over which time the release is less than 20%.
28
  
Therefore, to achieve high bioavailability via the oral route with any of the tens of 
thousands of high pI-exhibiting proteins, adjustments to the proteins or the hydrogel 
vehicle are needed. 
Of the over 150 currently FDA-approved protein therapeutics, at least 46 exhibit 
high isoelectric points (likely more, as not all of the approved drugs have accepted pI 
values available).
7,36
  These therapeutics are used to treat a wide variety of diseases: 
breast, lung, colorectal, and head and neck cancers; rheumatoid arthritis; osteoporosis; 
Crohn’s disease; infertility; non-Hodgkin’s lymphoma; multiple sclerosis; macular 
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degeneration; anemia; and growth failure, among others.
7
  Because these diseases 
together account for many millions of patients who may benefit from repeated 
administration of protein therapeutics, it is imperative that any oral delivery strategy be 
able to accommodate the high isoelectric point exhibited by the proteins. 
The aims of this thesis are to explore different strategies for achieving high 
bioavailability of therapeutic proteins delivered via the oral route in general, with 
emphasis on seeking innovations that could allow the previously studied systems to be 
expanded or modified to function with high isoelectric point exhibiting proteins.  The 
focus will be on salmon calcitonin—a protein used for treating osteoporosis and Paget’s 
disease—as a model, as it exhibits a high isoelectric point of 8.86 and has a small size 
similar to insulin (3.4 kDa compared to 5.8 kDa),
36
 thereby isolating isoelectric point as 
the primary difference between proteins and eliminating significant differences that 
would arise from vastly different sizes.  However, experiments with other high pI 
proteins urokinase and rituximab are also described. 
2.4 BIOCONJUGATION 
Bioconjugation refers to the attachment of additional molecules to a biomolecule 
such as a protein via covalent linkages.  It is widely used across various fields in order to 
impart additional functionality to a biomolecule without significantly inhibiting its 
original activity.  Bioconjugation reactions are used for a broad variety of purposes, 
finding uses in research, medicine, and materials synthesis. 
2.4.1 PEGylation and Its Utility in Medicine 
For one relevant and illustrative example, in medicine, attachment of a 
hydrophilic chain of poly(ethylene glycol) has shown to be an effective means of 
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providing stealth properties to proteins, particles, and surfaces, preventing rapid protein 
recognition by opsonins which cause protein removal by the reticuloendothelial system.  
This reaction, termed “PEGylation,” has multiple advantages; it can:  increase the 
hydrophilicity and solubility of highly hydrophobic drugs; increase the residence time of 
proteins by protecting against proteolysis and opsonization; protect against 
immunological reaction to the injected drug; or provide charge shielding interactions for 
ionic or dipolar molecules.
40–51
 
Such beneficial effects were first reported in a 1977 paper by Abuchowski et al.
52
 
in the lab of Dr. Frank Davis, where attachment of 1900 and 5000 Da PEG chains to 
bovine liver catalase prevented reaction with antiserum, granted protection from 
enzymatic degradation, and enhanced circulation time in mice, even as the catalase 
retained 93 and 95% of its native activity.  Since this seminal work, PEGylation has 
become a common approach to enhancing the efficacy of biotherapeutics, and is now 
used as a fundamental feature in many pharmaceuticals, including Movantik, Omontys, 
Krystexxa, Cimzia, Mircera, Macugen, Neulasta, Somavert, Pegasys, Doxil, PegIntron, 
Oncaspar, and Adagen.  Further, it has been used as a surface treatment for implants, 
preventing protein adhesion and therefore improving biocompatibility.  
2.4.2 Bioconjugation reactions 
Although bioconjugation reactions such as PEGylation have broad applicability, 
conjugation is typically performed through one of several common reactions.  With 
protein therapeutics, one of the most common reactions employed is reaction of the 
primary amines in lysine residues with N-hydroxysuccinimide (NHS) esters through 
nucleophilic substitution.  The NHS-ester is often formed from carboxylic acids using 1-
ethyl-3-(3-dimethylaminopropyl)carbodiimide (EDC) and NHS (thus often referred to as 
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EDC/NHS chemistry).  The reaction proceeds as shown in Figure 2-3.  A carboxylic acid 
is first activated by EDC to form a urea intermediate that is then susceptible to 
nucleophilic attack, either directly by a primary amine (such as that found in lysine) or by 
NHS or sulfo-NHS.  Attack by an NHS forms a stable intermediate that remains 
susceptible to nucleophilic attack by a primary amine while also increasing overall 
conjugation efficiency to over 90% and allowing storage of intermediates in a dry 
state.
53–57
  This reaction is slightly pH sensitive, with optimal pH between 4.7 and 6.0, 
although pH can go as high as 7.5 without significant yield loss.
58
 
The EDC/NHS reaction is especially useful for protein modification, as lysines 
are one of the most commonly observed amino acids in multiple, well-studied proteomes, 
upregulated consistently compared to what random probability would suggest and highly 
upregulated in the terminal position.
60–65
  As a result, there are many sites available in a 
typical protein for the EDC/NHS coupling reaction, and upregulation at the terminal 
position makes attachment to a terminal site frequently possible, enabling conjugation at 
a location that generally does not cause steric interference with the active site of the 
protein.  In addition, as can be seen in Figure 2-3, the reaction is a “zero-length” 
crosslinking reaction, in that the final product contains no portions of the EDC or NHS 
(i.e., no spacer), and the carboxylic acid-containing molecule and the amine containing 
molecule are directly attached.  For these reasons, this highly versatile and valuable 
reaction will be utilized both for PEGylation and crosslinking in this dissertation as 
described later. 
Although the ubiquity of lysine residues makes EDC/NHS coupling work with 
most proteins, it also has the drawback of having generally low selectivity with regard to 
particular reaction sites since most proteins will have multiple lysines.  Therefore, other 
reactions exist to take advantage of less common amino acids.  One particular reaction, as 
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seen in Figure 2-4, utilizes the thiol groups that are found only on cysteine—one of the 
(generally) least common amino acids
60,66—which can therefore greatly increase site-
specificity.  In the reaction, a reagent with a maleimide functional group reacts with the 
thiol group present on cysteine via a Michael addition, forming a stable product with a 
thioether linker.
58,59,67,68
  Maleimides will also react with amines, although tight control of 
the reaction pH between 6.5-7.5 can yield specificity toward thiol groups, as reaction 
with thiols proceeds 1000 times faster than with amines at pH 7; at higher pH values 
above 7.5, cross-reaction with amines becomes more common.
69–73
 
Although the maleimide reaction with cysteine enables facile conjugation with 
greater site specificity than EDC/NHS chemistry with lysine, many cysteine residues 
present in proteins are coupled together with other cysteine residues (forming cystine 
residues) through disulfide bridges, especially in proteins typically found in the 
extracellular milieu.
66,74
  These linkages are at times a mere structural motif to enhance 
stability, but also can either impart tertiary structure to proteins that is vital to proper 
function or be simply an inert structural motif.
74
  If conjugation with a disulfide-linked 
cysteine does not impair functionality, the cystine will first need to be reduced to 
cysteines, as maleimides do not react with disulfides.
75
  Common reducing agents are 
dithiothreitol (DTT), 2-mercaptoethanol, or tris(2-carboxyethyl)phosphine (TCEP).  
Following reduction, the maleimide-thiol reaction can proceed as described.  In the event 
that reducing the disulfide does impair protein function, a dibromomaleimide may be 
used, which reacts with both sulfhydryls, maintaining the approximate disulfide-bonded 
structure through a two carbon linker while also attaching the desired conjugate, as seen 
in the PEGylation of salmon calcitonin scheme shown in Figure 2-5.
76–78
 
Many additional reactions are available for bioconjugation which take advantage 
of different functional groups for improved reaction selectivity with various molecules.  
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Hermanson has written an excellent compendium of these reactions.
58
  Due to the ease 
and versatility of EDC/NHS chemistry, it will be used as the predominant conjugation 
technique in this dissertation, with brief mention of the maleimide-thiol chemistry. 
2.5 APTAMERS 
Aptamers are single-stranded oligonucleotide (RNA or DNA) sequences that form 
tertiary structures based on complementary base-pair hybridization which allow the 
resulting molecule to bind to and interact with virtually any class of target molecule with 
high specificity and affinity.
79
  They are analogous to antibodies, which have been 
utilized for over four decades for molecular recognition, with the difference that they are 
comprised of nucleotides instead of amino acids. 
This distinction makes aptamers very appealing, because the polymerase chain 
reaction (PCR) allows rapid, exponential amplification of oligonucleotides through 
simple chemical means, enabling aptamers to be developed and reproduced rapidly and 
cheaply.  Antibodies are not easily amplified by chemical means and require a biological 
system because of the numerous potential components (20 unique amino acids versus 4 
unique nucleotides) and the lack of natural enzymes for reproduction since natural protein 
production consists of translation of mRNA into a protein rather than copying proteins 
already present.
80
  Additionally, aptamers are significantly smaller in size than antibodies.  
Aptamers are often successfully selected using 15 to 40 random nucleotides, thus ranging 
in molecular weight from only 5 to 40 kDa;
80
 antibodies are regularly on the order of 150 
kDa in size, which can prevent them from being used effectively in many applications.  
Finally, aptamers are advantageous for having unlimited shelf-life and no 
immunogenicity; antibodies can denature in time and have significant immunogenicity in 
many cases.
80
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Aptamers became a popular class of molecules for the reasons described above 
following the description of the SELEX process in 1990.
81,82
  SELEX, standing for 
“systematic evolution of ligands by exponential enrichment,” also known as “in vitro 
selection” or ”in vitro evolution,” is a powerful tool for designing aptamers tailored for 
specific targets or specific functions.  It is essentially a directed evolution process for 
chemicals rather than organisms.  A large library of DNA or RNA strands, each 
containing a long random sequence in between primer sequences, is generated.  The 
library is then screened by placing the library in the presence of the target molecule, 
allowing the small fraction of aptamers that will bind the target molecule to bind, and 
isolating the bound nucleic acids from the non-functioning nucleic acids by washing or 
some other process.  The bound aptamers are then amplified by PCR and the process is 
repeated 5-15 times.  Because PCR exponentially amplifies the nucleic acids isolated by 
the selection step, it will widen the gap in moles of aptamers binding with high affinity 
and those binding with low affinity such that after repeated cycles, the most suitable 
nucleic acid sequence is almost exclusively selected.
83–85 
 This process has been used for 
selection of many high affinity detection molecules with dissociation constants in the low 
picomolar to low nanomolar range.
80 
One of the limitations of using nucleic acids is their rapid degradation in vivo by 
RNases and DNases.  An unmodified RNA aptamer, for example, has a half-life of a 
mere 8 s in vivo, far too short for any sort of therapeutic use.
86
  Fortunately, there are 
several approaches to greatly improve the longevity of aptamers in a living system.  The 
most common modification is to use nucleotides containing either amine (2’-NH2) or 
fluoride (2’-F) substitutions at the 2’-OH site of the pyrimidines.87,88  Using 2’-F-RNAs 
has been shown to extend the half-life of the RNA in vivo by up to 38,700 times to 86 h, 
more than sufficient for therapeutic use.
86  
The first FDA-approved aptamer therapeutic, 
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Macugen for treatment of wet age-related macular degeneration (approved in December 
2004), is made with 2’-F-pyrimidines and is conjugated to PEG to slow renal clearance.89 
An interesting alternative method of improving half-life is to exploit the chirality 
of nature to avoid degradation by nucleases.  Naturally occurring nucleases are all made 
of L-amino acids which only recognize D-nucleotides.  As such, L-nucleotides will 
escape degradation by nucleases present in vivo.  Aptamers taking advantage of this are 
termed Spiegelmers, and display half-lives in vivo upwards of 24 h.
89
  Selecting the 
proper enantiomeric L-nucleotide is performed not with L-nucleotides, but with D-
nucleotides binding the enantiomer of the desired target protein.  In other words, since 
PCR works with D-nucleotides alone, the amplification step would be impossible with 
the Spiegelmer; however, by targeting the mirror image of the desired target, the selected 
aptamer’s mirror image will bind the actual target.90,91  While this is perhaps the most 
elegant solution to achieving long half-lives in vivo, the formation of the D-protein target 
for the SELEX process must be performed synthetically, which limits the size of the 
target to something that may be synthesized by peptide synthesis.  Therefore, in this 
work, aptamer selection for therapeutic use will be performed using more simple 2’-F-
modified pyrimidines. 
While aptamers have been primarily used as immobilizing agents or signaling 
ligands for detection assays, they are also useful as therapeutic inhibitors (such as 
Macugen) and can even have enzymatic activity.  Riboswitches and ribozymes are a 
natural example of RNA aptamers that contain catalytic and regulatory activity.
92
 
Because aptamers can exhibit these widely varying functions, it is hypothesized in 
this work that they may similarly be designed for improving transport capabilities of 
protein therapeutics across the intestinal epithelium.  Transport of antigens across the 
intestinal epithelium is accomplished naturally by IgA antibodies,
93
 and previous work in 
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the lab has shown that transferrin (a protein for iron transport) may be used to improve 
protein transport by up to 15 times,
21
 so it is expected that an aptamer analog of 
antibodies/proteins can be designed to have similar transcytosis-initiating capabilities to 
significantly enhance transport into the bloodstream.  Choosing a known transporter like 
transferrin targets only a single receptor which can rapidly become saturated, limiting 
transport,
94
 despite there being many different potential transcytosis-initiating binding 
receptors on a cell.  Therefore, aptamer selection using a cellular-based modification of 
the SELEX process will utilize the multiple potential cellular receptors and 
systematically select the optimal receptor to target for the greatest improvement in 
transport capability without requiring detailed understanding of each available receptor. 
2.6 PROPOSED DELIVERY SYSTEMS 
2.6.1 Redesigned Hydrogels 
While the previously studied anionic hydrogels P(MAA-g-EG) and P(MAA-co-
NVP) have been shown to be capable of delivering insulin—a relatively low molecular 
weight (5.8 kDa) protein therapeutic with low isoelectric point of 5.39—studies using this 
technology platform to release proteins with high isoelectric points such as salmon 
calcitonin have identified drug delivery problems associated with charge interactions.  
Therefore, further design and investigation of different hydrogel formulations is needed 
to allow for high bioavailability of high pI proteins via the oral route. 
Because one of the limiting factors in releasing sCT within the small intestine is 
the charge interaction between the anionic hydrogel and the net cationic protein, one 
possibility would be to use a cationic or neutral hydrogel.  Unfortunately, with pH-
responsive cationic gels, due to the nature of the pH-responsive behavior (transitioning 
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from a protonated –NH3
+
 group at low pH to a deprotonated –NH2 group at neutral pH), 
the gel is in the swollen state at the low pH found in the stomach and collapsed at neutral 
pH, with an idealized pH-swelling profile seen in Figure 2-6.   
While this behavior may work for small molecule delivery by acting as a sponge 
that “squeezes out” the drug upon shrinking, proteins are much larger, so a gel with 
sufficiently small pore size to protect proteins from enzymes in the stomach would only 
entrap the protein drug to a greater degree upon collapse in the small intestine.  
Therefore, although the anionic nature of the gel is largely to blame for the observed 
release issues, it is also an unavoidable consequence of utilizing pH-responsiveness as the 
targeting strategy. 
Furthermore, is has been proposed that the anionic nature of the gel allows 
binding of extracellular Ca
2+ 
ions in the small intestine, causing reversible opening of the 
tight junctions between epithelial cells and enhancing transport of the drug to the blood 
via paracellular transport.
21,23,96–98
  The anionic nature thus may be beneficial after the 
protein has been released in the small intestine.  Therefore, this dissertation details efforts 
to mitigate, rather than eliminate, the negative effects of the ionic interactions while 
simultaneously taking advantage of these interactions in appropriate situations. 
Increasing the overall swelling and swelling speed would yield larger pore sizes, 
providing greater diffusivity through the polymer matrix and reduced average coulombic 
forces, and a longer timeframe for diffusive release, thus increasing the probability of 
protein release.  Coulomb’s law (Equation 2-1) states that the force is inversely 
proportional to the square of the distance between charged particles, so even a small 
increase in pore size can allow for significantly reduced coulombic attraction to the 
hydrogel’s carboxylic acid groups. 
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|𝐹| = 𝑘𝑒
|𝑞1𝑞2|
𝑟2
 Equation 2-1 
To achieve a greater distance between charges, the methacrylic acid pH-
responsive moiety will be exchanged for its diprotic analogue, itaconic acid.  Itaconic 
acid shares a similar structure, with the exception of a second –COOH group present, as 
seen in Figure 2-7.  The expected result of this monomeric substitution is that the second 
acid group, although providing a second anion per monomer unit for protein binding, will 
yield greater complexation behavior and increased anionic repulsion between monomer 
units, resulting in improved swelling and significantly reduced swelling response time.  
Furthermore, if the number of acid groups per unit volume is kept constant between 
methacrylic acid and itaconic acid-based gels, the itaconic acid offers the advantage of 
more localized anionic groups, since two anions are attached to the same monomer rather 
than being spread out across two separate monomers.  This yields a larger distance 
between anionic groups, and because, per Coulomb’s law (Equation 2-1), force is directly 
proportional to charge while inversely proportional to the square of the distance, 
increasing distance has a more significant effect than increasing charge, meaning a 
greater distance of approach will typically yield smaller attractive forces, even if the 
charge difference is increased proportionally. 
 This dissertation therefore focuses on gels based on itaconic acid, such as 
poly(itaconic acid-co-N-vinylpyrrolidone) (P(IA-co-NVP)) and poly(itaconic acid-
grafted-poly(ethylene glycol)) (P(IA-g-EG)), and the resulting effects on the delivery of 
high pI protein therapeutics. 
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2.6.2 Effects of Protein Conjugation 
As described in section 2.4, conjugation of proteins can lead to substantially 
improved properties, such as longer half-life, improved solubility, and multiple functions.  
PEGylation of proteins is quite common, but the increased size and different properties of 
the conjugate may alter protein delivery capability.  The increased size is likely to affect 
oral delivery by decreasing the diffusion rate, especially in the tortuous pathways out of 
the hydrogel mesh and through the size-selective tight junctions in the intestinal 
epithelium.  However, there may be a beneficial response to PEG as well, as the 
formation of a water cage around the protein can act to shield charge interactions between 
the protein and the hydrogel, preventing the electrostatic binding that has limited the oral 
delivery of high isoelectric point proteins with pH-responsive systems. 
In order to examine the effects of PEGylation on protein delivery, salmon 
calcitonin was PEGylated and evaluated using in vitro techniques to assess the impact on 
loading and release inside of the hydrogels as well as intestinal transport.  The 
experimental protocols used and the ensuing results are discussed in Chapters 6 and 7. 
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2.6.3 Design of Aptamers for Enhancing Intestinal Absorption 
The final obstacle preventing a protein from reaching the bloodstream for 
therapeutic action is the small intestinal epithelium.  The epithelium is a size selective 
barrier designed to absorb digested nutrients while preventing uptake of macromolecules 
and foreign organisms that can cause sickness.  As such, the absorption of whole proteins 
is almost negligible.  However, some proteins such as transferrin or some IgA antibodies 
have biological function that requires active transport across the intestinal epithelium, and 
receptor proteins enable the selective uptake of these proteins by transcellular transport. 
I hypothesized that one of these transcellular pathways can be used by designing 
an aptamer ligand that selectively binds to transcellular transport receptors on the cell 
surface, initiating active transport of proteins into the bloodstream.  Aptamers are well 
suited for this task because the chemical amplification through PCR (which is not 
available with proteins) enables a facile, evolutionary approach (SELEX) to discovery 
that requires minimal prior knowledge about the target and thus the ideal characteristics 
of the ligand. 
In this work, a modified selection protocol is used to enable the selection of 
aptamers achieving high levels of absorption across the epithelium by using a Caco-2 
model of the intestine.  Modified pyrimidine nucleotides containing fluorine atoms at the 
2’ position were used to prevent rapid degradation by RNases, and transport across the 
monolayer was used as the selection step to separate sequences that bind transcellular 
transport receptors from those that are not adequately transported.  Incorporating high 
throughput sequencing is used in favor of traditional Sanger sequencing as the final step 
of the protocol, enabling a faster selection cycle by reducing the required number of 
cycles.  In sum, the presented work aims to achieve an aptamer ligand that can be used to 
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significantly enhance the transport of therapeutic proteins across the intestinal epithelium, 
effectively overcoming the final and most significant barrier to high bioavailability via 
the oral route.
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Figure 2-1: Intestinal Epithelium and Methods of Transport. Adapted from Blanchette et 
al.
26 
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Figure 2-2:  Chemical Structures of Monomers and Polymer Network of P(MAA-co-
NVP) Hydrogels.   
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Figure 2-3:  EDC/NHS Conjugation Reaction Scheme.  Reprinted from Thermo 
Scientific Pierce.
59
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Figure 2-4: Maleimide-Thiol Conjugation Reaction Scheme.  Reprinted from Thermo 
Scientific Pierce.
59
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Figure 2-5:  PEGylation of Salmon Calcitonin Using Dibromomaleimide to Maintain 
Disulfide Bridge.  Reprinted with permission from Jones et al., J. Am. 
Chem. Soc., 2011.
76
  Copyright 2011 American Chemical Society. 
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Figure 2-6: Characteristic Swelling Profiles for Anionic and Cationic pH-Responsive 
Hydrogels. 
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Figure 2-7: pH-Responsive Monomers:  Methacrylic Acid and Itaconic Acid.  Molecular 
structure of itaconic acid (right), which will be substituted for methacrylic 
acid (left) in pH-responsive hydrogels. 
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Table 2-1:  Protein Therapeutics Appearing in the Top 20 Best-Selling Drug Products. 
Rank 
Drug 
Name 
Protein Manufacturer Indications 
Sales 
(Q4 2013, $MM) 
3 Humira Adalimumab AbbVie 
Crohn’s disease; Rheumatoid 
arthritis; Plaque psoriasis; 
Ulcerative colitis; Ankylosing 
spondylitis 
1,461.9 
6 Enbrel Etanercept Amgen Rheumatoid arthritis 1,189.8 
8 Remicade Infliximab 
Centocor Ortho 
Biotech, Inc. 
Crohn’s disease; Rheumatoid 
arthritis 
994.0 
9 Neulasta 
Filgrastim (G-
CSF) 
Amgen Neutropenia 854.5 
11 
Lantus 
Solostar 
Insulin glargine Sanofi Diabetes mellitus 839.7 
12 Rituxan Rituximab Genentech 
Non-Hodgkin’s lymphoma; 
rheumatoid arthritis 
746.8 
16 Lantus Insulin glargine Sanofi Diabetes mellitus 675.5 
17 Avastin Bevacizumab Genentech Cancers 650.2 
20 Epogen Epoetin alfa Amgen Anemia 503.5 
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Chapter 3:  Specific Aims 
The use of pH-responsive hydrogels as delivery carriers for the oral delivery of 
therapeutic proteins is quite promising, and much work has been done to design and 
study such systems, such as poly(methacrylic acid-grated-poly(ethylene glycol)) 
(P(MAA-g-EG)) or poly(methacrylic acid-co-N-vinylpyrrolidone) (P(MAA-co-NVP)).  
However, proteins exhibiting high isoelectric point have shown limited bioavailability in 
these systems due to electrostatic interactions with the hydrogels.  Furthermore, the 
intestinal epithelium presents another significant obstacle to effective oral delivery at the 
current time, and therefore needs to be addressed in order to make an effective protein 
delivery platform. 
The objective of this work was to make judicious modifications to previously 
studied P(MAA-g-EG) or P(MAA-co-NVP) hydrogel systems to overcome the 
limitations that have prevented oral delivery of protein therapeutics thus far.  Substitution 
of itaconic acid as the pH-responsive moiety and incorporation of degradable peptide 
crosslinks targeted to degrade in the small intestine were explored as methods of 
enhancing the delivery of high isoelectric point-exhibiting proteins to the small intestine.  
Numerous design parameters were tested to determine the most important design criteria 
for proteins and suggest design rules for tailoring the systems to different proteins.  
Additionally, conjugation using PEG (PEGylation) is a common method of improving 
therapeutic bioavailability by enhancing in vivo half-life.  The effects of this modification 
on delivery and intestinal absorption were elucidated.  Finally, in an effort to overcome 
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the final barrier of limited intestinal absorption of macromolecules, a discovery protocol 
for transcellular transport initiating aptamer ligands was developed and used to identify 
optimal nucleic acid sequences for this purpose.  The subsequently described experiments 
were designed to systematically investigate these strategies and thereby develop a safe 
and effective oral delivery platform for delivery of high isoelectric point-exhibiting 
proteins. 
Therefore, the specific aims of the research presented herein were to: 
1. Synthesize, characterize, and evaluate pH-responsive hydrogels and 
enzymatically-degraded hydrogels as vehicles for the oral delivery of 
protein therapeutics exhibiting high isoelectric point; 
2. Optimize available hydrogel design parameters—such as monomer ratios, 
crosslinking density, particle size, and drug loading procedure—to achieve 
high bioavailability of protein therapeutics; 
3. Evaluate the effects of bioconjugation on oral protein delivery properties; 
4. Develop a novel aptamer ligand to target transcellular transport receptors 
in order to enhance protein transport across the intestinal epithelium; 
5. Investigate the performance of designed oral delivery platforms in vivo 
using a closed-loop rat model. 
  
 42 
Chapter 4:  Synthesis and Characterization of Responsive 
Hydrogels1 
4.1 INTRODUCTION 
Numerous techniques have been studied in an effort to enable site-specific 
delivery of therapeutics, often with controlled or extended release capabilities.  Although 
some of these systems have been inspired by natural processes found in the body, such as 
liposomes or micelles, the use of synthetic hydrogel matrices as drug carriers has been 
one of the foremost areas of research.  Hydrogels have a wide range of properties that are 
easily tailored to the desired application.  The nearly limitless spectrum of monomers that 
may be incorporated into the polymer backbone can give wide differences in function, 
based on variations in electronegativity, hydrophilicity, acidity, bond motility, etc.  
Furthermore, the structure plays a fundamental role in the behavior of the hydrogel.  For 
example, low crosslinking density yields increased translational degrees of freedom for 
the polymer chains and larger effective mesh size, and may therefore be used to increase 
hydrogel swelling, to speed the release of compounds from the matrix, or to enable 
delivery of larger molecules.  Furthermore, randomly ordered polymers will have 
significantly different behavior than block copolymers or those formed with isotactic 
backbones.  Because both the chemical moieties and the physical structure of the 
                                                 
1 Portions of this chapter have been previously published in Koetting, M. C.; Peppas, N. A. pH-Responsive 
Poly(itaconic Acid-Co-N-Vinylpyrrolidone) Hydrogels with Reduced Ionic Strength Loading Solutions 
Offer Improved Oral Delivery Potential for High Isoelectric Point-Exhibiting Therapeutic Proteins. 
International Journal of Pharmaceutics 2014, 471, 83–91.1  Writing is reprinted herein with permission.  
Copyright Elsevier, 2014. 
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hydrogel have such strong effect on function, the range of behaviors observed in 
hydrogels is highly varied and highly customizable. 
One of the most interesting and useful classes of hydrogels is stimulus-responsive 
hydrogels.  Such hydrogels utilize chemical moieties in the polymer backbones or 
crosslinks that are chosen to yield a change in hydrogel behavior upon changes in the 
environment.  Hydrogels have been successfully produced that exhibit responsiveness to 
a wide variety of stimuli, including pH, temperature, light, electromagnetic fields, and 
specific chemicals or analytes.
2–4
   
Such hydrogels have obvious implications for drug delivery.  The responsive 
behavior enables site-specific delivery of drug compounds by yielding a protecting or 
encapsulating phase that is wholly separate from the drug release phase, as well as a 
mechanism by which these phases may be easily switched.   Site-specific drug delivery is 
ideal as it assures high concentration of therapeutic at the desired site of action while 
limiting off-target side effects associated with systemic application.  It also enables 
precise temporal control of drug release, allowing for pulsatile release kinetics to keep 
drug concentrations within therapeutic ranges, as illustrated in Figure 4-1, or feedback-
controlled release so that the drug is only released when needed (e.g., insulin released 
only when glucose levels are high; anti-inflammatory drugs released only in presence of 
inflammatory cytokines).
2,5–7
  By offering control over the spatial and the temporal 
delivery of drugs, stimulus-responsive hydrogels will enable currently used therapeutics 
to be more effective and have fewer side effects while also enabling use of effective 
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potential therapeutics that would otherwise be unusable due to systemic toxicity 
concerns. 
For enabling the oral delivery of protein therapeutics, pH-responsive hydrogels 
are especially auspicious because the wide transition in pH from the stomach to the small 
intestine offers a simple and effective triggering mechanism for site-specific drug release 
in the small intestine.  Research in the Peppas lab over the past two decades has identified 
pH-responsive hydrogels of poly(methacrylic acid-grafted-poly(ethylene glycol)) 
(P(MAA-g-EG)) or poly(methacrylic acid-co-N-vinylpyrrolidone) (P(MAA-co-NVP) as 
suitable drug delivery carriers for enabling the oral delivery of insulin and human growth 
hormone.  These systems exhibit a collapsed state at low pH as found in the stomach, 
effectively encapsulating and protecting the protein therapeutic, and transition to a 
swollen state at neutral pH as found in the small intestine, increasing the effective mesh 
size significantly and therefore releasing the protein therapeutic by diffusion for transport 
across the intestinal epithelium into the bloodstream.  However, these systems still suffer 
from low bioavailability compared to injection, resulting in wasted drug and therefore 
higher cost.
8–13
  Additionally, studies seeking to deliver proteins exhibiting high 
isoelectric points (pI) have been hampered by coulombic interactions in the small 
intestine between the anionic hydrogel and cationic protein, resulting in binding rather 
than release for uptake into the bloodstream.
9
 
In this work, I focus on enabling oral delivery of salmon calcitonin as a model for 
high pI therapeutic proteins.  Our group has previously synthesized and characterized pH-
sensitive copolymer hydrogels comprised of poly(itaconic acid-grafted-poly(ethylene 
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glycol)) (P(IA-g-EG)) which showed potential as drug delivery carriers due to their 
favorable equilibrium swelling behavior in acidic and neutral pH environments.
14
  The 
additional carboxylic acid residue present in itaconic acid compared to methacrylic acid 
can yield superior swelling behavior and drug delivery capability that would assist in 
delivery of high pI proteins.  However, these hydrogels were initially studied on their 
own and not compared directly against previous P(MAA-g-EG) or P(MAA-co-NVP) 
systems, and were not tested in drug loading and release experiments, so I herein extend 
work with these systems by determining their swelling behavior in time-limited, 
dynamic-pH swelling experiments, by comparing against P(MAA-g-EG) and P(MAA-co-
NVP) systems, and by utilizing them in in vitro drug loading and release experiments. 
Furthermore, our group has previously demonstrated improved drug delivery 
behavior resulting from use of N-vinylpyrrolidone as a hydrogen-bond accepting 
comonomer instead of poly(ethylene glycol), as it offers stronger complexation behavior 
for improved protein protection and faster diffusive drug release.
9,15
  Therefore, we also 
synthesize and test P(IA-co-NVP) hydrogels alongside P(MAA-g-EG), P(MAA-co-
NVP), and P(IA-g-EG) hydrogels with the expectation that the stronger complexation 
behavior will also assist in enabling the oral delivery of high pI proteins. 
In this chapter, I discuss the synthesis and characterization procedures of the 
proposed hydrogel systems (P(IA-co-NVP) and P(IA-g-EG) microparticles, as well as 
peptide-degradable hydrogels) and demonstrate improved material responsiveness as 
compared to previous systems. 
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4.2 MATERIALS AND METHODS 
4.2.1 Synthesis and Purification of pH-Responsive Hydrogels 
Seven different hydrogels were formed via UV-initiated free radical 
polymerization.  Each hydrogel was comprised of a pH-responsive moiety—either 
methacrylic acid (MAA) (Sigma-Aldrich, St. Louis, MO) or itaconic acid (IA) (Acros 
Organics, Fair Lawn, NJ)—copolymerized with a hydrophilic comonomer containing a 
hydrogen bond-acceptor for complexation behavior—either N-vinyl pyrrolidone (NVP) 
(Sigma-Aldrich) or poly(ethylene glycol) monomethyl ether monomethacrylate 
(PEGMMA, molecular weight 1000) (Poly-sciences, Warrington, PA).  Methyl 
methacrylate (MMA) (Sigma-Aldrich) was also incorporated as a third monomer in one 
formulation.  Hydrogels were crosslinked using tetra(ethylene glycol) dimethacrylate 
(TEGDMA) (Sigma-Aldrich) or poly(ethylene glycol) dimethacrylate (PEGDMA, 
molecular weight 1000) (Sigma-Aldrich).  Irgacure 2959 (Ciba Specialty Chemicals 
Corp., Tarrytown, NY) was used as the UV-initiator. 
All polymerizations were carried out in a 50:50 w/w mixture of aqueous sodium 
hydroxide (NaOH) and ethanol.  Sodium hydroxide was prepared at a concentration such 
that there was a 1:2 molar ratio of NaOH to IA.  No NaOH was required for MAA-based 
gels.  Within this co-solvent, monomers were added at various molar ratios as shown in 
Table 4-1, along with crosslinker (3-5 mol% for IA-based gels; 1 mol% for MAA-based 
gels) and 1 mol% initiator.  Molar percent is defined with regard to the total moles of 
monomers and crosslinker. 
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The monomer solution was then introduced into a nitrogen environment in an 
MBraun Labmaster 130 glove box (MBraun, Garching, Germany) and purged with 
nitrogen for 10 minutes to remove oxygen, a free radical scavenger.  The solution was 
pipetted between two quartz glass plates (15 x 15 x 0.3 cm) separated by a 0.7 mm thick 
Teflon spacer, and then polymerized for 75 minutes in 35 mW/cm
2
 UV light using an 
IntelliRay 600 UV flood source (Uvitron International, West Springfield, MA).   
Disks 12 mm in diameter were collected from the resulting films immediately 
following polymerization for use in swelling studies.  The remaining hydrogel was then 
removed from the glass plates and washed in 1 L of 18.2 MΩ-cm deionized water, 
changed daily for 10 days to remove unreacted monomers.  Following washing, the films 
were dried under vacuum at 29 °C for at least 2 days, crushed into microparticles with a 
mortar and pestle, and sieved to 90–150 μm in size. 
4.2.2 Synthesis of Enzymatically Degradable Hydrogels 
Enzymatically degradable hydrogels using peptide crosslinks were prepared as 
described by Knipe et al.
16
  Uncrosslinked P(MAA-co-NVP) polymer was prepared by 
UV-initiated free radical polymerization.  Methacrylic acid (Sigma-Aldrich) and N-
vinylpyrrolidone (Sigma-Aldrich) were added to a 50:50 w/w mixture of water and 
ethanol at a molar ratio of 1:1 MAA:NVP and 30 wt% monomer to total solution weight.  
Irgacure 2959 (Ciba Specialty Chemicals Corp.) was added as a photoinitiator at 1 wt% 
relative to total monomer weight.  The solution was purged with nitrogen for 5 min and 
polymerized for 30 min in 35 mW/cm
2
 UV light using an IntelliRay 600 UV flood source 
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(Uvitron International).  After polymerization, the polymer was purified using 1 N 
hydrochloric acid (Fisher Scientific, Fair Lawn, NJ) and acetone to cause precipitation of 
the polymer, followed by centrifugation and resuspension in deionized water 3 times.  
The purified polymer was dried by lyophilization. 
The degradable P(MAA-co-NVP) hydrogel was formed by crosslinking using a 
synthetic peptide.  Uncrosslinked P(MAA-co-NVP) polymer was dissolved in a 50:50 
w/w mixture of water and ethanol at a concentration of 50 mg/mL.  1-ethyl-3-(3-
dimethylaminopropyl)carbodiimide hydrochloride (EDC) (Sigma-Aldrich) was dissolved 
in ethanol at 50 mg/mL concentration.  N-hydroxysuccinimide (NHS) (Thermo Scientific 
Pierce, Waltham, MA) was dissolved separately in ethanol at 16 mg/mL concentration.  
The EDC and NHS solutions were added to the polymer solution at a 6:3:1 ratio of 
polymer:EDC:NHS by weight, vortexed briefly, and reacted for 3 min.  The solution pH 
was raised to pH 8 using 1 N sodium hydroxide (Fisher Scientific).  A synthetic peptide 
with the sequence MMRRRKK (CHI Scientific, Maynard, MA) was dissolved in ethanol 
at a concentration of 100 mg/mL and added to the polymer solution at a 2:1 weight ratio 
of polymer:peptide.  The mixture reacted for 12 h, and the product was isolated by 
centrifugation.  The polymer was resuspended in deionized water and then isolated by 
centrifugation 3 times to remove remaining reactants.  The hydrogel was then dried by 
lyophilization, crushed using a mortar and pestle, and sieved to microparticles 90-150 µm 
in size for use in studies. 
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4.2.3 Hydrogel Characterization Studies 
4.2.3.1 Equilibrium Swelling Studies 
Hydrogel disks 12 mm in diameter were acquired from the 1:1 P(IA-co-NVP), 1:9 
P(IA-co-NVP), P(IA-co-NVP-co-MMA), and P(MAA-co-NVP) hydrogel formulations 
immediately following polymerization.  These disks were weighed in air and in heptane 
to obtain the relaxed state weight of the disk.  The disks were washed in deionized water 
for 10 days and dried at 30 °C under vacuum.  The dry weight of each disk was 
determined in air and heptane using an Ohaus Analytical Plus scale (Ohaus, Parsippany, 
NJ).  Disks were then placed in either a standard PBS buffer (0.150 M, pH 7.4) (Fisher 
Scientific) to simulate neutral small intestine conditions or a 0.01 N hydrochloric acid 
(HCl) solution (Sigma-Aldrich) (pH 2.0) to simulate acidic stomach conditions at 37 °C 
for 72 h, allowing the disks to swell to equilibrium.  The swelled disks were then 
removed from solution and weighed in air and heptane to obtain the swollen weight of 
the disks. 
4.2.3.2 Dynamic Swelling Studies 
Dry disks were weighed in air and subsequently swelled at 37 °C for 3 h in 0.01 N 
HCl (pH 2.0).  Ten dimethylglutaric acid (DMGA) buffers spanning a pH range from 3.2 
to 7.6 were prepared and preheated to 37 °C.  Following swelling in HCl, the disks were 
moved into the first of these ten buffers (pH 3.2), allowed to swell for 7 minutes, 
removed from the buffer, and weighed in air.  The disks were then moved to the next 
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buffer (in order of increasing pH), and the swelling and weighing process was repeated 
through all 10 buffers with 7 minute swelling intervals. 
4.2.3.3 Mesh Size Calculations 
Mesh sizes were calculated using a mixture of polymer swelling theory and 
rubber elasticity theory.  Polymer swelling behavior was modeled using three different 
equations for the 1:1 P(IA-co-NVP) hydrogel for comparison of the models.  These three 
models are the Peppas-Merrill equation (Equation 4-1),
17
 the Brannon-Peppas equation 
(Equation 4-2),
18
 and the Şen-Güven model (Equation 4-3).19  The Peppas-Merrill 
equation is the earliest and most easily used, but is valid for neutral hydrogel networks 
only: 
1
𝑀𝑐̅̅ ̅̅
=
2
𝑀𝑛̅̅ ̅̅
−
(
?̅?
𝑉1
) [ln(1 − 𝑣2,𝑠) + 𝑣2,𝑠 + 𝜒1𝑣2,𝑠
2]
𝑣2,𝑟 [(
𝑣2,𝑠
𝑣2,𝑟
)
1/3
− (
𝑣2,𝑠
2𝑣2,𝑟
)]
 
Equation 4-1 
 
In this model, 𝑀𝑐̅̅ ̅̅  is the average molecular weight of polymer between crosslinks [g/mol], 
𝑀𝑛̅̅ ̅̅  is the number average molecular weight of the linear polymer chains [g/mol], ?̅? is the 
specific volume of the dry polymer [mL/g], V1 is the molar volume of the solvent (water, 
18.1 mL/mol), v2,s is the volume fraction of the polymer in the swollen state, v2,r is the 
volume fraction of the polymer in the relaxed state (immediately after polymerization), 
and 𝜒1 is the Flory interaction parameter for the polymer and the solvent. 
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The Brannon-Peppas model (Equation 4-2) was derived for polyelectrolyte 
networks with monoprotic ionizable moieties such as poly(methacrylic acid): 
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Equation 4-2 
 
In this model, the terms are the same as in the Peppas-Merrill equation, with the additions 
that Mr is the molar average molecular weight of a repeat unit [g/mol], X is the molar 
fraction of ionizable monomers in the polymer, and I is the ionic strength of the solvent 
[mol/mL].
20
  (By error, the X and Mr terms were omitted from the equation in the original 
paper.  Without these terms, the units do not cancel appropriately and the concentration 
of ions is incorrect.  The error has been propagated through subsequent literature, and I 
am unaware of papers citing the correct form of the equation.  However, after 
rederivation of the ionic contribution, I am confident in the veracity of this form.)  
Although itaconic acid has two pKa values (one for each acid group), only the pKa most 
proximate to the conditions was used in applying this model (e.g., pKa = 3.85 for acidic 
conditions; pKa = 5.45 for neutral conditions). 
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 Finally, the model of Şen and Güven19 (Equation 4-3) follows the derivation of 
the Brannon-Peppas model and therefore looks quite similar, but is specifically for 
diprotic ionizing groups, such as in poly(itaconic acid), and should therefore be the most 
appropriate for itaconic acid-based gels: 
𝑉1
4𝐼
∙ (
2 ∙ 10−(𝑝𝐾𝑎1+p𝐾𝑎2) + 10−(𝑝𝐻+𝑝𝐾𝑎1)
2 ∙ [(10−𝑝𝐻)2 + 10−(𝑝𝐻+𝑝𝐾𝑎1) + 10−(𝑝𝐾𝑎1+𝑝𝐾𝑎2)]
)
2
 ∙ (
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)
2
= [ln(1 − 𝑣2,𝑠) + 𝑣2,𝑠 + 𝜒1𝑣2,𝑠
2] + (
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) ∙ (1 −
2
𝜑
)
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2/3 ∙ 𝑣2,𝑠
1/3 
Equation 4-3 
 
In this model, variables are the same as in the Peppas-Merrill (Equation 4-1) and 
Brannon-Peppas (Equation 4-2) equations, with the additions of φ being the functionality 
of crosslinks, and pKa1 referring to the more acidic unit (3.85 for itaconic acid) and pKa2 
referring to the less acidic unit (5.45 for itaconic acid).  It should be noted that the Mr 
term was omitted from this model in the original paper, as was the case with the 
Brannon-Peppas model.  To make units match, the authors erroneously cited the molar 
volume of water as being 18.1 g/cm
3
, which one will note is a density, not a molar 
volume, and 18x the actual density of water.  As with the Brannon-Peppas equation, the 
Mr term is needed to properly calculate the concentration of ions in the hydrogel and is 
therefore utilized in this work. 
Equilibrium swelling results from the 1:1 P(IA-co-NVP) disks were used with all 
three to determine 𝑀𝑐̅̅ ̅̅  for each disk.  The equilibrium swelling results for the remaining 
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itaconic acid gels were analyzed with the Şen-Güven model only, while the methacrylic 
acid gel was analyzed with the Brannon-Peppas model.  The Flory interaction parameter 
𝜒1 was assumed to have a value of 0.5, as is true for poly(methacrylic acid) and poly(N-
vinylpyrrolidone) in water.
21–23
   𝑀𝑛̅̅ ̅̅  was assumed to have a value of 40000 g/mol.  Mr 
was taken as a weighted average of the monomers present in the hydrogel.  𝑀𝑐̅̅ ̅̅  was 
determined using a generalized reduced gradient (GRG) nonlinear solution method 
implemented in Microsoft Excel. 
Using the calculated values of 𝑀𝑐̅̅ ̅̅ , rubber elasticity theory was applied to 
determine mesh sizes.  Rubber elasticity theory shows that the mesh size, ξ, can be 
calculated by Equation 4-4, 
𝜉 = 𝑣2,𝑠
− 
1
3 ∙ (
2 ∙ 𝐶𝑛 ∙ 𝑀𝑐̅̅ ̅̅
𝑀𝑟
)
1/2
∙ 𝑙 Equation 4-4 
 
where Cn is the Flory characteristic ratio and l is the carbon-carbon bond length (1.54 Å 
for vinyl polymers).
2,24
  The value of Cn used was a molar weighted average of the 
characteristic ratios for pure poly(itaconic acid), poly(methacrylic acid), and poly(N-
vinylpyrrolidone).  Values of 𝑀𝑐̅̅ ̅̅  and equilibrium disk swelling measurements were used 
with the above equation to determine average mesh size. 
4.2.3.4 Cytotoxicity Studies 
Caco-2 human colorectal adenocarcinoma cells (ATCC, Manassas, VA) were 
cultured normally up to a passage number of 60.  The cells were then plated into a 96-
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well plate at an initial concentration of 1.0x10
4
 cells/well in Dulbecco’s Modified Eagle’s 
Medium (DMEM) with 10% v/v fetal bovine serum, 1% v/v penicillin-streptomycin, and 
1% v/v L-glutamine added.  Each well received 200 μL DMEM (5.0 x 104 cells/mL).  
Cells were incubated for 72 h at 37 °C.  Microparticles of the 1:1 P(IA-co-NVP), 1:1 
P(IA-g-EG), and 1:1 P(MAA-g-EG) hydrogels ranging from 90-150 μm in size were 
sterilized by exposure to ultraviolet light and then suspended in DMEM at concentrations 
of 5.000, 2.500, 1.250, 0.625, 0.312, 0.156, 0.078, and 0.039 mg/mL.  DMEM was 
removed from all wells by vacuum aspiration and replaced with 120 μL of microparticle 
suspension (n=3 for each concentration of each hydrogel formulation), 1.5% v/v bleach in 
DMEM (negative control, n=8), or fresh DMEM (positive control, n=16).  Cells were 
incubated in presence of hydrogel microparticles at 37 °C for 2 h.  The microparticle 
suspensions were then removed from all wells by vacuum aspiration, and all wells were 
washed twice with 120 μL sterile phosphate-buffered saline.  Cell viability was 
determined using an MTS assay:  20 μL (3-(4,5-dimethylthiazol-2-yl)-5-(3-
carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium) (MTS) (Promega, Madison, 
WI) and 100 μL colorless DMEM were added to each well and incubated for 3 h before 
absorbance was measured at both 690 nm and 490 nm. 
4.2.3.5 Thermogravimetric Analysis 
The thermal degradation profiles of all the hydrogel formulations synthesized in 
section 4.2.1 were characterized using a Q500 thermogravimetric analyzer (TA 
Instruments, New Castle, DE).  Hydrogel microparticles weighing 5-10 mg were heated 
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in a nitrogen environment from room temperature to 550 °C at a constant rate of 10 
°C/min and maintained at 550 °C for 5 min before oxygen was added to eliminate any 
combustible degradation products. 
4.3 RESULTS AND DISCUSSION 
4.3.1 Synthesis of pH-Responsive Hydrogels 
Itaconic acid presents several challenges to polymer synthesis:  allylic hydrogen 
atoms act as chain transfer agents, inhibiting homopolymerization of itaconic acid;
25,26
 
the rate of homopolymerization is dependent on pH, with homopolymerization 
effectively halting above pH 4;
26
 and the solubility of itaconic acid in water is only 0.083 
g/mL, which is too low for creating a homogeneous hydrogel in water alone.
14
  The pH-
dependency is not as significant an issue with a copolymerization, as used here, but 
remains a key factor in determining the degree of incorporation of itaconic acid into the 
hydrogel.  The solubility issue was overcome by Betancourt et al.
14
 who achieved 
incorporation of IA up to 67 mol% by partially neutralizing acid groups in a sodium 
hydroxide, water, and ethanol solvent.  The co-solvent and the partial neutralization 
allows for significantly improved solubility of IA, allowing for homogeneous hydrogel 
formation by UV-initiated free radical polymerization.  Formulations of P(IA-g-EG) and 
P(IA-co-NVP) had been prepared by other groups prior to Betancourt et al., but these 
formulations required gamma ray irradiation as an initiation method and were unable to 
incorporate itaconic acid at greater than 9 mol% in the hydrogel.
27
  Because of the cost 
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and hazards of gamma ray irradiation as a polymerization technique, the far more facile 
technique of UV-initiated polymerization is highly preferable, and was used here. 
All hydrogels were successfully prepared by UV-initiated free radical 
polymerization using the procedures adapted from Betancourt et al.
14
  Qualitatively, IA-
based gels visibly required longer curing times than MAA-based gels.  MAA-based gels 
had successfully cured within 30 min, whereas IA-based gels required up to 1 h to form a 
visible gel. 
Qualitatively, IA-containing gels also exhibited lower mechanical strength than 
MAA-containing gels.  The IA-based gels were softer and broke into smaller pieces 
readily upon mild agitation, such as moving the hydrogel film or refilling the rinse water.  
MAA-based gels did not tear nearly as readily and could easily be picked up and moved 
by hand without tearing.  Methyl methacrylate was included as a third monomer in one 
formulation (P(IA-co-NVP-co-MMA)) at 10 mol% to add additional strength to the IA-
based gel.  The resulting gel did have improved strength, but was still softer and more 
easily broken than the MAA-based gels.  Nevertheless, the reduced mechanical strength 
is a bulk property and does not significantly affect microparticle integrity.  As a result, it 
is not expected to be a problem for end-use.  Furthermore, the softness suggests higher 
porosity or greater water imbibition, which would be beneficial for improving 
bioavailability of proteins by aiding in diffusive protein release from the microparticle 
carriers. 
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4.3.2 Synthesis of Enzymatically Degradable Hydrogels 
Enzymatically degradable hydrogels containing MMRRRKK peptide crosslinks 
were successfully prepared by the described method.  Use of degradable hydrogels is one 
potential method for enhancing the bioavailability of orally delivered therapeutic 
proteins.  The limitation of using previously studied systems with high isoelectric point 
exhibiting proteins is the low bioavailability resulting from electrostatic interactions 
between the protein and the anionic carriers, preventing diffusive release into the 
intestinal lumen.  However, if the hydrogel particles degrade around the encapsulated 
protein, the protein does not have to diffuse through the hydrogel, ensuring it will reach 
the lumen. 
Peptide crosslinks provide a highly beneficial method for targeting protein release 
to the small intestine through degradation.  Careful selection of peptide sequence enables 
use of the enzymatic environment of the small intestine as a triggering mechanism for 
degradation and protein release.  Using the peptides as crosslinks rather than as the 
fundamental monomer in the network enables degradation while using a minimal 
quantity of peptide, which is expensive to synthesize at large scale, thus greatly reducing 
cost.  Finally, use of the peptide as a crosslinker allows the hydrogel to add degradability 
as a property while retaining the beneficial properties of the primary monomers, namely 
hydrophilicity, biocompatibility, and pH-responsiveness—which will act as a secondary 
mechanism for protein release that simultaneously assists external enzymes in reaching 
degradation sites within the hydrogel. 
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In order to target degradation to the small intestine, the peptide sequence must be 
carefully selected.  Pepsin is the primary digestive enzyme in the stomach and 
preferentially cleaves proteins at the N-terminal side of phenylalanine, tryptophan, and 
tyrosine residues.
28,29
  Therefore, these amino acids cannot be used in the crosslinker, as 
their incorporation would allow rapid degradation in the stomach where the encapsulated 
proteins would also be digested, yielding negligible bioavailability.  The digestive 
enzymes in the small intestine are primarily trypsin and chymotrypsin.  Chymotrypsin 
degrades at the same preferential sites as pepsin, but also has activity on leucine and 
methionine residues.  This similarity in degradation sites makes it difficult to utilize 
chymotrypsin for hydrogel degradation, but it can be used with the incorporation of 
methionine residues.  Trypsin, on the other hand, cleaves proteins at the carboxyl side of 
lysine or arginine residues, and is therefore quite easy to utilize for hydrogel degradation. 
To take advantage of the enzymatic profile of the small intestine, the peptide 
MMRRRKK was chosen as a crosslinker.  The three amino acids in the center of the 
crosslinker are arginine residues, providing several potential cleavage sites for trypsin.  
The carboxyl end of the peptide is comprised of lysine residues, which also enable 
degradation at these sites by trypsin.  Methionine residues are also incorporated at the N-
terminus in order to also utilize chymotrypsin while avoiding amino acids most 
susceptible to cleavage by pepsin.  Therefore, the crosslinker is designed to enable 
degradation at any of the seven amino acids and by either of the two primary intestinal 
enzymes. 
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The MMRRRKK peptide crosslinker was successfully incorporated into the 
hydrogel using EDC/NHS crosslinking chemistry, linking primary amines in the peptide 
to carboxylic acids present in the P(MAA-co-NVP) polymer.  Primary amines will be 
found at the N-terminus, on the arginine side chains, and on the lysine side chains, 
providing multiple locations for crosslinking.  Although this means that the length of the 
incorporated crosslink is variable, the fact that all amino acids are potential degradation 
sites ensures that degradation can occur regardless of the actual crosslinking location.  As 
such, the successfully prepared hydrogels will exhibit degradation specific to the small 
intestine. 
4.3.3 Hydrogel Characterization 
4.3.3.1 Equilibrium Swelling Studies 
The fundamental feature of our hydrogel systems is their pH-responsive behavior.  
At low pH, the carboxylic acid residues in MAA or IA are protonated, allowing hydrogen 
bonding complexation between these residues and the electronegative oxygen in NVP or 
PEG, yielding a collapsed conformation with small mesh size.  At neutral pH, the 
carboxylic acid residues are deprotonated, losing the hydrogen bonding complexation 
behavior and becoming anionically charged, thus swelling to a larger conformation with 
large mesh size due to entropic and enthalpic mixing interactions, osmotic pressure, and 
coulombic repulsion.  As a result, the protein can be imbibed into the hydrogel in neutral 
conditions, encapsulated by acidification, and released once in neutral conditions again.  
Without this environmentally-responsive behavior, the hydrogels do not yield protection 
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from proteolytic enzymes and therefore will not work for oral protein delivery.  
Furthermore, the extent to which swelling occurs is suggestive of the achievable delivery 
efficiency. 
Equilibrium weight swelling experiments were performed to determine the 
suitability of the synthesized hydrogels.  The swelling behavior of P(IA-g-EG) hydrogels 
was not measured due to low physical stability of the material at the macro-scale.  
Although the hydrogel remains crosslinked and highly stable as microparticles, the large 
bulk disks used in weight swelling studies are too prone to breaking, especially when 
swelled in neutral conditions, to be accurately measured with gravimetry.  P(MAA-g-EG) 
disks were also not studied, as their swelling behavior has been previously very well-
characterized.
30–33
 
As shown in Figure 4-2, during equilibrium swelling studies, the weight swelling 
ratio, q, defined as the swelled weight divided by the dry weight of a hydrogel disk, is 
very low for all tested formulations at low pH.  All tested formulations exhibit weight 
swelling ratios ranging from 1.3 to 2.2, indicating that the average mesh size remains 
small in the acidic conditions expected in the stomach, keeping proteins encapsulated 
inside the hydrogel and preventing proteolytic enzymes from entering and degrading the 
protein.  When swelled at neutral pH, the disks all achieve significantly greater swelling 
ratios ranging from 13.7 to 23.1, approximately one full order of magnitude greater than 
at low pH.  This result indicates that the mesh size is significantly increased in the neutral 
conditions expected in the small intestine, such that the protein may diffuse out into the 
small intestine to cross the epithelial cell layer and enter the bloodstream.  All of the 
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tested IA-based gels swelled significantly more (p < 0.01) than the MAA-based hydrogel, 
up to a 69% increase observed with the 45:45:10 P(IA-co-NVP-co-MMA) terpolymer, 
indicating the potential for the IA-based gels to encapsulate and therefore deliver greater 
amounts of the protein drug. 
4.3.3.2 Dynamic Swelling Studies 
In dynamic swelling studies, the difference in swelling behavior between IA and 
MAA-based gels is even more apparent.  Figure 4-3 shows the results of the dynamic 
swelling studies, where there are 7 minutes of swelling time between each data point.  
The IA-based gels all achieved swelling ratios ranging from 11.2 to 15.4 within the 70 
min of cumulative swelling time—on the same order of magnitude as the equilibrium 
swelling ratios.  However, the MAA-based gel exhibited nearly imperceptible swelling, 
achieving a swelling ratio of only 1.5—a full order of magnitude less than its equilibrium 
weight swelling ratio.  Because the residence time in the small intestine is limited—
approximately 4 h for both fasted and fed patients
34—it is important that the 
microparticles undergo a rapid transition from collapsed to swollen states to maximize 
the available time in which the encapsulated protein may diffuse out into the small 
intestine.  The significantly improved time-dependent swelling characteristics of the IA-
based gels compared to the MAA-based gels should therefore assist in maximizing 
protein release in the target region by maximizing the time available for diffusive release 
of the drug. 
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4.3.3.3 Mesh Size Calculations 
The mesh size of a hydrogel used for drug delivery is an important quantity to 
determine, as it helps predict the probability of successful drug encapsulation and release.  
The mesh sizes of all disks at equilibrium conditions were determined using the Şen-
Güven model for determining the average polymer weight between crosslinks, 𝑀𝑐̅̅ ̅̅ , 
coupled with rubber elasticity theory.  Only equilibrium swelling measurements were 
used.  Although the mesh size correlates to the swelling ratio, q, the Şen-Güven and 
Brannon-Peppas models were derived using the condition of equilibrium as a basic 
assumption and are therefore only accurate when the gel has swelled to equilibrium.
19,20
 
Despite the fact that the Brannon-Peppas and Şen-Güven models have been 
present in literature for nearly two decades, these equations have not yet been widely 
used in determining the mesh size of P(MAA-g-EG) or P(MAA-co-NVP) hydrogels, with 
researchers opting to use the more pliable Peppas-Merrill equation.
14,15,17,35,36
  The 
shortcoming of this approach is that the Peppas-Merrill equation is derived specifically 
for neutral hydrogels and does not take into account the ionic contribution to the free 
energy change of swelling.  Therefore, a model that takes such ionic interactions into 
account, such as the Brannon-Peppas or Şen-Güven model, is more appropriate.  
However, the Brannon-Peppas equation does not consider the effect of monomers with 
multiple ionizing groups (e.g, diprotic or triprotic acids).  The Şen-Güven model is 
essentially a rederivation of the Brannon-Peppas equation that assumes a diprotic acid in 
calculating the degree of ionization, making it the most ideal for hydrogels based on 
itaconic acid, and uses a newer phantom network model developed by Erman
37
 rather 
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than an affine model developed by Flory in calculating the elastic contribution to the free 
energy change.  Because it takes into account ionic contributions from both acid groups, 
the Şen-Güven model was used here for calculation of average mesh size in all itaconic 
acid-containing hydrogels.  The Peppas-Merrill and Brannon-Peppas equations were also 
used with the 1:1 P(IA-co-NVP) hydrogel for comparison of the models, and the 
Brannon-Peppas model was used with the methacrylic acid gel because it is based on a 
monoprotic acid. 
A comparison of the results from the three models applied to the 1:1 P(IA-co-
NVP) hydrogel formulation is provided in Table 4-2.  The calculated mesh size and 
molecular weight between crosslinks for each gel are tabulated in Table 4-3. 
Comparing the resulting mesh sizes and molecular weights between crosslinks for 
the 1:1 gel from the three models, one sees that the models give nearly identical results 
for mesh sizes in the acidic state.  In the neutral conditions, the numbers vary widely 
from mesh sizes as high as 232 Å with the Peppas-Merrill model down to 70.6 Å with the 
Şen-Güven model.  Most notably, the Peppas-Merrill equation is the outlier, with a 
calculated mesh size approximately 3x as large as the Brannon-Peppas and Şen-Güven 
models, which are in much closer agreement.  This is an expected result, as the primary 
difference with the Peppas-Merrill equation is that it does not take into account the 
significant ionic contribution to swelling, which is not present at highly acidic conditions 
when the carboxylic acid groups on itaconic acid are all protonated.  At neutral 
conditions, these acid groups deprotonate, resulting in ionic interactions that result in 
generally increased swelling. 
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Furthermore, the much larger values of 𝑀𝑐̅̅ ̅̅  calculated at neutral conditions 
compared to acidic conditions is expected as well.  The protonation of acid groups at 
acidic conditions leads to hydrogen bonding interactions between the hydrogen-bond 
donor (the carboxylic acids) and the hydrogen bond acceptor (the electronegative oxygen 
in NVP) that act as crosslinks, even though they are not covalent.  Therefore, the 
molecular weight between crosslinks is significantly larger in neutral conditions because 
these hydrogen-bonding crosslinks are lost. 
One question arises:  why does the Peppas-Merrill equation so significantly 
overstate the mesh size compared to the other models if ionic interactions promote 
swelling?  This effect arises because we are applying the model to the data rather than 
using the model to create data.  Because the gel actually experiences significant swelling 
enhancement due to the ionic interactions that create osmotic pressure and coulombic 
repulsion that both promote swelling while the model does not account for this, it must 
assume that the improved swelling is due only to lower crosslinking density rather than 
due to ionic contributions.  Thus the model calculates a significantly higher 𝑀𝑐̅̅ ̅̅  than the 
Brannon-Peppas or Şen-Güven models, since it can only assume fewer crosslinks is the 
reason for the enhanced swelling, leading to significantly larger calculated mesh size. 
These results therefore demonstrate several salient points.  First, the ionic 
contributions to swelling are significant, leading to multi-fold differences in the 
calculated geometry of the hydrogels when taken into account.  Therefore, although all 
models are useful when applied in the proper systems, it is vital that one take into 
consideration the limitations of the models.  Using an incorrect model, such as the 
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Peppas-Merrill model for describing methacrylic acid or itaconic acid-based systems, can 
yield extreme error in the calculated mesh size which can then lead to overconfidence in 
the gel’s drug delivery capability.14,15,35  Therefore, it is important to use the most 
appropriate model.  In this case, the most appropriate model for the itaconic acid gels 
studied herein is the Şen-Güven model, which also proves to yield the most conservative 
estimate of the mesh size.  This is advantageous, as we want large mesh sizes to help 
enable better release of the protein in the small intestine, and therefore do not want to use 
a model that will overstate the function of our systems.  As a result, the Şen-Güven was 
applied to all itaconic acid gels, while the Brannon-Peppas equation was used for the 
methacrylic acid gel. 
Comparing the results of the different hydrogel formulations, one can see that the 
mesh sizes of all gels are quite small in acidic conditions, as implied by the swelling 
results and as expected.  The largest mesh size is 12.7 Å in the 1:9 P(IA-co-NVP) 
hydrogel.  Comparing this to the size of a model protein like bovine serum albumin (140 
x 40 x 40 Å prolate ellipsoid), it is apparent that a typical protein will be effectively 
encapsulated within the hydrogel since even the largest mesh size is significantly smaller 
than the size of a typical protein, thus preventing diffusion.  This also implies sufficient 
protection of encapsulated protein from pepsin, which has dimensions of 41 x 48 x 65 Å 
that are much larger than the mesh size.
38
 
At neutral conditions, the mesh sizes are all significantly larger, ranging from 
36.7 Å in the P(MAA-co-NVP) gel all the way to 280 Å in the 1:9 P(IA-co-NVP) 
formulation.  Importantly, the mesh size for all itaconic acid hydrogels was calculated to 
 66 
be significantly higher than the mesh size of the methacrylic acid gel, even with what 
proved to be the slightly more conservative model, which is a vital improvement for 
enhancing bioavailability of high pI proteins.  The mesh sizes of these itaconic acid 
gels—70.6, 99.8, and 280 Å for the 1:1 P(IA-co-NVP), P(IA-co-NVP-co-MMA), and 1:9 
P(IA-co-NVP) formulations, respectively—are sufficiently large to allow for diffusion of 
typical proteins.  However, for larger proteins such as antibodies, which have typical 
dimensions on the order of 100 Å may have difficulty diffusing through the hydrogel 
mesh.
39
 
In conclusion, these calculated mesh sizes are indicative of hydrogels that perform 
as desired.  The mesh remains small in acidic conditions, offering encapsulation and 
protection of proteins from proteolytic enzymes in the stomach, while expanding to 
dimensions sufficient for diffusion of typical proteins in neutral conditions.  While 
improvement may be needed for very large proteins, possibly by decreasing crosslinking 
density, these systems seem ideal for use with proteins like salmon calcitonin.  Finally, 
these calculations show improved hydrogel architecture with the itaconic acid gels as 
compared to the methacrylic acid hydrogel.  This improvement is most likely due to the 
additional ionic contribution that is offered by a diprotic acid monomer compared to a 
monoprotic monomer. 
4.3.3.4 Cytotoxicity Studies 
Having shown a modest improvement in pH-responsive swelling behavior and 
mesh size by utilizing IA as the pH-responsive moiety, cytotoxicity studies were 
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performed to assure that the polymers were biocompatible and safe for use.  Using Caco-
2 cells, a proven, effective model of the human small intestine,
40–42
 a cell viability study 
was performed in vitro.  After culturing cells, cells were exposed to varying microparticle 
concentrations (0.039 – 5 mg/mL) of all 7 hydrogels, and viability was measured using an 
MTS assay.  The results of this study are shown in Figure 4-4, with all cell viability 
values normalized to the positive control. 
Even at very high concentrations of 5 mg/mL, the microparticles are still well 
tolerated, achieving over 80% relative viability with nearly every formulation.  Only the 
1:9 P(IA-co-NVP) shows any indication of toxicity at concentrations of 1.25 and 5.00 
mg/mL, achieving only 59% and 74% viability at these concentrations, respectively.  
However, since 99% viability is observed at 2.50 mg/mL, the potential toxicity at 1.25 
mg/mL is likely a random artifact rather than true toxicity.  Nevertheless, no significant 
decrease in cell viability was observed with any concentration tested with the other 6 
formulations.  Therefore, the results indicate a high degree of safety with regard to 
cytotoxicity, even at high concentrations. 
4.3.3.5 Thermogravimetric Analysis 
Thermogravimetric analysis was performed on the hydrogels to assure a thermally 
stable delivery system that could withstand temperatures likely to be experienced during 
processing and transport.  The combined results of the analysis are shown in Figure 4-5.  
Results for methacrylic acid-based hydrogels only are shown in Figure 4-6, and results 
for itaconic acid-based hydrogels only are shown in Figure 4-7. 
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The degradation profiles for all polymer formulations indicate that all 
formulations are sufficiently stable that thermal degradation will not be a concern for end 
use.  A delivery system that changes properties over time is likely to experience issues 
with FDA approval and limited shelf life, but the observed degradation profiles indicate 
that this is not a concern for the developed systems.  A slight reduction in weight is 
observed in all formulations up to 100 °C representing the loss of residual water from the 
hydrogels.  However, no degradation is observed in any hydrogel below 150 °C—a 
temperature well above what will be experienced for end use. 
The methacrylic acid-containing formulations are slightly more thermally stable 
than the itaconic acid-containing hydrogels.  The first instance of degradation occurs at 
225 °C.  This corresponds to formation of methacrylic anhydrides between adjacent 
methacrylic acid units with loss of CO2, reported to occur in poly(methacrylic acid) at 
220 - 240 °C.
43,44
  The next degradation step begins at 290 °C, with maximum rate of 
decomposition at 400 °C, corresponding to full decomposition and generation of carbon 
monoxide, carbon dioxide, and various carbonyls.
43,44
 
The itaconic acid-containing formulations are less thermally stable.  
Decomposition begins as low as 150 °C in the P(IA-g-EG) formulation, with a second 
degradation step occurring as low as 190 °C in the same P(IA-g-EG) formulation.  While 
these degradation temperatures are much lower than those observed in the methacrylic 
acid-containing gels, they are still significantly above anything that would reasonably be 
achieved during hydrogel processing or transport.  Therefore, the thermogravimetric 
 69 
analysis reveals sufficient stability for the intended biological applications of these 
hydrogels. 
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Figure 4-1:  Drug concentration profiles for bolus, pulsatile, and extended release. 
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Figure 4-2:  Equilibrium Weight Swelling Results. Swelling ratios (weight of swelled 
disk / weight of dry disk) recorded following 72 h swelling in 0.01 N HCl 
(pH 2.0) or 150 mM PBS buffer (pH 7.4).  Reported as average ± standard 
deviation. 
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Figure 4-3:  Dynamic Weight Swelling Results.  Time-sensitive swelling results as disk 
transitioned between DMGA buffers in order of increasing pH.  Swelling 
time was 7 minutes between each data point.  Reported as average ± 
standard deviation. 
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Figure 4-4:  Caco-2 Cell Cytotoxicity. Relative cell viability following 2 h incubation 
with microparticles, as determined by MTA proliferation assay and 
normalized to positive control in Caco-2 cell culture.  Each bar represents 
n=5 samples, and is reported as average ± standard deviation. 
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Figure 4-5:  Thermogravimetric Analysis—Thermal Degradation Profiles for All 
Hydrogels. 
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Figure 4-6:  Thermogravimetric Analysis—Thermal Degradation Profiles for Methacrylic 
Acid-Based Hydrogels. 
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Figure 4-7:  Thermogravimetric Analysis—Thermal Degradation Profiles for Itaconic 
Acid-Based Hydrogels. 
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Table 4-1:  Hydrogel Feed Compositions. 
Hydrogel Formulation Monomer Feed Ratio Crosslinker Molar % Crosslinker 
1:1 P(IA-co-NVP) 1:1 IA:NVP TEGDMA 5 
1:2 P(IA-co-NVP) 1:2 IA:NVP TEGDMA 3 
1:9 P(IA-co-NVP) 1:9 IA:NVP TEGDMA 4 
P(IA-co-NVP-co-MMA) 45:45:10 IA:NVP:MMA PEGDMA 5 
P(IA-g-EG) 1:1 IA:PEGMMA PEGDMA 4 
P(MAA-co-NVP) 2:1 MAA:NVP TEGDMA 1 
P(MAA-g-EG) 1:1 MAA:PEGMMA TEGDMA 1 
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Table 4-2:  Mesh Size and Molecular Weight Between Crosslinks for 1:1 P(IA-co-NVP) 
Hydrogel Calculated by Three Swelling Models. 
 
Acidic, pH 2 Neutral, pH 7.4 
𝑴𝒄̅̅ ̅̅  (g/mol) 
Mesh Size, ξ 
(Å) 
𝑴𝒄̅̅ ̅̅  (g/mol) 
Mesh Size, ξ 
(Å) 
Peppas-Merrill 154 ± 22 9.69 ± 0.82 18177 ± 523 232 ± 9.9 
Brannon-Peppas 153 ± 22 9.66 ± 0.81 2652 ± 220 88.5 ± 6.1 
Şen-Güven 154 ± 18 9.72 ± 0.70 1688 ± 150 70.6 ± 5.1 
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Table 4-3:  Comparison of Calculated Mesh Sizes for Hydrogel Formulations. 
 
Acidic, pH 2 Neutral, pH 7.4 
𝑴𝒄̅̅ ̅̅  (g/mol) 
Mesh Size, ξ 
(Å) 
𝑴𝒄̅̅ ̅̅  (g/mol) 
Mesh Size, ξ 
(Å) 
1:1 P(IA-co-NVP) 154 ± 18.5 9.72 ± 0.70 1688 ± 150 70.6 ± 5.1 
1:9 P(IA-co-NVP) 175 ± 3.3 12.7 ± 0.13 
20661 ± 
1040 
280 ± 9.1 
P(IA-co-NVP-co-
MMA) 
133 ± 2.4 8.94 ± 0.10 2985 ± 138 99.8 ± 2.4 
P(MAA-co-NVP) 16.6 ± 2.8 3.68 ± 0.35 310 ± 16.6 36.7 ± 1.36 
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Chapter 5:  Evaluation and Optimization of Hydrogel Drug 
Delivery Vehicles 
5.1 INTRODUCTION 
After successful synthesis and characterization of the hydrogel systems, beneficial 
changes in the hydrogel response were observed in terms of mesh size, equilibrium 
swelling ratio, and speed of swelling response, as well as strong evidence of 
biocompatibility of the materials.  However, the enhanced material properties may not 
necessarily translate into improvements in drug delivery capability or final 
bioavailability. 
The problems observed with delivery of high isoelectric point exhibiting 
therapeutic proteins to the small intestine using previous P(MAA-g-EG) or P(MAA-co-
NVP) systems arise primarily from charge interactions between the anionic carriers and 
the cationic proteins in the neutral conditions of the small intestine.  Unfortunately, the 
anionic character of the hydrogels cannot be removed without adversely affecting the 
direction of the pH-responsive swelling profile, so we must therefore mitigate these 
adverse effects through charge localization and increased swelling.  Therefore, the 
actions taken to improve material properties rely on a delicate balance of increasing 
charge while increasing distance from the charges in the expectation that the benefits will 
outweigh the limitations.  In this chapter, the in vitro experiments used to test the protein 
delivery capabilities of the modified hydrogel systems are discussed, as well as various 
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studies to elucidate the possible improvements in protein delivery available from 
mechanical and procedural changes. 
Multiple factors that could affect the delivery of proteins theoretically are 
explored in this chapter.  The monomers used in making a polymer are the primary 
determinants of the resulting behavior of the system, and should therefore have a large 
impact on drug delivery capability.  For example, previous work has shown that the 
electronegativity of the lactam oxygen in N-vinylpyrrolidone yields stronger 
complexation behavior with methacrylic acid, allowing for wider shifts in swelling ratio, 
and imparts some mucoadhesive capability.
1–5
  Although the monomers used in this work 
are functionally and structurally similar to those used in previous systems of P(MAA-g-
EG) or P(MAA-co-NVP), as shown in Chapter 4, even a small change in the structure of 
the monomers (IA instead of MAA) or the ratio of monomers had a profound effect on 
swelling behavior—both in terms of magnitude and kinetic rate.  The improved swelling 
dynamics shown in Chapter 4 should result in preferable delivery of high isoelectric 
point-exhibiting proteins due to both increased mesh size and more time available for 
diffusional release.  Thus, the effect of monomers and monomer ratios on in vitro 
delivery is explored. 
Another variable explored is the size of the microparticles used.  With the primary 
mechanism of release in these systems being diffusion through the hydrogel mesh after 
swelling, the diffusional distance the protein must travel through the hydrogel determines 
the time needed for release.  Because the residence time in the small intestine is typically 
only 4 h,
6
 a rapid release must be attained.  Reducing the size of the particle may 
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therefore benefit the delivery potential of the system by reducing the average diffusional 
distance to the exterior of the particle.  However, due to the complications presented by 
coulombic interaction between the drug and the delivery vehicle, an improvement in 
delivery resulting from reduced particle size may not manifest itself at the micrometer 
length scale.  Therefore, an experiment to test the effect of microparticle size on protein 
delivery is presented here. 
Another structural characteristic of the hydrogels that could potentially be used 
for tailoring drug delivery is the crosslinking density.  Qualitatively, with higher 
crosslinking density, the hydrogel mesh size decreases due to a greater number of tie 
points between polymer chains that inhibit entropic swelling.  Although large mesh size 
is desirable in the small intestine to maximize protein release, it is not ideal in the 
stomach, where proteins must be protected from proteolytic enzymes.  Furthermore, the 
mesh size affects diffusive release relative to the size of the protein.  Large proteins may 
require very low crosslinking density for sufficient mesh size to diffuse through, whereas 
very small proteins may benefit from high crosslinking density to promote encapsulation 
through the stomach.  As a result, the crosslinking density that works best for one protein 
may not work well for a different protein.  However, crosslinking density provides a 
facile potential method for tuning the physical properties of the hydrogel to enable 
delivery of different proteins.  Experiments testing the effect of crosslinking ratio and 
protein size are presented in this chapter seeking to determine if protein size is a potential 
limiting factor and if so, to determine if crosslinking density provides a control knob for 
tuning the vehicle to a particular protein. 
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5.2 MATERIALS AND METHODS 
5.2.1 Effect of Hydrogel Formulation on Protein Delivery 
A solution of salmon calcitonin (sCT) (Selleck Chemicals, Houston, TX) was 
prepared at a concentration of 0.40 mg/mL in 0.0150 M PBS buffer (pH 7.4), and 1.5 mL 
of this solution was added to each of 21 (n=3 per hydrogel formulation), 2.0 mL, low-
adhesion microcentrifuge tubes.  Microparticles 90-150 μm in size were added to this 
solution at 10 mg of dry hydrogel per tube.  The mixture was agitated for 1 h using an 
Eppendorf Thermomixer (Eppendorf, Hauppauge, NY), allowing the microparticles to 
swell and sCT to diffuse into the interior of the particles.  The particles were collapsed 
using 75 μL of 0.1 N HCl and isolated by centrifugation and decanting.  The supernatant 
was collected for analysis.  The particles were resuspended in two subsequent washes 
consisting of 1.0 mL of 0.01 N HCl to remove surface-bound protein.  After each wash, 
the particles were isolated by centrifugation and decanting, and the rinse was collected 
for analysis.  The isolated microparticles with encapsulated sCT were lyophilized until 
dry.  Samples of the stock solution, the supernatant following particle collapse, and the 
two acid rinses were analyzed by a Micro BCA protein concentration assay (Thermo 
Fisher Scientific, Rockford, IL). 
Once the microparticles were dry from lyophilization, 1.0 mL of 0.150 M PBS 
buffer at a pH of 3.0 (from adding HCl) was added to each microcentrifuge tube and 
agitated for 1 h at 37 °C.  A 150 μL sample was removed for analysis and replaced with 
150 μL fresh, pH 3.0 PBS before raising the pH back to 7.4 by addition of 1 N NaOH.  
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The neutralized mixture was agitated for 24 h at 37 °C, with 150 μL samples collected at 
time points of 1, 2, 4, and 24 h, each time being replaced by 150 μL fresh PBS (pH 7.4).  
All samples were analyzed for sCT concentration using a Micro BCA protein 
concentration assay. 
5.2.2 Effect of Ionic Strength on Protein Delivery 
Three separate trials were undertaken to examine the effects of changing the ionic 
strength of the loading solution on salmon calcitonin delivery.  In the first trial, three 
different concentrations of PBS buffer at pH 7.4 were used:  1.5 M (10x concentrated 
PBS), 150 mM (1x standard PBS), and 15 mM (0.1x concentrated PBS).  In these 
solutions, salmon calcitonin was dissolved at a concentration of 0.1 mg/mL.  Using 40 
mL of each solution, 100 mg of purified 1:1 P(IA-co-NVP) microparticles, sieved to 90-
150 μm in size, were added to each solution and mixed for 1 h.  Particles were collapsed 
by addition of 1 N HCl to reduce pH to 2.0, isolated by decanting, and lyophilized.  
Samples of the stock solutions and post-collapse supernatant were analyzed for sCT 
concentration using high performance liquid chromatography to determine sCT loading 
levels.  After lyophilization, 30 mg of each sample were added to 30 mL of 150 mM (1x), 
pH 3.0 PBS buffer and stirred for 1 h at a temperature of 37.0 °C using a Distek 
dissolution apparatus (Distek, North Brunswick, NJ).  After 1 h, a 500 μL sample was 
taken for analysis and replaced with fresh, pH 3.0 PBS.  The pH was then raised to pH 
7.4 by addition of 1 N NaOH.  Samples were collected at time points of 45, 75, and 120 
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minutes following neutralization.  Salmon calcitonin concentration in all samples was 
determined by a Micro BCA protein assay. 
In the second trial, another sCT solution in 1.5 mM PBS (0.01x) was added for 
study.  The four solutions (0.01x, 0.1x, 1x, and 10x PBS) were prepared, and salmon 
calcitonin was dissolved in 7 mL of each solution at a concentration of 250 μg/mL.  To 
each of these solutions, 10 mg of purified 1:1 P(IA-co-NVP) microparticles were added 
and allowed to imbibe sCT for 1 h while agitated.  The particles were then collapsed by 
addition of 1 N HCl to reduce pH to 2.0 and were collected by centrifugation and 
decanting.  Samples from the stock solutions and supernatant were analyzed for sCT 
concentration by HPLC.  The collected particles were dried by lyophilization.  Following 
drying, the microparticle samples were added to 2.0 mL microcentrifuge tubes containing 
1.75 mL of 150 mM (1x), pH 3.0 PBS buffer and agitated at 37 °C using an Eppendorf 
Thermomixer.  After 1 h, 150 μL samples of the solutions were collected for analysis and 
replaced with fresh PBS (pH 3.0).  The solutions were then neutralized by addition of 0.2 
N NaOH to a pH of 7.4.  Release at neutral conditions was carried out for 2 h, with 
samples acquired at time points of 1 and 2 h.  All samples were analyzed for sCT 
concentration using a Micro BCA protein concentration assay. 
In the third trial, the same four solutions were used as in the second trial.  
Calcitonin was dissolved in 30 mL of each solution at a concentration of 0.20 mg/mL.  
To each solution, 100 mg of 1:1 P(IA-co-NVP) microparticles were added, and the pH 
was maintained at 7.0 by addition of NaOH.  The solutions were mixed for 18 h at room 
temperature to allow for drug loading prior to collapse by acidification to pH 2.5 with 
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HCl.  The particles were isolated by decanting, washed twice with 1 mL 0.01 N HCl, and 
lyophilized.  Following drying, 20 mg of each of the dried, drug-loaded microparticle 
samples were added to 40 mL of pH 3, 0.150 M PBS buffer (acidified with HCl) and 
stirred for 1 h in a Distek dissolution apparatus at 37 °C.  The solutions were then 
neutralized to pH 7.4 by addition of NaOH and stirred for 2 h.  Samples were acquired at 
time points of 1 h during acidic conditions, 1h following neutralization, and 2 h following 
neutralization.  The samples were analyzed for sCT concentration by a Micro BCA 
protein concentration assay. 
5.2.3 Effect of Particle Size on Protein Delivery 
A solution of salmon calcitonin (sCT) (Selleck Chemicals, Houston, TX) was 
prepared at a concentration of 0.40 mg/mL in 0.00150 M PBS buffer (pH 7.4), and 1.5 
mL of this solution was added to each of 15 x 2.0 mL, low-adhesion microcentrifuge 
tubes.  Microparticles of the 1:2 P(IA-co-NVP) formulation were added to this solution at 
10 mg of dry hydrogel per tube, with particles sieved into size ranges of 45-75 μm, 75-90 
μm, and 90-150 μm (n = 5 per size range).  The mixture was agitated for 24 h using an 
Eppendorf Thermomixer, allowing the microparticles to swell to equilibrium and sCT to 
diffuse into the interior of the particles.  The particles were collapsed using 25 μL of 1 N 
HCl and isolated by centrifugation and decanting.  The supernatant was collected for 
analysis.  The particles were resuspended in two subsequent washes consisting of 1.0 mL 
of 0.01 N HCl to remove surface-bound protein.  After each wash, the particles were 
isolated by centrifugation and decanting, and the rinse was collected for analysis.  The 
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isolated microparticles with encapsulated sCT were lyophilized until dry.  Samples of the 
stock solution, the supernatant following particle collapse, and the two acid rinses were 
analyzed by a Micro BCA protein concentration assay (Thermo Fisher Scientific, 
Rockford, IL). 
Once the microparticles were dry from lyophilization, 1.5 mL of 0.150 M PBS 
buffer at pH 3 (from adding HCl) was added to each microcentrifuge tube and agitated 
for 1 h at 37 °C.  A 150 μL sample was removed for analysis and replaced with 150 μL 
fresh, pH 3.0 PBS before raising the pH back to 7.4 by addition of 1 N NaOH.  The 
neutralized mixture was agitated for 4 h at 37 °C.  A 250 μL sample was collected after 4 
h to test end point release.  All samples were analyzed for sCT concentration using a 
Micro BCA protein concentration assay. 
5.2.4 Effect of Crosslinking Density on Protein Delivery 
A solution of salmon calcitonin (sCT) (Selleck Chemicals, Houston, TX) was 
prepared at a concentration of 0.20 mg/mL in 0.00150 M PBS buffer (pH 7.4), and 1.0 
mL of this solution was added to each of 12 x 2.0 mL, low-adhesion microcentrifuge 
tubes.  Microparticles of three hydrogels were added to this solution at 5 mg of dry 
hydrogel per tube.  All hydrogels were 1:2 IA:NVP monomer molar ratio P(IA-co-NVP) 
hydrogels prepared as described in Chapter 2, crushed and sieved into 90-150 μm 
microparticles, with varying crosslinker mole percent in the monomer feed:  1%, 5%, and 
10% TEGDMA crosslinking (n = 4 per formulation).  The mixture was agitated for 24 h 
using an Eppendorf Thermomixer, allowing the microparticles to swell to equilibrium 
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and sCT to diffuse into the interior of the particles.  The particles were collapsed using 1 
N HCl to reduce pH to 2.0 and isolated by centrifugation and decanting.  The supernatant 
was collected for protein quantification.  The particles were resuspended in two 
subsequent washes consisting of 1.0 mL of 0.01 N HCl to remove surface-bound protein.  
After each wash, the particles were isolated by centrifugation and decanting, and the rinse 
was collected for analysis.  The isolated microparticles with encapsulated sCT were dried 
overnight in air.  Samples of the stock solution, the supernatant following particle 
collapse, and the two acid rinses were analyzed by a Micro BCA protein concentration 
assay (Thermo Fisher Scientific, Rockford, IL). 
Once the microparticles were dry, 1.0 mL of 0.150 M PBS buffer at pH 3 (from 
adding HCl) was added to each microcentrifuge tube and agitated for 1 h at 37 °C.  A 150 
μL sample was removed for analysis and replaced with 150 μL fresh, pH 3.0 PBS before 
raising the pH back to 7.4 by addition of 1 N NaOH.  The neutralized mixture was 
agitated for 24 h at 37 °C, with 150 μL samples collected at time points of 1, 2, 4, and 24 
h, each time being replaced by 150 μL fresh PBS (pH 7.4).  All samples were analyzed 
for sCT concentration using a Micro BCA protein concentration assay. 
5.2.5 Loading and Release of Larger Proteins 
A protocol identical to that presented in section 5.2.4 was used, with a 0.40 
mg/mL solution of Rituxan (rituximab) substituted for the 0.20 mg/mL sCT.  Rituxan 
was generously provided for our research by Genentech.  The same 1%, 5%, and 10% 
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TEGDMA crosslinked, 1:2 P(IA-co-NVP) microparticles were used in identical loading 
and release conditions.  Protein samples were quantified using a MicroBCA assay. 
Additionally, a second experiment was performed using salmon calcitonin, 
urokinase, and rituximab as high pI proteins.  Solutions of the three proteins were 
prepared at 200 μg protein/mL concentration in 1.5 mM PBS (0.01x).  In 15 x 2.0 mL 
low adhesion tubes, 5 mg of 1:2 P(IA-co-NVP) hydrogel microparticles (90-150 μm in 
size) was added to each tube and incubated with 1.5 mL of protein solution (n = 5 per 
protein) for 24 h at pH 7.4.  The solutions were collapsed using 1 N HCl to reduce the pH 
to 2, isolated by centrifugation and decanting, washed two times with 0.5 mL of 0.01 N 
HCl, and lyophilized.  Following drying, 1.0 mL of 150 mM PBS (1x) at pH 3 was added 
to each tube and incubated at 37 °C for 1 h.  A 150 μL sample was taken and replaced 
with pH 3 PBS, and the solutions were then raised to pH 7.4 using 1 N NaOH.  The 
solutions were stirred at 37 °C for 24 h, with 150 μL samples acquired and replaced with 
fresh PBS at time points of 1, 2, 4, and 24 h.  All loading and release samples were 
analyzed for protein concentration using a MicroBCA assay. 
5.2.6 Degradable Hydrogel Loading and Release 
In a study with salmon calcitonin, 10 mg of purified, degradable P(MAA-co-
NVP) microparticles crosslinked with MMRRRKK and sieved to 90-150 μm in size were 
added to 1.5 mL of a 400 μg/mL solution of salmon calcitonin (Selleck Chemicals) in 
1.50 mM PBS buffer at pH 7.4 (n = 3).  The mixture was agitated for 24 h using an 
Eppendorf Thermomixer, allowing the microparticles to swell to equilibrium and sCT to 
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diffuse into the interior of the particles.  The particles were collapsed using 25 μL of 1 N 
HCl and isolated by centrifugation and decanting.  The supernatant was collected for 
analysis.  The particles were resuspended in two subsequent washes consisting of 1.0 mL 
of 0.01 N HCl to remove surface-bound protein.  After each wash, the particles were 
isolated by centrifugation and decanting, and the rinse was collected for analysis.  The 
isolated microparticles with encapsulated sCT were lyophilized until dry.  Samples of the 
stock solution, the supernatant following particle collapse, and the two acid rinses were 
analyzed for sCT concentration using high performance liquid chromatography. 
Once the microparticles were dry from lyophilization, 1.5 mL of USP-standard 
simulated gastric fluid (containing 3.2 mg/mL pepsin) at pH 1.2 was added to each 
microcentrifuge tube and agitated for 1 h at 37 °C.  The particles were isolated by 
centrifugation, and the simulated gastric fluid supernatant was removed.  The 
microparticles were resuspended in 1.5 mL of USP-standard simulated intestinal fluid 
(containing 10 mg/mL pancreatin) at pH 6.8 and agitated for 4 h at 37 °C.  250 μL 
samples were collected at times of 1 h, 4 h, and 48 h after adding simulated intestinal 
fluid and subsequently replaced with fresh simulated intestinal fluid. All samples were 
analyzed for sCT concentration using high performance liquid chromatography. 
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5.3 RESULTS AND DISCUSSION 
5.3.1 Effect of Hydrogel Formulation on Protein Delivery 
The ultimate goal of this work is to develop a system enabling oral delivery of 
high isoelectric point-exhibiting proteins with high bioavailability.  The swelling and 
cytotoxicity studies show that the developed systems exhibit the proper behavior and are 
biocompatible for use with human cells, but a direct test of delivery capability with high 
isoelectric point-exhibiting therapeutic proteins was needed.  For this test, salmon 
calcitonin was encapsulated in microparticles of the 7 hydrogel formulations by 
imbibition and subsequently released by diffusion out of the polymer matrix following 
swelling in neutral conditions.  The observed delivery potential for sCT (mg of sCT 
released at a certain time per mg of hydrogel used) for each of the hydrogel formulations 
is shown in Figure 5-1 and tabulated in Table 5-1. 
The ideal behavior would be to have zero protein release at the 1 h time point, 
which is taken at the end of the acidic portion of the release, meaning no protein is lost 
due to premature release in the stomach, and to have very high delivery potential at the 4 
h time point that is of similar magnitude as the 24 h time point, indicating fast and 
complete release in a timeframe and pH similar to what would be observed in the small 
intestine.  None of the systems studied exhibited such ideal behavior, as all tested systems 
released a fraction of encapsulated sCT in acidic conditions; however, subtracting the 
amount of sCT released at 1 h from that released at 4 h provides a good indication of 
which formulation best approximates ideal behavior.  The best candidate is the 1:2 
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formulation of P(IA-co-NVP), which released 12.4 μg sCT/mg hydrogel after 3 h in 
neutral conditions—2.7 times more than the previously studied P(MAA-g-EG) hydrogel, 
and 16.8 times more than the previously studied P(MAA-co-NVP) hydrogel.  Although 
6.26 μg sCT/mg hydrogel were released in stomach conditions, the remaining 6.15 μg 
sCT/mg hydrogel delivered in subsequent small intestinal conditions far exceed the 1.7 
μg sCT/mg hydrogel that the P(MAA-g-EG) hydrogel delivered in the same conditions. 
The large, significant (p < 0.01) increase in delivery potential observed with the 
1:2 molar ratio of IA to NVP compared to the other formulations shows that the 1:2 ratio 
of monomer reactants optimizes swelling and binding behavior to best accommodate oral 
delivery of sCT, likely due to the localization of anions through the hydrogel.   
The anionic groups in the polymer backbone are useful in achieving high drug 
loading by taking advantage of the same coulombic interactions that are best avoided 
during release and by improving hydrogel swelling via anionic repulsion for greater 
loading and release.  The important distinction between IA and MAA is that IA has two 
potential anions (–COO-) present per molecule while MAA possesses only one.  
Therefore, by having 1 in 3 monomer subunits ionizable (IA) in the 1:2 P(IA-co-NVP) 
hydrogel versus 2 in 3 ionizable subunits (MAA) in the 2:1 P(MAA-co-NVP) hydrogel, 
the overall number of anions will be identical between the two gels, yielding identical 
levels of osmotic pressure and hydrogen bond crosslinking to drive swelling.  However, 
with IA, the 2 anions are localized on a single subunit rather than spread out among 2 
different monomers, which results in a greater average distance between anionic regions 
for the sCT to diffuse through during release.  Coulombic forces decrease by the square 
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of the distance between ions while only increasing linearly with charge; therefore, any 
significant increase in distance of approach during diffusion will have a significant effect 
in assisting diffusive release, even if it comes at the cost of having additional ions. 
Therefore, the localization of anions to a single monomer is likely to be a 
contributing factor in the improved delivery potential observed with the 1:2 P(IA-co-
NVP) hydrogel formulation.  Coupled with faster and greater overall swelling response, 
which further increase the average approach distance and maximize time available for 
diffusive release, the 1:2 molar ratio experimentally proves to best take advantage of 
these multiple factors to achieve improved delivery potential. 
5.3.2 Effect of Ionic Strength on Protein Delivery 
In addition to using different materials based on IA instead of MAA, there may be 
delivery improvements available from a procedural standpoint without requiring all new 
materials.  Unfortunately, the release environment is set entirely by the small intestine 
and is not easily or safely alterable.  Therefore, only variables involved in the loading are 
easily utilized for improving bioavailability of high isoelectric point-exhibiting proteins.   
One of the ideal variables available for study is the ionic strength of the loading 
solution.  The ionic strength can affect the loading of the drug into the hydrogel in two 
ways.  First, ionic strength strongly affects the swelling behavior of the pH-responsive 
hydrogel as described by Brannon-Peppas and Peppas,
7,8
 with higher ionic strength 
resulting in decreased swelling and lower ionic strength resulting in increased swelling, 
since more medium must be imbibed to equilibrate the osmotic pressure of the hydrogel-
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generated ions if the medium has low ion concentration.  Therefore, by reducing the ionic 
strength of the loading solution, the hydrogel will swell to a greater degree, allowing it to 
imbibe a greater amount of the protein.  With more drug loaded, the driving force for 
diffusive release is increased, resulting in greater delivery capability.   
Second, the ionic strength affects the degree to which coulombic interactions take 
place, as described by the Debye length.  The Debye length is the effective distance over 
which an ion’s charge is offset by the charges of ions present in the surrounding medium.  
The Debye length can be calculated using Equation 5-1, 
𝜆𝐷 = √
𝜀𝑘𝐵𝑇
2𝑁𝐴𝑒2𝐼
∝ √
1
𝐼
 Equation 5-1 
 
where I is the ionic strength (mol/m
3), ε is the permittivity of the medium, kB is the 
Boltzmann constant, T is the absolute temperature, NA is Avogadro’s number, and e is the 
elementary charge.  The important relationship is that the Debye length is inversely 
proportional to the square root of the ionic strength.  Therefore, by decreasing the ionic 
strength of the loading solution, in addition to increasing swelling, the distance over 
which ionic interactions are expected to occur increases, meaning there is a greater 
likelihood of coulombic binding.  Although we hope to avoid such interactions during 
drug release, they can be used beneficially during loading by encouraging binding to the 
interior of the microparticles, further increasing the driving force for diffusive release. 
To test the hypothesis that reducing the ionic strength of the loading solution may 
be beneficial for high pI protein delivery, an experiment involving loading and releasing 
 98 
sCT in four loading solutions of different ionic strength was performed in three different 
trials.  The results are shown below in Figures 5-2 through 5-4 and Tables 5-2 through 5-
4. 
In Trial 1 (Figure 5-2, Table 5-2), it is observed that lower ionic strength loading 
solution (0.1x PBS) results in an overall improvement in delivery potential compared to 
the previously used standard (1x) PBS solution.  The loading level is 54% lower in the 
0.1x PBS buffer compared to the 1x PBS buffer, contrary to expectations, but the percent 
release is 164% greater, yielding 20% greater overall delivery potential.  This result is 
preferable, because it means that less hydrogel is required to deliver a therapeutic dose of 
drug and that less of the drug is being wasted by remaining in the hydrogel—both of 
which are benefits that will help decrease cost of an oral drug formulation. 
In Trial 2 (Figure 5-3, Table 5-3), the experiment was extended to include an even 
lower ionic strength loading solution (0.01x PBS).  The results show that the further 
reduction provides even greater benefits to the delivery potential.  Within three hours of 
release (2 h at neutral pH), the 0.01x-PBS-loaded sample delivered 48.4 μg sCT/mg 
hydrogel, compared to the 0.1x-PBS-loaded sample delivering 16.1 μg sCT/mg (a 3.0-
fold improvement) and the 1x-PBS-loaded sample delivering only 0.6 μg sCT/mg (an 83-
fold improvement).  Percent release also increased with decreasing ionic strength in the 
loading solution.  Again, lower ionic strength loading solutions yielded greater percent 
release and greater overall delivery, which results in a smaller pill for the user at cheaper 
cost due to less wasted drug. 
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Finally, in Trial 3 (Figure 5-4, Table 5-4), similar, but less pronounced behavior is 
observed.  The 0.01x-PBS-loaded sample releases 6.18 mg sCT/mg hydrogel within 2 h 
at neutral pH, compared to the 0.1x-PBS-loaded sample delivering 4.67 μg sCT/mg (a 
1.3-fold improvement) and the 1x-PBS-loaded sample delivering only 2.23 μg sCT/mg (a 
2.8-fold improvement).  Additionally, the percent release increases with decreasing ionic 
strength of the loading solution.  Once again, this data collectively shows that a small 
procedural change using a reduced ionic strength loading solution yields a cheaper, better 
delivery system that requires less hydrogel and wastes less of the drug. 
Unfortunately the degree of improvement achieved by utilizing a lower ionic 
strength loading solution was not consistent across all three trials, ranging from a 2.8-fold 
improvement to an 83-fold improvement by moving to the 0.01x PBS loading solution 
from the 1x.  However, the general trend is consistent across all three trials:  that a 
reduced ionic strength loading solution yields higher delivery potential and a higher 
percentage of encapsulated drug being released, which holds true from the 0.01x solution 
to the 10x solution.  Of course, this trend is only necessarily true for salmon calcitonin as 
tested here, not other proteins with different sizes and shapes.  Nevertheless, given the 
core principles behind the improvement (altering swelling and coulombic binding 
properties), the trend is expected to extend to all high isoelectric point-exhibiting 
proteins. 
The variation in improvement between trials is likely an artifact of using different 
protein concentrations and particle/protein ratios in the loading solutions, which as shown 
in section 5.3.5, strongly affects final delivery potential.  Therefore, the differences 
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between trials are indicative of systemic differences rather than invalidity of the results.  
Inability to easily control the loading pH at the scales used could also lead to some of the 
variation in the final results.  However, this is merely an issue at the laboratory scales 
used here, as pH control becomes significantly easier with larger quantities of solution. 
Although not tested here, using a lower ionic strength loading solution may yield 
improvement for low isoelectric point-exhibiting proteins as well.  Although the Debye 
length changes are unfavorable (encouraging repulsion from the microparticles rather 
than binding for loading), the improvement in swelling may be more beneficial than the 
slight increase in ionic repulsion will be detrimental, yielding improved delivery 
capability. 
5.3.3 Effect of Particle Size on Protein Delivery 
The mechanism for release of the therapeutic proteins from the hydrogel 
microparticles is based on diffusion through the hydrogel network, so it is reasonable to 
assume that length scales will be an important factor in drug delivery capability.  During 
release, the protein must overcome charge interactions by diffusion or osmotic pressure.  
The further the drug must travel by diffusion through the hydrogel mesh to the exterior of 
the particle, the more likely it is to encounter strong ionic interactions that overwhelm the 
diffusional “force” and prevent its release.  Likewise, the average time scale required for 
ordinary diffusion at a given distance scales as 
𝑡 ∝  
𝑙2
𝐷
 Equation 5-2 
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where l is the diffusional distance [m] and D is the diffusional coefficient [m
2
/s].  As a 
result, even in the case where coulombic interactions are not present and therefore do not 
impede release, a longer diffusional distance will require significantly more time, scaling 
by the square of the distance.  For example, if encapsulated proteins are distributed 
uniformly through a particle, those proteins near the center of a 50 μm particle would be 
expected to take 4 times as long to escape as those near the center of a 100 μm particle.  
Because there is a limited time frame available for release in the small intestine 
(approximately 4 h total through the duodenum, jejunum, and ileum
6
), the diffusional 
time is limited, and particles too large in size will waste encapsulated protein due to 
incomplete release of protein within the biologically-imposed time constraints.  
Therefore, it is logical to hypothesize that using smaller particles, thus increasing the 
surface area to volume ratio and decreasing diffusional distance, will significantly 
enhance protein delivery capabilities. 
To study the effect of decreased particle size on oral protein delivery, 
microparticles of the 1:2 P(IA-co-NVP) formulation (the best-performing formulation 
from the study in section 5.3.1) were crushed and sieved into size ranges of 45-75 μm, 
75-90 μm, and 90-150 μm and used in a loading and release experiment using salmon 
calcitonin as the model high pI drug.  The results of this experiment are shown in Figure 
5-5. 
The results do not show any statistically significant difference in the final delivery 
potential of the differently-sized hydrogel samples (p > 0.23 for all pair-wise 
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comparisons), either in acidic conditions or neutral conditions.  In terms of loading levels, 
the 90-150 μm size range loaded the most amount of protein (29.0 μg sCT/mg hydrogel), 
significantly more than the 45-75 μm size range (p = 0.03) but not significantly more than 
the 75-90 μm size range, which is to be expected given the juxtaposed size boundaries.  
Thus, although there was no statistically significant difference in overall delivery levels 
on a per mass basis, the 45-75 μm size range exhibited a statistically significant increase 
in percent release (29.3%) of encapsulated protein compared to the 90-150 μm size range 
(22.3%). 
The improved percent release does support the previous hypothesis that smaller 
particles could improve drug delivery, but the degree of improvement at this length scale 
is small.  Nevertheless, the improved percent release is beneficial in that less protein is 
lost due to not releasing in the small intestine.  Protein not loaded can be recovered and 
recycled for loading into other particles, but protein that is not released is forever lost, so 
percent release is important from the perspective of reducing cost of such a delivery 
system.  Therefore, from a cost perspective, these results indicate moderate benefit to 
using smaller size microparticles. 
That the overall release levels per mass of hydrogel are so similar is more difficult 
to explain.  Presumably, the percent release is an accurate verification of the hypothesis 
that smaller particles improve delivery due to smaller diffusional distance and increased 
surface area to volume.  However, the larger size range seems to make up for the lower 
percent release by having a higher loading level.  This result is most likely due to the 
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washing steps employed during loading to minimize the burst release of surface-bound 
protein.  A uniform weight of hydrogel particles is used across the different size ranges, 
meaning equal volume of hydrogel, since all particles are from the same formulation and 
therefore should have uniform density.  As a result, the particles will load approximately 
the same amount of protein on a per mass basis if protein loads uniformly through the 
particles.  However, the smaller particles will have a larger cumulative surface area than 
the larger particles, meaning more of the volume is made up of surface or near surface 
level binding sites.  When the wash steps occur, therefore, a larger proportion of the 
protein is washed away, making the overall loading appear to be lower than with larger 
particles. 
 Therefore, the results of this experiment suggest that there is some benefit 
associated with use of smaller particles, although it may be limited to higher percent 
release rather than higher delivery per mass of hydrogel.  This further shows that the 
protein release is limited by the diffusional time expected in the small intestine, so 
experiments that seek to increase the residence time of the particles in the small intestine, 
such as those by Wood et al.
9,10
 or Schoener et al.,
11–13
 can potentially improve the 
delivery system at the microparticle scale.  However, even though the improvement in 
percent release is statistically significant, it is still not a large increase in efficiency.  
Large improvement may not be observed from reducing the size of the particles without 
using nano-scale particles, which require more complicated synthesis procedures.  
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5.3.4 Effect of Crosslinking Density on Protein Delivery 
Another factor that could have a significant effect on the protein delivery 
capability of the hydrogel systems is the crosslinking density.  Crosslinking density 
determines the value of 𝑀𝑐̅̅ ̅̅ , the average molecular weight between crosslinks which, as 
described by the swelling models in Chapter 4 and shown graphically in Figure 5-6,
8
 
directly affects the swelling of the hydrogel.  Lower crosslinking density will lead to 
larger 𝑀𝑐̅̅ ̅̅ , which in turn leads to larger swelling ratios and larger mesh sizes.  This effect 
can be highly beneficial in enabling the delivery of macromolecules and should grant the 
ability to tailor mesh sizes for delivery of differently sized molecules.  For example, a 
small protein like salmon calcitonin (3.4 kDa) may benefit from high crosslinking density 
to prevent diffusion out of the mesh at low pH, whereas much larger monoclonal 
antibodies like rituximab (144 kDa) may need low crosslinking density to achieve 
sufficiently large mesh size for diffusion in and out of the hydrogel. 
To test the effect of crosslinking density on protein delivery capability, a standard 
loading and release experiment was conducted using salmon calcitonin and Rituxan as 
test proteins loaded into 90-150 μm microparticles of 1:2 P(IA-co-NVP) using 1%, 5%, 
or 10% TEGDMA crosslinker.  As expected, the hydrogels with higher crosslinking 
density exhibited qualitatively greater mechanical toughness; the 10% crosslinked gel 
was easily formed as a film and remained as a film throughout all wash steps, while the 
5% broke after multiple water changes, and the 1% formulation rapidly broke into pieces 
sufficiently small to necessitate the use of a sieve during washes after hydration, even 
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with minimal shear stress.  This implies successful incorporation of higher crosslinking 
densities in the gels as expected. 
The results of the salmon calcitonin loading and release are shown in Table 5-5 
and Figure 5-7.  As shown by the release profiles, the 5% crosslinked formulation 
achieves the highest total release of sCT within 4 h at neutral conditions, while releasing 
no more than the 10% formulation in the 1 h at acidic conditions.  The 1% formulation, 
although achieving similar loading level as the 10% formulation, did not release as much 
sCT at either acidic conditions or in neutral conditions.  This may seem counterintuitive 
that a hydrogel with less crosslinker would release a lower percentage of its payload than 
more crosslinked hydrogels.  However, lower crosslinking density also equates to higher 
concentrations of anions per unit of polymer backbone, yielding more binding sites for 
coulombic interactions.  Thus, this implies that for a small, high pI protein like sCT, the 
release is determined by an interplay of mesh size and coulombic interactions, with the 
optimal crosslinking density appearing to be around 5% (somewhere between 1 and 
10%). 
5.3.5 Loading and Release of Larger Proteins 
The results of the Rituxan loading and release experiment with different 
crosslinking densities are shown in Figure 5-8 and Table 5-6.  Interestingly, despite the 
much larger size of Rituxan (144 kDa), the release levels and percent release seen in this 
experiment are higher than were observed with salmon calcitonin.  This result is due to 
higher loading levels (56-64 μg/mg hydrogel) that result primarily from the higher 
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protein loading concentration used (400 μg/mL rather than 200 μg/mL), although other 
possible contributors could be greater coulombic interactions with the carriers, reduced 
penetration of the protein into the carriers (due to the size), or minor shifts in the pH 
during the loading step.  Further experimentation with confocal microscopy or simply 
altering the loading pH could potentially elucidate the mechanisms for this result. 
What this experiment clearly demonstrates, however, is the greatly enhanced 
delivery resulting from use of the 1% crosslinked hydrogels as compared to the 5% or 
10% formulations.  Although all profiles are nearly ideal in terms of limited release at the 
1 h, acidic time point and enhanced release over a physiological time at neutral 
conditions, the release level observed by the 1% crosslinked formulation significantly 
exceeds that of the 5% and 10% formulations (p = 0.0004).  Meanwhile, the 5% and 10% 
crosslinked formulations are not significantly different at any time point (p > 0.35).  
Unlike with the much smaller sCT, the release seems to be very strongly affected by the 
crosslinking density with the much larger rituximab protein.  This further demonstrates 
that the release is determined by a competing combination of mesh size and coulombic 
interactions.  While the coulombic interactions seemed to dominate with the much 
smaller protein, likely due to the large size of all the tested hydrogels’ meshes compared 
to the protein, the mesh size appears to dominate with the much larger protein. 
In conclusion, these two tests demonstrate two important points.  First, these 
results indicate that the delivery potential for any given protein is largely specific to that 
protein due to wide differences in charge and size between proteins.  While the 5% and 
10% crosslinked formulations proved best for the small peptide salmon calcitonin, the 
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1% crosslinked formulation was vastly better for the large antibody rituximab.  Second, 
these results also demonstrate that these P(IA-co-NVP) hydrogel systems may be easily 
tuned using varying crosslinking density to accommodate a wide range of proteins, 
ranging from the 3.4 kDa salmon calcitonin to the 144 kDa rituximab. 
In an additional experiment, the loading and release of urokinase was also 
compared to that of sCT and rituximab using P(IA-co-NVP) microparticles synthesized 
with a monomer ratio of 1:2 IA to NVP.  This experiment utilized urokinase as another 
high pI protein (pI = 8.66) with a molecular weight (54.0 kDa) between that of salmon 
calcitonin (3.4 kDa) and rituximab (144 kDa), allowing us to see the effects across a 
range of sizes, rather than just two endpoints.  Urokinase is used clinically as a 
thrombolytic agent for myocardial infarction, pulmonary embolism, and deep vein 
thrombosis.  As such, it is not a strong candidate for therapeutic use with our systems, 
due to the need for very fast application to the bloodstream, but does work well as a 
commercially available, medium-sized, high pI exhibiting drug.   
The results of the experiment are shown in Figure 5-9 and Table 5-7.  The loading 
level of the proteins vary considerably:  salmon calcitonin had high loading levels with 
44.8 μg sCT/mg hydrogel, while urokinase (19.0 μg/mg) and rituximab (24.1 μg/mg) 
exhibited similar, but significantly lower loading levels.  This is likely due to mesh size 
limitations of the hydrogel that prevent easy access into the particle for larger proteins.  
Accordingly, both the amount of protein released and the percent release of urokinase and 
rituximab were lower than those of salmon calcitonin.  This result further supports that 
protein size is a strong determining factor in the delivery potential of these hydrogels, 
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with larger proteins requiring larger mesh sizes in order to facilitate their diffusive 
transport through the tortuous paths into and out of the hydrogel mesh. 
Another feature of the results of this experiment is that the Rituxan delivery 
potential is significantly lower than what was observed in the previous experiment.  This 
difference arises from two results.  First, the hydrogels used in this experiment were 
crosslinked using 3 mol% TEGDMA in the monomer feed.  As a result, the rituximab 
release level observed is more similar to what was observed with the 5% crosslinked 
particles than the 1% crosslinked particles that exhibited such high release.  Secondly, 
and most importantly, this experiment utilized loading solutions of proteins at only 200 
µg/mL rather than at 400 µg/mL as was used in the preceding experiment.  The lower 
concentration causes lower loading levels due to less protein being available for loading 
as well as reduced driving force for the protein to enter into the swollen hydrogels.  With 
lower loading levels comes both lower overall delivery and lower percent release, as the 
lower loading level means less protein to be released even at 100% efficiency and, since 
concentration difference is the driving force for diffusion, less entropic gain due to 
diffusive release which therefore shifts the equilibrium toward coulombic binding rather 
than diffusive release. 
These two factors account for the reduced loading and overall delivery of 
rituximab in this experiment, and thus show that the delivery capability of these gels is 
strongly dependent on the loading conditions.  Higher concentration loading solutions can 
be used to promote higher percent release and overall delivery.  The main limitation 
imposed by high concentration solutions is protein aggregation,
14,15
 although this is 
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strongly dependent on the individual protein’s structure and was not an observed issue at 
the relatively low concentrations studied here.   
This experiment shows that the hydrogel delivery systems are capable of 
delivering high pI-exhibiting therapeutic proteins across a wide spectrum of molecular 
weights to the small intestine.  However, in accordance with the results of the previous 
experiments, the system must be tailored for the individual protein being used, with 
molecular weight being one of the primary determining factors.  The crosslinking density 
provides one simple means of tailoring these particles to the size of the protein, with 
larger proteins benefitting from lower crosslinking density (larger mesh size) and small 
proteins benefitting from higher crosslinking density (smaller mesh size).  Additionally, 
the loading procedures used are also very important.  Low ionic strength conditions 
(specifically for high pI proteins) and high protein concentrations in the imbibition 
loading procedure promote enhanced delivery capability and higher bioavailability. 
5.3.6 Degradable Hydrogel Loading and Release 
The results of the loading and release study are shown in Figure 5-10 and Table 5-
8.  The degradable hydrogels displayed reduced loading levels of sCT compared to what 
has been observed with the P(IA-co-NVP) systems, achieving only 12.4 μg sCT/mg 
hydrogel of encapsulated protein despite the relatively high concentration of sCT in the 
loading solution (400 μg/mL).  The percent release of encapsulated protein, however, was 
approximately 100% at all time points in the simulated intestinal conditions.  Although 
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the calculated averages are slightly above 100%, the values are not significantly different 
from 100% (p > 0.064), indicating complete release of encapsulated sCT. 
The observed overall delivery level was only 13 μg sCT/mg hydrogel, 
necessitating the use of more hydrogel to accommodate a therapeutic dose of protein 
compared to the P(IA-co-NVP) system.  However, because the entirety of the 
encapsulated protein is released by degradation of the hydrogel, the bioavailability of the 
protein by this method would be higher, as no protein drug would be wasted due to 
incomplete release in the small intestine.  Furthermore, no release was observed in the 
simulated gastric fluid as measured by HPLC.  Therefore, this system performed very 
well in terms of delivering protein to the small intestine, losing none of the encapsulated 
protein to degradation in the stomach conditions and achieving complete release in the 
small intestine conditions.  As such, this hydrogel is very promising for achieving the 
highest possible bioavailability of therapeutic proteins via the oral route. 
The primary limitation of the system, however, is that is difficult and costly to 
synthesize large quantities of the peptide crosslinker.  Peptides are not easily 
manufactured at large scales and therefore generally are not.  One notable exception is 
the HIV fusion inhibitor peptide, Fuzeon, which was manufactured at near-ton annual 
quantities because of the large daily dose needed.
16
  However, the excessive cost of the 
manufacturing process prevented the drug from reaching blockbuster status.  As a result 
of the high cost of peptide synthesis, this hydrogel is likely too costly to make a 
financially viable product at the current time.  The system could find utility with protein 
drugs that are sufficiently expensive to manufacture that complete release in the small 
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intestine makes up for the increased cost of the hydrogel.  However, until technological 
improvements in peptide synthesis are made, making inexpensive, large-scale synthesis 
of peptides a reality, this system may be limited to academic interest, despite its ideal 
performance in this in vitro experiment. 
5.3.7 Pharmacological Feasibility 
The normal recommended dosage of salmon calcitonin for a patient treating 
osteoporosis is 50-100 IU/day by injection, equating to 8.3-16.7 μg/day.  Rituxan is used 
in multiple indications, but the highest recommended dose for any indication is 500 
mg/m
2
 (for chronic lymphocytic leukemia).  For a typical adult male (50
th
 percentile of 
weight and height), the body surface area is 1.97 m
2
, which amounts to 985 mg of 
Rituxan administered in a single infusion.  Urokinase as used for pulmonary embolism 
and deep vein thrombosis is typically administered at 4400 IU/kg, which for a typical 
male (80 kg) and typical activity of 100,000 IU/mg amounts to 3.52 mg of urokinase.  To 
deliver an equivalent amount of protein by the oral route, a greater amount will need to 
be delivered to the small intestine, which can be estimated by a simple calculation. 
To ensure a conservative determination of feasibility, the required dose used in 
the calculation will be the high end values of 16.7 μg for sCT, 985 mg of Rituxan, and 
3.52 mg of urokinase.  Aside from limited delivery potential from the microparticle 
carriers, loss of bioavailability resulting from intestinal enzymatic degradation and low 
intestinal absorption must also be accounted for.  Data from Youn et al.
17
 showed 0.05% 
of unmodified sCT was transported across a Caco-2 monolayer in in vitro conditions over 
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60 min.  Assuming a constant permeability (as is observed during those 60 min), this 
means 0.15% of released sCT can be expected to be transported across the intestinal 
epithelium into the bloodstream over the 3 h average residence time.  The actual 
percentage will likely be significantly higher than this, as Caco-2 monolayers are 
reported to exhibit less permeable tight junctions than are observed in vivo.
18–22
  
Correlations between Caco-2 permeability and in vivo absorption
19,23
 suggest that the 
apparent permeability of 1.5 x 10
-7
/cm
2
 reported by Youn et al.
17
 lies in the range of 
poorly absorbed compounds (0-20% uptake); indeed, compounds with similar 
permeability in Caco-2 cultures such as doxorubicin (1.6 x 10
-7
/cm
2
) or 1-deamino-8-D-
arginine-vasopressin (1.3 x 10
-7
/cm
2
) show 5% and 1% absorption respectively, so the 
actual absorption could be expected to be somewhere between 1 and 5%.  Furthermore, 
the presence of P(MAA-g-EG) microparticles has been shown to inhibit enzymatic 
degradation following intestinal release and enhance permeability by reversible opening 
of the tight junctions in the intestinal epithelium, which would further enhance 
bioavailability and intestinal absorption.
24–27
  However, for the purpose of maintaining a 
conservative estimate of feasibility, the very low 0.15% absorption for Caco-2 cultures 
over 3 h will be used. 
With the selection of a high dosage and a low level of absorption, the approximate 
amount of polymer microparticles needed for a daily dose using the largest delivery 
potentials observed in experiment (48.2 μg sCT/mg hydrogel; 2.68 μg urokinase/mg 
hydrogel; and 81.7 μg Rituxan/mg hydrogel) are 
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Hydrogel required (sCT) =  
16.7 
μg sCT
day
48.2 
μg sCT
mg hydrogel × 0.0015
= 230 
mg hydrogel
day
 
Hydrogel required (urokinase) =  
3.52 mg urokinase
2.68 
μg urokinase
mg hydrogel × 0.0015
= 876 g hydrogel 
Hydrogel required (Rituxan) =  
985 mg Rituxan
81.7 
μg Rituxan
mg hydrogel × 0.0015
= 8.0 kg hydrogel 
 
Given a density of 0.66 g/mL for dry P(IA-co-NVP) microparticles, 230 mg will 
easily fit within a size 2 gel capsule (15.3 mm in length), meaning a daily dose of salmon 
calcitonin could be given with one pill that is smaller than a standard Tylenol gel capsule 
(19 mm in length) per day.  Unfortunately, due to the comparatively large doses of 
urokinase and Rituxan, the amount of hydrogel required at this point is unreasonable.  
However, as stated previously, this estimation uses a low value of intestinal absorption 
that would be unlikely to be observed in vivo, and the enormous quantities of hydrogel 
required as calculated are due largely to this figure.  It is likely that the actual amount 
required could be as much as 6–33x less than calculated (assuming 1-5% actual intestinal 
absorption), although a dose of Rituxan would still require an unreasonable 240 g of 
hydrogel. 
Depending strongly on the actual absorption in the small intestine and the 
prescribed dosage, our results show that a normal regimen of salmon calcitonin may be 
received with our system with the improved loading procedures and delivery materials 
described herein, likely with no more than one or two pills taken per day.  Unfortunately, 
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despite high delivery capability observed using low crosslinking ratio in the hydrogels 
with Rituxan, the delivery of proteins that require high doses does not seem to be 
reasonable without further improvement.  Because crosslinking density and loading 
conditions can be used to overcome low levels of delivery to the small intestine, the 
passage across the intestinal epithelium is the primary remaining obstacle to oral protein 
delivery.  Better intestinal absorption well beyond 0.15% absorption is needed to make 
both the amount of hydrogel ingested and the cost reasonable.  Some improvement in 
absorption is expected to result from greater in vivo permeability compared to Caco-2 
cultures, as described above, and from the reversible opening of tight junctions by the 
polymer microparticles.  However, further improvement is likely necessary before such 
systems are pharmaceutically feasible. 
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Figure 5-1: Salmon Calcitonin Release from pH-Responsive Hydrogel Microparticles 
Based on Methacrylic Acid or Itaconic Acid. Time point at 60 min is in 
acidic (pH 3.0) conditions immediately before neutralization with NaOH.  
All other time points were collected in neutral (pH 7.4) conditions.  Delivery 
potential reported as mg sCT per mg hydrogel, as determined by Micro 
BCA assay. 
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Figure 5-2:  Salmon Calcitonin Release—Ionic Strength Trial 1.  All profiles are for 
release of salmon calcitonin following loading into 1:1 P(IA-co-NVP) 
microparticles in 0.1x, 1x, or 10x concentrated PBS buffer.  Time points 
from 0 – 60 min are in acidic conditions (pH 3.0) and time points from 65 – 
180 minutes are in neutral conditions (pH 7.4). 
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Figure 5-3:  Salmon Calcitonin Release—Ionic Strength Trial 2.  All profiles are for 
release of salmon calcitonin following loading into 1:1 P(IA-co-NVP) 
microparticles in 0.01x, 0.1x, 1x, or 10x concentrated PBS buffer.  Time 
point at 60 min is in acidic conditions (pH 3.0), and time points at 120 and 
180 minutes are in neutral conditions (pH 7.4). 
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Figure 5-4:  Salmon Calcitonin Release—Ionic Strength Trial 3.  All profiles are for 
release of salmon calcitonin following loading into 1:1 P(IA-co-NVP) 
microparticles in 0.01x, 0.1x, 1x, or 10x concentrated PBS buffer.  Time 
point at 60 min is in acidic conditions (pH 3.0), and time points at 120 and 
180 minutes are in neutral conditions (pH 7.4).  
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Figure 5-5:  Loading and Release of Salmon Calcitonin from P(IA-co-NVP) 
Microparticles of Varying Sizes.  All microparticles are comprised of 1:2 
P(IA-co-NVP).  Acidic release data reported after 1 h at pH 3, and neutral 
release data reported after 4 h at pH 7.4. 
  
0
5
10
15
20
25
30
35
1 2 3
Loading Level (μg/mg) 
Release, Acid (μg/mg) 
Release, Neutral (μg/mg) 
    45-75 μm           75-90 μm           90-150 μm 
 120 
 
Figure 5-6:  Theoretical Swelling of Anionic Hydrogel with Varying Crosslinking 
Density.  Swelling profiles obtained by solution of Brannon-Peppas 
equation for varying values of 𝑀𝑐̅̅ ̅̅ :  (1) 𝑀𝑐̅̅ ̅̅  = 2000; (2) 𝑀𝑐̅̅ ̅̅  = 4000; (3) 𝑀𝑐̅̅ ̅̅  = 
6000; (4) 𝑀𝑐̅̅ ̅̅  = 8000; (5) 𝑀𝑐̅̅ ̅̅  = 10,000; (6) 𝑀𝑐̅̅ ̅̅  = 12,000; and (7) 𝑀𝑐̅̅ ̅̅  = 
15,000.  Reprinted from Brannon-Peppas and Peppas
7
 with permission from 
Elsevier.  
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Figure 5-7:  Effect of Crosslinking Density on Delivery of Salmon Calcitonin, Release 
Profiles.  For t = 0-1 h, release conditions were acidic at pH 3.  The release 
solutions were then neutralized, to pH 7.4 for t > 1 h. 
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Figure 5-8:  Release of Rituxan (rituximab) from 1:2 P(IA-co-NVP) Microparticles of 
Varying Crosslinking Density.  For t = 0-1 h, release conditions were acidic 
at pH 3.  The release solutions were then neutralized, to pH 7.4 for t > 1 h. 
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Figure 5-9:  Release Profile of Calcitonin, Urokinase, and Rituxan from 1:2 P(IA-co-
NVP) Hydrogel Microparticles.  For t = 0-1 h, release conditions were 
acidic at pH 3.  The release solutions were then neutralized, to pH 7.4 for t > 
1 h. 
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Figure 5-10:  Salmon Calcitonin Release Profile from Enzymatically Degradable 
P(MAA-co-NVP) Hydrogel Microparticles Crosslinked with MMRRRKK 
Peptide.  For t = 0-1 h, protein release occurred in USP-standard simulated 
gastric fluid (pH 1.2, 3.2 mg/mL pepsin).  For t > 1 h, protein release 
occurred in USP-standard simulated intestinal fluid (pH 6.8, 10 mg/mL 
pancreatin).  Salmon calcitonin release reported as average ± standard 
deviation (n = 3). 
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Table 5-1:  Salmon Calcitonin Loading and Release Levels from Various Hydrogel 
Formulations. 
Hydrogel Formulation 
Loading Level 
(μg sCT/mg 
hydrogel) 
Delivery Potential, t=4 h 
(μg sCT/mg hydrogel) 
Percent Release, 
t=4 h (%) 
1:2 P(IA-co-NVP) 45.0 12.4 27.7 
P(IA-co-NVP-co-MMA) 29.1 5.5 19.0 
P(MAA-g-EG) 23.4 4.6 19.8 
1:1 P(IA-co-NVP) 22.3 4.1 12.3 
P(IA-g-EG) 38.1 3.8 10.0 
1:9 P(IA-co-NVP) 35.9 2.4 7.4 
P(MAA-co-NVP) 9.8 0.7 8.0 
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Table 5-2:  Salmon Calcitonin Loading and Release Levels, Ionic Strength Trial 1. 
Loading Solution 
Loading Level 
(μg sCT/mg hydrogel) 
Delivery Potential,  
t=180 min  
(μg sCT/mg hydrogel) 
Percent Release, 
t=180 min  
(%) 
0.1x PBS (15 mM) 10.7 6.74 63.0 
1x PBS (150 mM) 23.5 5.62 23.9 
10x PBS (1500 mM) 7.4 0.16 2.1 
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Table 5-3:  Salmon Calcitonin Loading and Release Levels, Ionic Strength Trial 2. 
Loading Solution 
Loading Level 
(μg sCT/mg hydrogel) 
Delivery Potential,  
t=180 min  
(μg sCT/mg hydrogel) 
Percent Release, 
t=180 min  
(%) 
0.01x PBS (1.5 mM) 105.6 48.4 45.8 
0.1x PBS (15 mM) 171.0 16.1 9.4 
1x PBS (150 mM) 12.2 0.6 4.8 
10x PBS (1500 mM) 53.4 0.6 1.1 
 
  
 128 
Table 5-4:  Salmon Calcitonin Loading and Release Levels, Ionic Strength Trial 3. 
Loading Solution 
Loading Level 
(μg sCT/mg hydrogel) 
Delivery Potential,  
t=180 min  
(μg sCT/mg hydrogel) 
Percent Release, 
t=180 min  
(%) 
0.01x PBS (1.5 mM) 57.8 6.18 10.7 
0.1x PBS (15 mM) 54.8 4.67 8.5 
1x PBS (150 mM) 49.6 2.23 4.5 
10x PBS (1500 mM) 47.3 -0.90 -1.9 
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Table 5-5:  Loading and Release of Salmon Calcitonin from 1:2 P(IA-co-NVP) 
Microparticles with Varying Crosslinking Density. 
Crosslinking 
Density 
Loading Level 
(μg sCT/mg hydrogel) 
Protein Released,  
t=4 h  
(μg sCT/mg hydrogel) 
Percent Release, 
t=4 h (%) 
1% TEGDMA 33.7 ± 0.4 4.53 ± 1.13 13.4 ± 3.2 
5% TEGDMA 36.2 ± 0.4 7.08 ± 0.63 19.5 ± 1.6 
10% TEGDMA 33.7 ± 0.3 6.17 ± 0.30 18.3 ± 0.9 
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Table 5-6:  Loading and Release of Rituxan (rituximab) from 1:2 P(IA-co-NVP) 
Microparticles with Varying Crosslinking Density. 
Crosslinking 
Density 
Loading Level 
(μg Rituxan/mg hydrogel) 
Protein Released,  
t=4 h  
(μg Rituxan/mg hydrogel) 
Percent Release, 
t=4 h (%) 
1% TEGDMA 56.3 ± 0.7 64.1 ± 3.7 113.8 ± 5.2 
5% TEGDMA 60.4 ± 3.4 19.1 ± 2.5 31.5 ± 2.6 
10% TEGDMA 64.1 ± 3.9 16.8 ± 3.4 26.4 ± 6.2 
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Table 5-7:  Loading and Release of Salmon Calcitonin, Urokinase, and Rituxan from 1:2 
P(IA-co-NVP) Microparticles. 
Protein 
Loading Level 
(μg/mg hydrogel) 
Protein Released,  
t = 24 h  
(μg/mg hydrogel) 
Percent Release,  
t = 24 h (%) 
Salmon Calcitonin 44.8 ± 4.7 15.5 ± 1.8 35.2 ± 7.2 
Urokinase 19.0 ± 1.1 2.7 ± 0.5 14.2 ± 3.2 
Rituxan 24.1 ± 1.5 4.8 ± 1.1 20.0 ± 3.6 
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Table 5-8:  Loading and Release of Salmon Calcitonin from Enzymatically Degradable 
P(MAA-co-NVP) Microparticles Crosslinked with MMRRRKK Peptide.  
Microparticles were incubated in USP simulated gastric fluid (pH 1.2, 3.2 
mg/mL pepsin) for 1 h, then incubated in USP simulated intestinal fluid (pH 
6.8, 10 mg/mL pancreatin) for 48 h.  All values reported as average ± 
standard deviation (n = 3). 
Release 
Conditions 
Time in Release 
Conditions (h) 
Loading Level 
(μg sCT/mg hydrogel) 
Protein Released 
(μg sCT/mg hydrogel) 
Percent Release 
(%) 
Gastric 1 12.4 ± 0.7 0 0 
Intestinal 
1 
12.4 ± 0.7 
12.9 ± 0.7 103.8 ± 2.6 
4 12.8 ± 1.5 102.8 ± 9.5 
48 13.4 ± 1.2 107.9 ± 7.6 
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Chapter 6:  PEGylation of High Isoelectric Point Proteins and Its 
Effects on Oral Drug Delivery 
6.1 INTRODUCTION 
As discussed in section 2.4, bioconjugation has been a method explored by 
scientists and pharmaceutical developers for imbuing therapeutics with additional, 
beneficial properties that enhance the physiological properties of the molecule.  The 
improvements achieved through bioconjugation are manifold.  For example, many drug 
molecules are poorly soluble, with 25% of the medicines on the World Health 
Organization’s Essential Medicines List being classified as poorly soluble1 and many 
more promising candidates being unexplored because of poor solubility.  The solubility 
can be enhanced by conjugation of a hydrophilic molecule to the poorly soluble 
molecule.  Alternatively, attachment of an enzymatically non-degradable molecule to a 
protein may offer significantly enhanced half-life in vivo for enhanced efficacy.  
Conjugation of a targeting molecule, such as an antibody, can help ensure that a 
therapeutic reaches its desired location within the body or within a cell.  Or, conjugation 
of two therapeutic agents to one another can provide multiple mechanisms of action 
while localizing the two compounds to the same delivery site to enhance efficacy.  The 
possibilities are diverse and numerous. 
However, one of the most widely used conjugation strategies involves attachment 
of a poly(ethylene glycol) chain to a protein—a process termed “PEGylation.”  
PEGylation imparts many of the beneficial properties named above.  PEG has several 
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interesting properties, including a surprisingly high degree of hydrophilicity compared to 
the largely hydrophobic poly(methylene oxide) and poly(butylene oxide), which are a 
mere carbon link different at the monomer level, as well as some hydrophobic character, 
exhibited by its tendency to form monolayers at air-water interfaces.
2
  Nevertheless, the 
generally highly hydrophilic polymer has been widely used as a conjugate to increase the 
solubility of compounds.
3–8
 
Furthermore, it has been shown that PEG demonstrates repulsive interactions with 
typical proteins at long distance, but can instead demonstrate an attractive interaction at 
close range.
9
  The effect is thought to occur due to competitive binding of water 
molecules and the proteins, with the water molecules dominating due to the smaller size 
until the protein gets sufficiently close to bind.  As such, the effect is often described as a 
water cage that forms around the PEG-protein conjugate. 
The repulsive aspect is highly useful in biomedical applications, as it provides 
stealth properties to the protein by preventing binding of opsonins, therefore extending 
the half-life of the protein in vivo by preventing recognition and removal by 
macrophages.  Because of the attractive interaction at close range, adsorption of proteins 
is kinetically, but not thermodynamically limited, meaning in time opsonins will 
eventually bind and cause the removal of the conjugate.
2,9
  While this limits the 
therapeutic’s half-life in vivo, this is beneficial, as it means therapeutics will not 
accumulate in the body over time and cause long acting side effects.  PEGylation has 
therefore been used in 13 FDA-approved drugs and used extensively in research to 
extend the half-life of rapidly removed or degraded drugs.
3,4,6–8,10–16
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One final benefit of PEGylation that could prove useful in our drug delivery 
systems is the ability to provide charge shielding, limiting electrostatic interactions.  This 
effect has been shown in several studies
15,17
 and likely results from the formation of the 
water cage, which disperses electrostatic interactions via dipolar rearrangement of the 
water molecules.  This effect could be beneficial for oral delivery of proteins using our 
systems; because high pI proteins are bound by electrostatic interactions between the 
anionic polymer and the cationic protein, charge shielding through PEGylation could 
promote protein release by reducing the strength of these interactions. 
Because PEGylation is a widely used method of imparting numerous beneficial 
properties to biotherapeutics, I sought to determine what effects PEGylation would have 
on the delivery of high pI exhibiting proteins using the P(IA-co-NVP) delivery system.  
PEGylation often imbues additional hydrophilicity to particles and can shield charge 
interactions, which could promote release of proteins from our systems.  However, the 
attachment of a PEG chain to a biotherapeutic agent necessarily increases the size of the 
protein, due to increased molecular weight and increased hydrodynamic radius from the 
water cage, which could potentially reduce the probability of diffusion through the 
tortuous pathway through the hydrogel mesh.  Therefore, the effects of PEGylation on 
protein delivery were studied and are reported here in Chapter 6.  Effect of PEGylation 
on the later process of intestinal absorption is subsequently reported in Chapter 7. 
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6.2 PEGYLATION REACTION 
Salmon calcitonin consists of only 32 amino acids, so conjugation sites are 
inherently limited.  At the N-terminus, there are two cysteine residues at the 1 and 7 
positions bonded together by a disulfide linkage.  Additionally, there are 2 lysines, at the 
11 and 18 positions, and the N-terminus where primary amines are found. 
The cysteine residues could potentially be reduced using dithiothreitol or TCEP 
and used as conjugation sites with a PEG-maleimide or PEG-dibromomaleimide.  Using 
a PEG-maleimide would react with one of the thiols, providing PEGylation at the 1 or 7 
amino acid, but would leave the disulfide broken, which could impair the structure and 
function of the protein.  Use of PEG-dibromomaleimide would approximately maintain 
the disulfide with a two carbon linker in between sulfurs, and would provide site specific 
conjugation at the disulfide site.
18–20
  However, the dibromomaleimide reactant is not 
commercially available and has a demanding synthesis procedure. 
The primary amines in the protein may be used by EDC/NHS coupling, as 
described in Chapter 2.  Monofunctional NHS esters of PEG are available commercially, 
making the PEGylation reaction a simple one-step procedure where the pre-activated 
NHS ester is mixed in solution with the protein, enabling it to react with primary amines 
and form a zero-length crosslink between the PEG and the amine.  The drawback of this 
synthesis is that it does not provide site specificity.  All three sites will readily react, and 
depending on molar ratio of the reactants, the degree of substitution could vary between 
proteins.  For the sake of this research, the location of the conjugation is not important.  
Lee et al. have shown that conjugation to the Lys
18
 is preferable for maximizing 
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bioavailability,
21
 so care to ensure conjugation to this site would be important if we were 
seeking to maximize bioavailability in a clinical setting.   
However, the goal of this study is merely to study the effect of increased size and 
hydrophilicity on the drug delivery capability with the P(IA-co-NVP) hydrogel systems, 
which should not require site specificity.  The degree of substitution is important, 
however, as the number of PEG chains conjugated to the protein determines the 
conjugate’s size and hydrophilicity.  Therefore, the more straightforward PEGylation 
procedure of conjugating to primary amines will be used in lieu of the cysteine 
conjugation, and the degree of substitution will be maintained at 1 PEG chain per sCT 
protein, as controlled by reactant ratio and verified by mass spectrometry. 
6.3 MATERIALS AND METHODS 
6.3.1 PEGylation of Salmon Calcitonin 
An equimolar mixture of salmon calcitonin (Selleck Chemicals, Houston, TX) 
and methoxy poly(ethylene glycol) succinimidyl carboxy methyl ester (mPEG2k-SCM, 
number average PEG molecular weight of 2 kDa) (NanoCS, Boston, MA) were dissolved 
in methanol (Sigma Aldrich, St. Louis, MO).  Both reactants were added at a 
concentration of 0.873 mM.  The reaction proceeded for 1 h on a rotary mixer.  The 
PEGylated salmon calcitonin (sCT-PEG) was isolated by dialysis.  The reaction mixture 
was placed inside a 10 mm regenerated cellulose membrane tube with a 3.5 – 5 kDa 
molecular weight cutoff (Spectrum Laboratories, Inc., Rancho Dominguez, CA), which 
was then placed in 1 L of deionized water.  The water was changed every 24 h for 3 days, 
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at which time the sCT-PEG was removed from the inside of the tube, dried by 
lyophilization, and stored at -20 °C. 
6.3.2 MALDI-TOF Characterization of sCT-PEG 
The PEGylated product was characterized using matrix assisted laser desorption 
ionization time of flight (MALDI-TOF) mass spectrometry.  Samples of both the final 
reactant mixture and the purified, isolated product were analyzed.  The matrix solution 
used consisted of α-cyano-4-hydroxycinnamic acid (CHCA) at 10 mg/mL concentration 
in 40 vol% of 0.1% trifluoroacetic acid and 60 vol% of acetonitrile.  0.5 μL samples were 
placed on the spot plate and covered with 0.5 μL of matrix solution.  Spots were allowed 
to dry at room temperature before being analyzed using an AB-Sciex Voyager-DE Pro 
MALDI-TOF mass spectrometer. 
6.3.3 Loading and Release of sCT-PEG 
Separate solutions of sCT and sCT-PEG were prepared at 500 μg protein/mL 
concentration in 1.5 mM PBS (0.01x).  In 12 x 2.0 mL low adhesion tubes, 5 mg of 1:2 
P(IA-co-NVP) hydrogel microparticles (90-150 μm in size) were added to each tube and 
incubated with 1.5 mL of protein solution (n = 6 per protein compound) for 24 h at pH 
7.4.  The solutions were collapsed using 1 N HCl to reduce the pH to 2, isolated by 
centrifugation and decanting, washed two times with 0.5 mL of 0.01 N HCl, and 
lyophilized.  Following drying, 1.0 mL of 150 mM PBS (1x) at pH 3 was added to each 
tube and incubated at 37 °C for 1 h.  A 300 μL sample was taken and replaced with pH 3 
 141 
PBS, and the solutions were then raised to pH 7.4 using 1 N NaOH.  The solutions were 
stirred at 37 °C for 24 h, with 200 μL samples acquired and replaced with fresh PBS at 
time points of 1, 2, 3, and 24 h.  All loading and release samples were analyzed for 
protein concentration using a MicroBCA assay. 
6.4 RESULTS AND DISCUSSION 
6.4.1 PEGylation and MALDI-TOF Characterization 
The most important aspect of the PEGylation reaction for the sake of this research 
was to demonstrate control over the degree of substitution, maintaining a uniform degree 
of substitution so that molecular weight and hydrophilicity would be consistent.  In an 
initial trial, reactants were mixed at a molar ratio of 3 to 1 mPEG-SCM to sCT.  A multi-
fold molar excess of the NHS-ester reactant (mPEG-SCM) to the protein is recommended 
by several conjugation texts as standard procedure to drive the reaction to completion.
22,23
  
After reaction, the reaction mixture was analyzed by MALDI-TOF mass spectrometry, 
with the resulting molecular weight profile shown in Figure 6-1.  The molecular weight 
distribution of unreacted mPEG2k-SCM is clearly seen as a Gaussian distribution around 
2200 Da.  There is a small, broad peak around 7800 Da that corresponds to a degree of 
substitution of 2, and a larger broad peak around 10000 Da that corresponds to a degree 
of substitution of 3. 
The relative sizes of these peaks indicates a high yield of protein with 3 
conjugated PEG chains, with a small quantity of protein with only 2 PEG chains per 
molecule.  Such a mixture of products is not ideal for study, and the high degree of 
 142 
substitution would likely interfere with the activity of the protein for end use.  Wu et al. 
have demonstrated that conjugate size can have an effect on activity of proteins,
24
 and 
singly-PEGylated sCT has been shown to have an already reduced activity of 74% 
compared to unmodified sCT (although a 3-fold longer half-life yields overall better 
bioavailability),
12
 so attachment of multiple PEG chains to sCT may yield a largely 
inactive molecule, making study irrelevant. 
Therefore, the reactant ratio was reduced to a 1:1 molar ratio of mPEG2k-SCM to 
sCT to limit degree of substitution to approximately 1.  The final reaction mixture was 
analyzed using MALDI-TOF mass spectrometry, and the resulting mass profile is shown 
in Figure 6-2.  The broad peak around 2200 Da is not seen in this spectrum, although a 
tall, narrow peak at 3432 Da is seen, corresponding to unreacted sCT.  Although the 
height of the peak relative to all others may seem to indicate very low yield, the height of 
the sCT peak is misleading:  all of the unreacted sCT is at exactly this molecular weight, 
giving that one mass a very tall peak, whereas the polydispersity of the PEG makes the 
conjugate appear lower in intensity at each point, but broader in terms of molecular 
weight.  The areas under the peaks should be similar, indicating a similar number of 
unreacted sCT and PEG, but the broadness of the PEG peak makes it imperceptibly 
small.  As a result, the perceptible peak seen at 5400 Da indicates that sCT-PEG is 
actually the dominant species, meaning a high yield of the desired product.  Importantly, 
very little doubly-conjugated sCT is seen in the spectrum, so this molar ratio of reactants 
appears to provide a favorable combination of high yield of the desired product with 
minimal mixture of products due to excessive substitution per molecule. 
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The 1:1 molar ratio was then used at a larger scale to prepare sCT-PEG for 
experiments, and the product was purified by dialysis.  The MALDI-TOF mass spectra of 
the product mixture and the dialyzed product are shown in Figures 6-3 and 6-4, 
respectively.  Because the molecular weight cutoff of the dialysis tubing (3.5-5 kDa) is 
close to the molecular weights of the unreacted sCT (3.4 kDa) and the product (5.4 kDa), 
the process does not produce ideal separation of product from reactant.  However, the 
peaks around 5.4 kDa become noticeably more prominent after dialysis, indicating some 
level of purification. 
The ratios of identifiable peak areas at 3.4 kDa and 5.4 kDa (A3.4 kDa / A5.4 kDa) 
before and after dialysis were 238 and 0.55 respectively.  The peak areas are indicative of 
concentrations of species in the sample, but do not directly reflect the true ratio of 
concentrations due to different volatilities and susceptibilities to ionization between 
species.  Therefore, a 0.55 ratio does not necessarily mean that there are nearly 2 sCT-
PEG molecules for every sCT molecule; the actual ratio would likely favor sCT-PEG 
even more due to increased mass, requiring higher laser intensity to desorb from the 
matrix than sCT.  Nevertheless, the fact that the peak area ratio decreases by such a large 
degree (a 432x reduction) indicates that the dialysis process provides suitable separation 
that strongly favors retention of sCT-PEG over unreacted sCT. 
6.4.2 Loading and Release of sCT-PEG 
The purified sCT-PEG was used alongside unmodified sCT in a loading and 
release experiment to study the effects of increased size and hydrophilicity on drug 
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delivery in the P(IA-co-NVP) systems.  The results are shown in Figure 6-5 and Table 6-
1.  Figure 6-5 shows that the unmodified salmon calcitonin achieves significantly greater 
protein release levels at all time points (p < 0.005), with the difference increasing through 
the 4 h time point.  However, as shown in Table 6-1, this greater release level is not due 
to greater loading level:  the sCT-PEG had higher average loading levels than the 
unmodified sCT did in the 1:2 P(IA-co-NVP) microparticles, although the difference was 
not statistically significant (p = 0.094).  The similar loading levels mean that the 
unmodified salmon calcitonin also exhibited significantly higher (p = 0.000036) percent 
release of encapsulated protein than the sCT-PEG did.  Therefore, the PEGylation 
process does not appear to limit loading, but does cause reduced protein delivery levels, 
both in terms of quantity delivered and percent of encapsulated protein released. 
The difference in release level could be due to several factors.  The simplest 
explanation is that the increased size of the sCT-PEG compared to unmodified sCT 
impedes diffusion through the hydrogel mesh.  This doubtlessly plays some role in the 
reduced delivery levels, but the similar loading level implies that the size was not an 
impediment during diffusion into the hydrogel, meaning it is likely not the foremost 
factor in why the release levels were reduced. 
Another factor is that the protein loading solutions were identical in terms of 
weight concentration, rather than identical in terms of molar concentrations.  Similar 
loading levels in terms of weight of protein mean that there are fewer molecules of the 
larger sCT-PEG in the hydrogels compared to the number of sCT molecules in the sCT-
loaded microparticles.  The sCT-PEG weighs roughly 60% more than the sCT, meaning 
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nearly 40% fewer molecules per mass of hydrogel as compared to the sCT.  Because the 
entropic driving force for diffusion is based on molar concentration differences between 
the interior and exterior of the particles, rather than mass concentrations, the diffusional 
“force” for protein release from the hydrogel is smaller for the sCT-PEG loaded 
hydrogels compared to the sCT-loaded hydrogels at similar loading level.  This alone 
could explain the observed difference in release; further experiments maintaining equal 
molar concentrations during loading would be useful in identifying if this is the primary 
cause. 
Finally, the increased hydrophilicity of the sCT-PEG could be encouraging 
partitioning inside the highly hydrophilic interior of the hydrogel.  This could explain the 
similar, though slightly larger loading level for the sCT-PEG inside the particles, even 
though the larger protein size should reduce the rate of diffusion into the interior of the 
particles if diffusion were the only mechanism for drug loading.  Furthermore, with 
hydrophilicity promoting partitioning inside the hydrogel, the release level would be 
expected to be reduced due to more favorable free energy interactions for remaining in 
the hydrogel.  Such behavior is consistent with what is observed, indicating that the 
hydrophilicity of the drug compound is likely an important characteristic in determining 
the loading and release expected for a drug using our pH-responsive systems. 
This experiment clearly shows that PEGylation will have some effect on the drug 
delivery potential of our systems.  For a 2 kDa PEG chain attached to salmon calcitonin, 
the impact was negative, yielding similar loading level but reduced release level.  The 
difference was statistically significant, although even with the reduction, the sCT-PEG 
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still exhibited a respectable 27 μg/mg release level, which would not preclude its clinical 
use with our systems.  Indeed, the 3-fold improvement in half-life of PEGylated sCT with 
only a 26% reduction in activity more than makes up for the reduction in delivery with 
our systems in terms of overall efficacy.  Nevertheless, when coupled with the 
experiments with sCT, Rituxan, and urokinase discussed in Chapter 5, this experiment 
adds to the list of important characteristics to consider when tailoring our systems to a 
particular therapeutic:  isoelectric point, molecular size, crosslinking density of the 
hydrogels, and now hydrophilicity. 
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Figure 6-1:  Mass Spectrum of PEG2kSCM-sCT (3:1) Conjugation Product Mixture. 
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Figure 6-2:  Mass Spectrum of PEG2kSCM-sCT (1:1) Conjugation Product Mixture. 
  
 149 
 
Figure 6-3:  Mass Spectrum of Mono-PEGylated Salmon Calcitonin, Before Dialysis.  
 150 
 
Figure 6-4:  Mass Spectrum of Mono-PEGylated Salmon Calcitonin, After Dialysis. 
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Figure 6-5:  Release Profile of Salmon Calcitonin and PEGylated Salmon Calcitonin.  
From time t = 0-60 min, release conditions were acidic (pH 3).  At t = 60 
min, the release medium was neutralized and maintained at pH 7.4 for t > 60 
min.  Release levels reported as average ± standard deviation (n = 6). 
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Table 6-1:  Loading and Release Levels of Unmodified and PEGylated Salmon 
Calcitonin Using 1:2 P(IA-co-NVP) Microparticles. 
Protein 
Loading Level 
(μg/mg hydrogel) 
Protein Released, t=4 h  
(μg/mg hydrogel) 
Percent Release, 
t=4 h (%) 
sCT, Unmodified 103.0 ± 4.1 45.3 ± 4.8 43.9 ± 3.7 
sCT-PEG2 kDa 108.1 ± 4.5 26.9 ± 1.9 24.9 ± 1.2 
p-value 0.094 0.00013 0.000036 
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Chapter 7:   
In Vitro Models of Intestinal Absorption of Protein Therapeutics 
7.1 INTRODUCTION 
In the course of enabling the oral delivery of protein therapeutics, numerous 
obstacles had to be overcome:  protection from protein degradation in the stomach by 
hydrochloric acid or proteolytic enzymes; delivery to the small intestine (i.e., release 
from encapsulating delivery vehicles); protection from enzymatic degradation in the 
small intestine; and absorption of proteins into the bloodstream across the intestinal 
epithelium.  The last of these obstacles, intestinal absorption, is arguably the most 
significant barrier to achieving high bioavailability of proteins via the oral route. 
Intestinal cells have evolutionarily developed tight junctions—a collection of 
proteins between cells that regulate the permeability of the paracellular region—in order 
to control the absorption of compounds across the intestinal epithelium and prevent the 
transport of foreign molecules or organisms into the bloodstream.  Multiple proteins are 
responsible for forming and maintaining these tight junctions, most notably occludin, as 
seen in Figure 7-1.
1
  These proteins dynamically maintain the limited permeability 
between enterocytes, with permeability varying over multiple orders of magnitude 
between different epithelia and varying in response to numerous cellular signals, 
including:  electrolytes such as H
+
, Cl
-
, Na
+
, and Ca
2+
; electrical current; pressure; and 
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chemical agents such as bile salts, amphotericin B, nystatin, various detergents, cholera 
toxin, and theophylline.
2
 
In previous studies in our lab and other leading laboratories, Caco-2 cells have 
been widely used as a model of the small intestine.  These cells are human colon 
carcinoma cells that exhibit the main characteristics of the small intestine:  a polarized 
cell monolayer; tight junctions between cells; microvilli; and enzymes and transporter 
proteins characteristic of small intestinal enterocytes.
3–5
  Interestingly, cell lines derived 
directly from small intestinal cells fail to produce the polarized monolayer and tight 
junctions typical of them in vivo when cultured in vitro. 
Because it does express such features, the Caco-2 cell line provides one of the 
most accurate in vitro models of the small intestine, and its use has been widely adopted 
by the pharmaceutical industry and regulatory agencies as a result of Caco-2 models 
accurately predicting in vivo absorption of a wide range of compounds.
6–10
  Although 
Caco-2 cell monolayers exhibit lower permeability than the small intestine does in 
vivo,
11–13
 the observed permeabilities correlate strongly with observed in vivo 
absorption.
6,7
  A Caco-2 model may therefore be used to determine expected protein 
absorption across the small intestine in humans by measurement of the apparent 
permeability of the protein in vitro. 
Primarily due to their large size, macromolecules such as protein therapeutics 
ordinarily display very poor absorption across the small intestinal epithelium.  Although 
there are a select few proteins such as transferrin or various IgA antibodies that are 
actively transported across the epithelium by receptor-mediated transcytosis, most 
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proteins will exhibit only 1-10% absorption across the small intestine.  Caco-2 studies 
with insulin, a relatively small protein at only 5.8 kDa molecular weight, have shown 
only 0.05-0.1% absorption over 3 h (Papp = 1.1- 1.6 x 10
-9
 cm/s) across a monolayer in 
Transwell plates,
14,15
 which correlates to negligible absorption across the small intestine 
in vivo.
6,7
  Likewise, Youn et al.
16
 reported 0.05% of unmodified salmon calcitonin 
transport across a Caco-2 monolayer in 1 h (Papp = 1.5 x 10
-7
 cm/s), which correlates to 
low absorption in vivo, ranging from 0-15%.   
Such poor absorption of proteins, even small ones like insulin and salmon 
calcitonin, across the intestine results in very low bioavailability of orally delivered 
proteins.  Even if a theoretical delivery system achieved perfect release of encapsulated 
protein in the small intestine, the overall bioavailability would still be capped at 0-15%.  
At best, 85% of the administered drug would be wasted due to incomplete absorption 
across the intestinal epithelium into the bloodstream, requiring a prohibitively expensive 
amount of drug be used to achieve therapeutic effect.  As such, the intestinal barrier is a 
significant barrier to achieving high bioavailability of protein therapeutics delivered via 
the oral route. 
Studies have shown that the primary mode of transport across the intestinal 
epithelium for unmodified proteins is via paracellular transport through the tight 
junctions.
17
  The overall absorption can therefore be improved by either upregulating the 
paracellular pathway by opening of the tight junctions or enabling an active transport 
pathway through the cells.  The tight junctions may be disrupted by administration of 
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detergents or chloride ions, but these can potentially damage the epithelium with repeated 
administration. 
Several studies have shown that P(MAA-g-EG) microparticles can cause 
reversible opening of the tight junctions, increasing insulin permeability 1.5-fold to 9-
fold.
14,15,18–20
  In these studies, it has been hypothesized that chelation of Ca
2+
 ions by the 
anionic hydrogels is responsible for the opening of the tight junctions, especially since 
the apparent permeability increase is even greater (21-fold) when solutions with low Ca
2+ 
concentration are used in the apical chamber.
18
  The effect of the microparticles was also 
seen with salmon calcitonin, 
14
C-mannitol, fluorescein sodium, and fluorescein 
isothiocyanate dextran, although the degree of upregulation seemed to be correlated to 
the presence of PEG chains in the hydrogels rather than the methacrylic acid; this was 
further shown by the fact that pure PEG nanospheres caused increased permeability while 
pure PMAA nanospheres did not have such an effect.
21
  Because the methacrylic acid is 
responsible for the anionic charges that would bind Ca
2+
, these results cast some doubt as 
to the mechanism of the upregulation, instead demonstrating that some interaction of 
PEG with the cellular monolayer is instead the mechanism for enhanced permeability. 
Indeed, in a study by Carr and Peppas,
22
 P(MAA-co-NVP) hydrogels did not 
cause cellular disruption (as monitored by transepithelial electrical resistance) and did not 
cause a significant increase in insulin permeability across a Caco-2 cellular monolayer.  
Therefore, it is likely that the beneficial, reversible opening of the tight junctions 
associated with use of P(MAA-g-EG) hydrogels is due solely to PEG interaction with the 
cell layer rather than due to Ca
2+
 binding. 
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Interestingly, Youn et al.
16
 reported no significant change in salmon calcitonin 
permeability following conjugation with a 2 kDa PEG chain.  Although the increased 
hydrodynamic radius of the conjugate should decrease permeability because of the 
narrow passage through the tight junctions, the presence of the PEG chain seems to have 
offset the decrease.  It is unusual that the conjugated PEG merely offset the sCT 
permeability decrease in this study, while the presence of PEG in hydrogel particles 
enhanced insulin permeability multi-fold in other studies.  This could be due to the 
overall amount of PEG chains or perhaps PEG chain length differences, or any number of 
other factors; however, the salient point is that PEG seems to have a beneficial effect on 
the intestinal absorption of proteins. 
In this chapter, Caco-2 studies are presented to determine the effects of the 
hydrogel microparticles and/or PEGylation on the intestinal absorption of salmon 
calcitonin and Rituxan.  Any changes in the intestinal absorption could significantly 
improve the overall bioavailability of protein therapeutics delivered via the oral route and 
therefore increase the clinical feasibility of the delivery system.  Therefore, it is important 
to determine what factors are responsible for determining protein transport across the 
epithelium and obtain an estimate of the possible bioavailability. 
7.2 MATERIALS AND METHODS 
7.2.1 Caco-2 Cell Culture 
Caco-2 human colorectal adenocarcinoma cells (ATCC, Manassas, VA) were 
cultured normally using Dulbecco’s Modified Eagle’s Medium (DMEM) (Sigma-
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Aldrich, St. Louis, MO) with 10% v/v fetal bovine serum (Hyclone Laboratories, Logan, 
UT), 1% v/v penicillin-streptomycin (Fisher Scientific, Waltham, MA), and 1% v/v L-
glutamine (Mediatech, Manassas, VA) added.  Cells were cultured in 75 cm
2
 flasks 
(Fisher Scientific) at 37 °C with 5% CO2.  The cells were passaged once the cells reached 
80-90% confluence, involving removal of cells from the flask surface by addition of 
trypsin in ethylenediaminetetraacetic acid (Sigma-Aldrich) and transfer to a new flask at 
3.0 x 10
3
 cells/cm
2
 seeding density. 
7.2.2 Caco-2 Transwell Intestinal Absorption Study 
At passage number 55, Caco-2 cells were seeded into Transwell plates (Corning, 
Tewksbury, MA), as shown in Figure 7-2.  All wells contained a 1.12 cm
2
 polycarbonate 
membrane with 0.4 μm mesh size.  Cells were seeded on this membrane at a density of 
1.0 x 10
5
 cells/well, using 0.5 mL of DMEM in each apical chamber and 1.5 mL in each 
basolateral chamber.  Cells were initially allowed to grow for 3 days before the media 
was changed.  Media was then changed every 2 days for a total of 21 days.  Over this 
time, the transepithelial electrical resistance (TEER) was monitored using a chopstick 
electrode and an ohmmeter to monitor the development of tight junctions within the 
monolayer. 
After 21 days of culture in the Transwell plate, the cell monolayers were used as a 
model small intestine.  The initial TEER of all wells was measured using a chopstick 
electrode and ohmmeter.  Culture media was then removed and all wells were rinsed with 
Hank’s Balanced Salt Solution (HBSS) (Life Technologies, Carlsbad, CA).  Bovine 
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serum albumin (BSA) (Sigma-Aldrich) was dissolved in HBSS at a concentration of 0.5 
mg/mL and added to the apical and basolateral chambers of all wells to adsorb to free 
binding sites on the polystyrene plates.  The solution was allowed to incubate for 30 min 
at 37 °C.   
Four solutions using either salmon calcitonin (sCT) (Selleck Chemicals, Houston, 
TX) or sCT-PEG (prepared and purified as described in Chapter 6) were prepared in 
BSA/HBSS solution at a concentration of 200 μg/mL, with or without 1 mg/mL of 
microparticles of the 1:2 P(IA-co-NVP) formulation (prepared and purified as described 
in Chapter 4).  Thus, the four test groups were: 
1. sCT only (200 μg/mL) in BSA/HBSS 
2. sCT-PEG only (200 μg/mL) in BSA/HBSS 
3. sCT (200 μg/mL) in BSA/HBSS + 1:2 P(IA-co-NVP) microparticles  (1 
mg/mL) 
4. sCT-PEG (200 μg/mL) in BSA/HBSS + 1:2 P(IA-co-NVP) microparticles  
(1 mg/mL) 
After the 30 min incubation of BSA/HBSS in the Transwell plates, the 
BSA/HBSS was removed from the apical chamber of all wells and replaced with 0.5 mL 
of the test solutions described above (n = 5 per study group).  The plates were incubated 
at 37 °C and 5% CO2 for 2 h.  At time points of t = 0.5, 1, and 2 h, 250 μL samples were 
taken from the basolateral chamber of all wells and replaced with 250 μL of BSA/HBSS 
solution.  At the end of the 2 h study, the final TEER of all wells was measured.  The 
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concentration of sCT or sCT-PEG absorbed into the basolateral chamber at each time 
point was determined using a salmon calcitonin EIA kit (Phoenix Pharmaceuticals, 
Burlingame, CA).  The apparent permeability of each well was calculated using Equation 
7-1, 
𝑃𝑎𝑝𝑝 =
𝑉𝑅
𝐴 ∙ 𝑐0
 
𝑑𝑐
𝑑𝑡
 Equation 7-1 
 
where Papp is the apparent permeability coefficient of the protein transported through the 
Caco-2 monolayer [cm/s], VR is the volume of the basolateral reservoir [cm
3
], A is the 
surface area of the membrane [cm
2
], 𝑐0 is the initial concentration of protein in the apical 
chamber [ng/mL], and 
𝑑𝑐
𝑑𝑡
 is the rate of concentration change in the basolateral chamber 
[ng/mL-s], calculated as the slope of the best-fit line running through the determined 
concentrations over the entire 2 h experiment.  Student’s t-test was used to test for group-
to-group statistical significance, and ANOVA was used to test for statistical significance 
between all groups. 
7.3 RESULTS AND DISCUSSION 
The study described in section 7.2.2 was performed to determine the effects of the 
presence of PEG and the presence of the P(IA-co-NVP) microparticles on the intestinal 
absorption of salmon calcitonin.  The inconsistent results of previous studies have led to 
confusion over whether the microparticles have inherent beneficial effects on the 
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intestinal absorption of proteins due to calcium chelation or whether PEG interacts with 
the cell layer in some manner, causing the increased permeability. 
The study of Torres-Lugo et al.
21
 indicated that the presence of PEG causes 
disruption of the tight junctions, rather than calcium binding by the anionic methacrylic 
acid residues present in the hydrogel.  However, with a diprotic acid monomer like 
itaconic acid, the hydrogels developed for use with high pI-exhibiting therapeutic 
proteins may exhibit different Ca
2+
 binding capability than the methacrylic acid-based 
gels showed.  Therefore, this study should provide some indication as to the overall 
bioavailability possible using the P(IA-co-NVP) hydrogel delivery system without further 
improvements to the intestinal absorption. 
The average apparent permeability (Papp) for each study group is reported in Table 
7-1.  Wide variations in Papp were observed within each study group:  calculated standard 
deviations were approximately equal in magnitude to the average values, ranging from 72 
– 104% of the average values.  As a result, the only statistically significant difference 
between study groups was between the sCT-PEG with microparticles group and the two 
groups using unmodified sCT, which was still not quite at the 95% confidence level (p < 
0.052). 
Despite the large standard deviations, the average values of Papp reveal an 
important distinction.  The study groups using PEGylated sCT exhibited Caco-2 cell 
permeability two orders of magnitude greater than the groups using unmodified sCT.  All 
10 wells in the unmodified sCT groups exhibited apparent permeability on the order of 
10
-9
 cm/s, while 7 of 10 wells in the sCT-PEG groups exhibited apparent permeability on 
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the order of 10
-7 
cm/s.  (The other 3 wells were on the order of 10
-9
 cm/s, causing the very 
wide standard deviations.)  Meanwhile, although the average Papp increased slightly due 
to the presence of the microparticles—a 33% increase for sCT groups and a 19% increase 
for sCT-PEG groups—the difference was not nearly as great as a full two orders of 
magnitude, and this difference could easily be due solely to intragroup variability rather 
than a true increase in permeability (p > 0.70). 
These results therefore support the findings of Torres-Lugo et al.
21
 that the 
presence of PEG causes increased intestinal permeability in Caco-2 cultures, while the 
presence of anionic hydrogels seems to have negligible effect.  Although previous studies 
did show significantly increased permeability with use of P(MAA-g-EG) microparticles, 
this study and that of Torres-Lugo et al. demonstrate that the increased permeability is a 
result of some interaction of PEG with the monolayer rather than a result of the anionic 
hydrogel binding Ca
2+
 ions as hypothesized in these previous studies.  Therefore, use of 
PEGylated proteins could lead to significantly improved bioavailability via the oral route 
due to increased intestinal absorption as well as increased half-life.   
Furthermore, these results suggest that use of PEG-containing hydrogels may be 
preferable for enhancing oral protein delivery capability compared to gels with no PEG 
monomers.  As reported in Table 5-1, three IA-based formulations with varying monomer 
ratios—namely the 1:2 and 1:1 molar monomer ratio formulations of P(IA-co-NVP) and 
the 45:45:10 P(IA-co-NVP-co-MMA) formulation—outperformed the lone P(IA-g-EG) 
hydrogel studied in terms of sCT loading and release in in vitro conditions.  However, 
because the primary obstacle to oral delivery of therapeutic proteins is intestinal 
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absorption, the increased permeability resulting from PEG interaction with the cell layer 
could more than make up for the decreased loading and release efficiency, especially if 
the increased permeability is over two orders of magnitude as observed with PEGylated 
sCT in this study. 
It is interesting to note that 4 kDa molecular weight PEG alone demonstrates 0% 
intestinal absorption in vivo,
6,7
 while 0.9 kDa molecular weight PEG demonstrates 10% 
intestinal absorption.
7
  This shows that the effect of PEG on intestinal absorption is size 
dependent.  Thus, the 2 kDa PEG chain used in the sCT-PEG conjugate seems to enhance 
absorption, although a larger chain may not have the same effect.  The PEG chain length 
should therefore be a well-controlled variable in the rational design of P(IA-g-EG) 
hydrogels for enhancing intestinal absorption:  hydrogels with high monomer ratios of 
PEG to itaconic acid and with short PEG chains (~1 kDa) would be expected to 
demonstrate the best intestinal absorption of the delivered protein.  However, the 
enhancement of intestinal absorption may be offset by reduced loading and release 
capability, necessitating a holistic study of both facets of the delivery system. 
The TEER of all wells was measured before and after the study in order to have a 
quantified value that is indicative of the permeability of the cell monolayer.  The 
compared average values for all groups are reported in Table 7-1.  Prior to the study, 
there was no significant difference in TEER between groups (p = 0.30), indicating no 
difference between groups in terms of confluence or permittivity of the tight junctions 
that would have affected the results of this study.  Likewise, after the study, the TEER 
values did not exhibit statistically significant difference between groups (p = 0.42).  The 
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TEER values, however, did increase in 16 of the 20 studied wells and for all group 
averages.   
TEER does not provide a complete picture of the integrity of the tight junctions 
since it measures the resistance to ion transport which can occur by paracellular or 
transcellular pathways and because the molecular bases for ion-selective and size-
selective paracellular transport have proven to be distinct.
23–25
  Therefore, it is not 
unexpected that PEGylation yields greater absorption despite the increased size while 
simultaneously increasing resistance to ion transport.  Nevertheless, a significant decrease 
in the TEER would be expected if the cellular layer was being harmed; thus an increase 
in TEER that is similar for all groups corroborates the previously described cytotoxicity 
studies that indicated good biocompatibility with P(IA-co-NVP) microparticles with 
Caco-2 cells (Chapter 4) and indicates that the interaction between PEG and the 
monolayer, whatever the mechanism may be, does not cause unusual and potentially 
dangerous changes to ion-selective permeability of the intestinal epithelium. 
The increased apparent permeability in response to the presence of PEG could 
have a great impact on the feasibility of the overall system.  Although Caco-2 
permeability tends to correlate well with human in vivo intestinal absorption, it is a rough 
correlation rather than a perfect match.  The apparent permeability on the order of 10
-9 
cm/s observed the unmodified protein test groups correlates to in vivo absorption on the 
order of 0-5%, severely limiting the economic feasibility of these delivery systems.  
However, the 2 order of magnitude increase in apparent permeability observed due to 
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PEGylation correlates to a wide range of possible in vivo absorption, ranging from 15-
75% absorption in vivo.
6,7,9
 
Because of the wide variability in intestinal absorption with compounds within 
this range of Caco-2 permeability, it is difficult to ascertain the true economic feasibility 
of the delivery system.  Nevertheless, it is clear that the increased permeability observed 
resulting from PEG will greatly enhance the ability of such delivery systems to reach 
clinical use.  Indeed, even though the 1:2 P(IA-co-NVP) hydrogel formulation showed 
over 3x better delivery capability of sCT compared to P(IA-g-EG) microparticles, as 
shown in Table 5-1, if the presence of PEG in the P(IA-g-EG) microparticles results in 
absorption closer to 75% compared to 5%, the increase in intestinal permeability would 
clearly yield greater benefit and enable higher, clinically useful bioavailability via the 
oral route.  
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Figure 7-1:  Hypothetical Model of Tight Junction and Adherens Junction Between 
Epithelial Cells.  The tight junction is formed by contact of the 
transmembrane protein occludin with occludin from the neighboring cell.  
Occludin is bound to zonula occluden-1 (ZO-1) within the cytoplasm.  ZO-1 
forms a dimer with ZO-2, which binds an uncharacterized 130 kDa protein.  
The interactions of cingulin and 7H6 antigen are undefined.  Adherens 
junctions are maintained by the transmembrane protein cadherin, which 
directly associates with cytoplasmic proteins α-, β-, and γ-catenin.  
Numerous regulatory signaling proteins are localized within the cytoplasm 
at the adherens junctional complex.  Reprinted with permission from 
Anderson and Van Itallie.
1
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Figure 7-2:  Schematic of Caco-2 Transwell Intestinal Absorption Model. 
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Table 7-1:  Caco-2 In Vitro Permeability Study.  Study comparing apparent permeability 
of unmodified and PEGylated salmon calcitonin in absence of and presence 
of 1:2 P(IA-co-NVP) hydrogel microparticles.  All values are reported as 
average ± standard deviation. 
Test Group 
Apparent Permeability, Papp 
(x 10
-9
 cm/s) 
TEER, t = 0 h 
(Ω-cm2) 
TEER, t = 2 h 
(Ω-cm2) 
sCT Only 2.71 ± 2.81 554 ± 18 760 ± 123 
sCT-PEG Only 221 ± 216 566 ± 85 602 ± 230 
sCT + Microparticles 3.60 ± 3.56 590 ± 68 794 ± 164 
sCT-PEG + Microparticles 263 ± 189 479 ± 124 668 ± 168 
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Chapter 8:  Aptamer Selection for Enhancing Intestinal 
Absorption of Therapeutic Proteins 
8.1 INTRODUCTION 
As discussed extensively in Chapter 7, the intestinal absorption of protein 
therapeutics into the bloodstream is the most significant remaining obstacle to effective 
oral delivery.  Typical protein absorption lies in the range of 0-5%, severely limiting the 
bioavailability of protein therapeutics even with complete release of protein in the small 
intestine.
1,2
  As shown in Chapter 7, the presence of PEG can enhance apparent 
permeability observed in Caco-2 models by orders of magnitude, raising the expected 
absorption of salmon calcitonin into a more functional range of 20-75%.  However, 
paracellular transport through the tight junctions is a size-selective process,
3–5
 meaning 
that absorption of larger molecules such as antibodies would remain too insignificant for 
oral delivery to be financially feasible as a therapeutic delivery option.  Therefore, 
improvements are needed to enhance intestinal absorption to overcome this barrier to 
clinical treatment options. 
Studies with insulin and salmon calcitonin have suggested that the primary 
method of transport of these proteins across the small intestine is via the paracellular 
route.
6,7
  Transport across the epithelium through the paracellular route is driven by 
diffusion through the tight junctions.  Diffusive processes operate on a relatively slow 
timescale compared to active transport within the body.  Therefore, even with the use of 
(potentially dangerous) permeation enhancers, the rate of intestinal absorption will be 
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limited by diffusion kinetics.  Utilizing one of the many cellular mechanisms for 
achieving active, transcellular transport of proteins across the epithelium could greatly 
enhance both the rate and overall magnitude of intestinal absorption. 
An increase in intestinal absorption has previously been demonstrated by 
conjugation of transferrin to a therapeutic protein.
8–11
  Transferrin is an 80 kDa protein 
that is responsible for regulating the level of iron in the bloodstream.  Each transferrin 
molecule can bind up to two iron (III) ions and undergoes receptor-mediated endocytosis 
upon binding to a transferrin receptor present on a cell surface.  Active cellular transport 
occurs at a rate that is almost always greater than the rate of diffusive paracellular 
transport, especially for large molecules that are otherwise prevented from passing 
through the tight junctions by size exclusion.
12
  Therefore, conjugation of a protein 
therapeutic to transferrin can effectively bypass the barrier of the small intestinal 
epithelium by hijacking a pathway already present in the body through evolution.  In a 
Caco-2 transport study using an insulin-transferrin conjugate, the apparent permeability 
of the conjugate proved to be 15x greater than that of the unmodified insulin, despite the 
significantly increased size of the conjugate.
8
 
Although this method presents one means of increasing the achievable 
bioavailability of orally delivered proteins, the size of the transferrin molecule presents 
some drawbacks.  Primarily, the increased size of the conjugate compared to the 
unmodified therapeutic will inhibit the protein loading and release capability using the 
P(IA-co-NVP) hydrogels.  As shown in Chapter 5, increased size has a significant impact 
on the delivery capability of a particular hydrogel formulation because the rate of 
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diffusion is reduced for a larger solute and the mesh size of the hydrogel must be large 
enough to accommodate.  The negative impact of conjugation with transferrin on delivery 
can be mitigated by using lower crosslinking density, but the diffusional kinetics will 
remain slower. 
Furthermore, conjugation of a large protein (transferrin) to a smaller protein (e.g., 
insulin, salmon calcitonin) can potentially inhibit the activity of the therapeutic protein 
due to steric hindrance.
13
  However, this effect can be largely negated by wise choice of 
crosslinking chemistry:  crosslinks made to degrade at some point after endocytosis, such 
as an acid labile crosslink triggered by the acidic pH shift to pH 5.5 inside the vesicle, 
can release the protein once active transport has been successfully initiated, leaving the 
original protein with full functionality. 
 Finally, it has been shown that transferrin receptors on cell surfaces can saturate, 
placing an upper limit on the transport rate of protein across the small intestine regardless 
of the apical dose.
14,15
  Although this rate remains significantly faster than the rate of 
paracellular transport of proteins, there may be other receptors present in the epithelium 
that achieve a faster rate of delivery, enabling higher bioavailability and higher doses.  
Furthermore, should receptor saturation occur, having a smaller conjugate that can 
simultaneously undergo paracellular transport would also be desirable. 
In this chapter, work towards developing a smaller, but nevertheless effective 
ligand for initiating active transcellular transport is presented.  Monoclonal antibodies are 
the current gold standard for binding to target molecules or receptors, but are even larger 
than transferrin (~144 kDa vs. 80 kDa) and require significant time and skill to develop 
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and manufacture.  Therefore, this work focuses on using aptamers, which are nucleic acid 
analogues of antibodies, as an auspicious substitute for an antibody. 
As described in Chapter 2, aptamers have several advantages over antibodies that 
make them a strong candidate for this application.  First and foremost, by virtue of being 
easily replicated and amplified in vitro through the polymerase chain reaction (PCR), 
aptamers can be quickly and inexpensively developed through evolutionary techniques 
that require no explicit knowledge about the target a priori.  Unlike antibodies, which are 
typically painstakingly manufactured individually in sufficient quantities using 
recombinant DNA technology, aptamers can be amplified as a complete library, enabling 
one single reaction to replicate an enormous variety of sequences.  Therefore, by using 
the SELEX protocol, as seen in Figure 8-1, a researcher can allow nature to determine 
both the optimal receptor and the optimal sequence to bind to it for maximizing 
transcellular absorption.
16,17
 
Beyond the relatively straightforward discovery process, aptamers also exhibit 
high specificity and binding, often on the order exhibited by antibodies.
18,19
  At the same 
time, the size of effective aptamers typically range from only 5 – 40 kDa in size, making 
them significantly smaller than transferrin or antibodies.
19
  The reduced size is especially 
important from an oral delivery perspective, as it benefits the loading and release 
properties, the rate of diffusion, the probability of paracellular transport, and the activity 
of the therapeutic following conjugation. 
On account of their relatively small size, selective binding capability, and facile 
discovery and amplification, aptamers were selected using Caco-2 models of the small 
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intestine in order to develop a suitable ligand for enabling transcellular uptake of protein 
therapeutics.  This chapter describes the selection procedure used, the sequencing of the 
selected aptamers, and the absorption of the aptamers across the model epithelium. 
8.2 MATERIALS AND METHODS 
8.2.1 Modified Cellular SELEX Protocol 
8.2.1.1 Initial Aptamer Library Preparation 
A library of DNA sequences consisting of a twenty-nucleotide random sequence 
(N20) flanked by forward promoter and reverse promoter sequences was used for the 
selection process (TriLink Biotechnologies, San Diego, CA).  A T7-promoter forward 
primer was incorporated in the sequence at the 5’ end by PCR amplification.  Three 
volumes of CleanAmp PCR master mix (TriLink Biotechnologies) were mixed with one 
volume each of 20 μM T7-promoter forward primer, 20 μM reverse primer, and 10 μM 
N20-library.  The solution underwent PCR amplification in an Applied Biosystems 2720 
thermocycler (Life Technologies, Carlsbad, CA), consisting of:  heating at 95 °C for 5 
min; 40 thermal cycles of 30 s at 95 °C, 30 s at 55 °C, and 30 s at 72 °C; and finally 10 
min at 72 °C.  The final reaction mixture was purified of unreacted components using a 
MinElute PCR purification kit (Qiagen, Valencia, CA).  The resulting library, termed the 
“naïve library,” was used as the starting point for selection cycles. 
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8.2.1.3 In Vitro Transcription 
The amplified dsDNA library for each selection round was transcribed into 2’-
fluorine-modified RNA using the DuraScribe T7 transcription kit (Epicentre, Madison, 
WI).  In brief, 3 volumes of dsDNA, 3 volumes of nuclease-free water, and 2 volumes of 
each reagent (DuraScribe T7 reaction buffer, 50 mM ATP, 50 mM GTP, 50 mM 2’-F-
dCTP, 50 mM 2’-F-dUTP, 100 mM dithiothreitol (DTT), and DuraScribe T7 enzyme 
mix) were combined and incubated for 4 h at 37 °C.  After incubation, DNA was digested 
by adding 1 volume of DNase I and incubating for 15 min.  The resulting RNA library 
was purified using a miRNeasy purification kit (Qiagen). 
8.2.1.4 Cellular Selection 
Cellular selection was performed using a Caco-2 Transwell model.  Caco-2 cells 
were seeded and grown in 12-well Transwell plates, as described in section 7.2.2.  After 
at least 21 days of culture in the Transwell plate, the culture media was removed from the 
transport wells and the wells were washed with Hank’s Balanced Salt Solution (HBSS) 
(Life Technologies).  The basolateral chamber was filled with 1.5 HBSS while the apical 
chamber received 0.5 mL HBSS with the RNA library added at a concentration of 5 
μg/mL or greater, uniform across all wells.  The wells were incubated for 1.5 h at 37 °C, 
after which the basolateral solution was collected for quantification and purification using 
a miRNeasy purification kit. 
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8.2.1.5 In Vitro Reverse Transcription 
The selected RNA was reverse transcribed to complementary DNA using 
SuperScript III reverse transcriptase (Life Technologies).  A mixture of 1 volume of 20 
μM T7-promoter forward primer, 1 volume of 20 μM reverse primer, 10 volumes of 
purified RNA, and 1 volume of dNTP mixture (Life Technologies) was heated to 65 °C 
for 5 min and placed on ice for 1 min.  Following this, 4 volumes of SuperScript First-
Strand Buffer, 1 volume 0.1 M DTT, and 1 volume of SuperScript III reverse 
transcriptase were added.  The reaction mixture was incubated at 55 °C for 1 h, followed 
by incubation at 70 °C for 15 min to stop the reaction.  The resulting cDNA was purified 
using a MinElute PCR purification kit. 
8.2.1.6 Nucleic Acid Quantification 
Following each step in the selection process—PCR amplification, transcription, 
selection, or reverse transcription—the DNA or RNA was quantified using 2 μL of 
sample in a Nanodrop 1000 UV-Vis spectrophotometer (Thermo Fisher Scientific, 
Wilmington, DE).  The amount of DNA or RNA was quantified by UV absorbance 
measurement at 260 nm.  Purity was ensured using ratios of absorbances at different 
characteristic wavelengths, namely the 260/230 and 260/280 ratios. 
8.2.1.7 Cycle Repetition 
Following reverse transcription and purification, the resulting DNA library 
functioned as a new starting library for another selection round.  The new library was 
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amplified using the PCR reaction described in section 8.2.1.1 and carried through the 
entire selection protocol 3 times.  A flowchart summarizing the process is shown in 
Figure 8-2.  The selection protocol was carried out in 4 parallel samples (n = 4). 
8.2.2 Sequencing of Selected Aptamers 
8.2.2.1 Sequencing Procedure 
After the final selection step, the selected RNA sequences were reverse 
transcribed to dsDNA and PCR amplified for sequencing.  Library preparation and 
sequencing was performed by the Genomic Sequencing and Analysis Facility at The 
University of Texas at Austin using standard Illumina library preparation kits and a 2 x 
150 MiSeq sequencer (Illumina, San Diego, CA).  Selected aptamer libraries and the 
naïve library were sequenced. 
8.2.2.2 Data Analysis 
Sequencing data were analyzed using Galaxy (usegalaxy.org).
20–22
  The FastQ 
files containing sequence reads were analyzed using the following workflow.  Data 
quality was ensured using the FastQC quality report tool.
23
  Sequence reads containing 
the expected T7 primer were selected and trimmed to isolate the N20 random sequence.  
The data was converted from FastQ to tabular format,
24
 to enable counting of the number 
of occurrences of each sequence.  Finally, the data was sorted to identify the most 
numerous N20 sequence reads.  This analysis was performed on the individual selected 
libraries, the naïve library, and the combined data from all selected aptamer libraries. 
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8.3 RESULTS AND DISCUSSION 
8.3.1 Modified Cellular SELEX Protocol 
The in vitro selection process was designed to enable the cellular selection of 
transcellular transport-initiating aptamers with minimal experimentation needed to 
determine optimal targets.  Although many aptamer design studies have been performed, 
these have used isolated binding targets that are easily separable, such as by 
immobilization on magnetic beads to enable magnetic separation of bound aptamers from 
unbound nucleic acids.
25
  Using isolated targets has been necessary largely due to the 
poor stability of nucleic acids in biological systems, thus necessitating a selection 
environment completely free of nucleases, but requires the researcher to know a priori 
what the desired target is. 
By using nucleotides with 2’-fluorine modifications on the pyrimidines, the in 
vivo half-life can be greatly extended,
26
 allowing selection to occur directly in a cellular 
environment without nuclease digestion destroying the aptamers.  Similar selection 
protocols have previously been reported, demonstrating successful use of cellular 
aptamer selection.
27,28
  Applying the systematic evolution protocol within the Caco-2 
cellular model should therefore enable discovery of the optimal aptamer sequences for 
enhancing intestinal absorption, without requiring prior knowledge of the optimal 
transport receptors for the aptamer to bind.  Therefore, the modifications incorporated 
into this protocol should enable a rapid, yet robust aptamer discovery process that mimics 
the full complexity of the system. 
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Furthermore, the use of high throughput sequencing rather than traditional Sanger 
sequencing greatly benefits the aptamer selection process.  Traditionally, SELEX 
protocols require 10 or more rounds of selection followed by cloning of a small number 
of sequences to isolate and amplify individual sequences before Sanger sequencing can 
accurately identify the sequence.  However, use of next-generation sequencing (NGS) 
enables tens of millions of unique sequences to be identified simultaneously, allowing the 
researcher to analyze the distribution of an entire library within a far faster time frame.  
As such, applying NGS to the traditional SELEX protocol allows for optimal aptamer 
sequences to be determined within a few selection rounds rather than 10 or more, greatly 
reducing the experimental time frame, reducing the chances of identifying sequences 
most present due to PCR amplification bias rather than optimal binding, and increasing 
the accuracy with which the library’s sequence distribution can be determined.25,29–38 
The protocol was successfully performed as described, with 4 aptamer libraries 
undergoing the selection protocol in parallel.  Only 3 of the aptamer libraries successfully 
formed sequencing libraries upon sample preparation; all analysis was carried out using 
these 3 libraries. 
8.3.2 Aptamer Sequencing 
The aptamer libraries were successfully sequenced and analyzed as described in 
section 8.2.2.  Table 8-1 shows the total number of sequence reads for each of the 
individual libraries studied.  Each library had over 4 million sequence reads.  However, 
with a 20 nucleotide random sequence, the potential number of sequences is 4
20 
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sequences, or approximately 1.1 trillion possibilities.  Therefore, 4 million reads can only 
cover at most 3.6 x 10
-4
% of all possible sequences, meaning the expected number of 
each sequence actually observed in the naïve library is only 1 because the odds of 
observing that sequence are so low.  This is reflected in our samples, as the number of 
unique sequences is 0.93x as many as the total observed, indicating an average observed 
copy number of only 1.07.  As such, sequences observed more than once in the native 
library are likely benefitting from PCR bias, where the PCR process amplifies a particular 
sequence to a greater degree than others due to one of numerous potential factors (e.g., 
preferable primer or enzyme binding).  In an effort to control for PCR bias in the final 
aptamer libraries, the observed number of aptamers will be compared to the observed 
number of the same aptamer in the naïve library. 
The top 10 most commonly observed N20 sequences in the combined aptamer 
library are shown in Table 8-2, along with the number of instances in each sample set.  
Although the selected aptamers are RNA molecules, sequencing requires complementary 
DNA.  Therefore, the sequences shown in Table 8-2 are actually the DNA sequences (as 
observed in the MiSeq results) that will transcribe into the desired RNA aptamers. 
As with the naïve library, the expected number of times a particular sequence 
would be observed in the combined aptamer sequencing data based purely on probability 
is 0.000015 times.  However, despite sheer probability suggesting a particular sequence 
would not even be observed, the most frequently observed sequence was sequenced 100 
times, indicating a significant degree of selection pressure making this sequence so 
prevalent compared to random chance. 
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The selection pressure could be due to one of several factors, including improved 
Caco-2 permeability (as desired), PCR bias, or sequencing bias.
39,40
  Unfortunately, 
sequencing bias cannot be easily controlled because it is inherent to the identification 
method at the current time.  PCR bias is also inherent to the selection process, but can be 
partially controlled for by comparing the relative number of sequence reads between the 
selected and naïve libraries.  Interestingly, all of the 6 most commonly observed 
sequences in the aptamer library (and 8 of the top 10) were also observed in the naïve 
library.  Given the low probability of observing a specific sequence in the naïve library, it 
is likely that these sequences benefitted from either PCR or sequencing bias to make 
them all appear in the naïve library sequences, most at more than one read.   
Nevertheless, the degree to which these sequences are overexpressed is quite 
significant.  After dividing the number of sequences observed in the selected libraries by 
the count in the naïve library and accounting for the difference in number of total reads, 
the degree to which these sequences were upregulated was determined.  This ratio of the 
number of observed reads in the aptamer libraries to the number of expected reads based 
on the naïve library is defined as the “selection ratio.”  The 6 sequences with the highest 
selection ratios are shown in Table 8-3, along with the 4 remaining sequences from the 10 
most prevalent (Table 8-2) that either were not in the top 6 sequences or did not appear in 
the naïve library sequence reads. 
After correcting for the prevalence in the naïve library, several sequences emerge 
as potential ligands for further study, such as the sequence 
GAGTCGTATTACCTGTTCAG with a selection ratio indicating 10-fold upregulation 
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over the course of the selection protocol.   Furthermore, the two sequences that were not 
observed in the naïve library reads that were in the top 10 most prevalent sequences—
ACGTATTACCTGAAAGATCG and GTTGTATTACCTGAAAGATC—are especially 
interesting.  The fact that they were not observed in the naïve library could indicate that 
they are becoming more prevalent in the sample due entirely to the selection process 
rather than PCR or sequencing bias, which would have likely shown in the naïve library.  
Finally, the most prevalent sequence in the aptamer libraries, 
AGTATTACCTGAAAGATCGG, remains in the top 5 sequences with the highest 
selection ratio, indicating strong selection preference, despite potential PCR bias.  These 
few sequences are worth studying individually to see if they do in fact aid in intestinal 
absorption, to what extent, and by what mechanism they achieve selective absorption. 
8.3.3 Caco-2 Intestinal Absorption 
The nucleic acids were quantified before and after selection in the Caco-2 
Transwell model to determine the percent absorption across the cellular monolayer.  The 
percent recovery after each selection round is shown in Figure 8-3.  It is interesting to 
note that each subsequent step in the selection process shows a greater percentage of the 
aptamer library applied to the apical chamber being absorbed across the Caco-2 
monolayer into the basolateral chamber.  Furthermore, the increase in absorption is 
statistically significant (p < 0.05) for each subsequent selection round.  This trend 
provides further support for the fundamental hypothesis that the selection process is 
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driving the aptamer library toward a distribution of sequences that are more adept at 
transport across the intestinal epithelium by eliminating poorly absorbed sequences. 
Given this data, the selection and sequencing processes were quite successful.  An 
initial library containing 1.1 trillion potential sequences was narrowed down to 5-10 
sequences that appear to be strong candidates for enabling high bioavailability across the 
intestinal epithelium.  The selection protocol required a minimal number of selection 
steps and little a priori knowledge of the optimal binding targets, yet demonstrated 
significant improvements in transport across a Caco-2 monolayer over subsequent 
selection rounds. 
Further studies would be needed to fully characterize the identified RNA 
aptamers.  Caco-2 studies using isolated sequences, both with free protein therapeutic and 
with protein-aptamer conjugates, could better determine if and to what extent these 
aptamers increase protein absorption, as well as the mechanism for the enhancement.  
Nevertheless, this work has successfully identified several promising candidate sequences 
for further study that could provide a relatively low molecular weight (6.6 - 21.3 kDa, 
depending on if primers are necessary for activity) alternative to transferrin that enables 
similar or improved levels of protein absorption across the intestinal epithelium. 
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Figure 8-1:  Steps of a Typical SELEX Aptamer Selection Protocol.  A random library of 
DNA or RNA molecules (S1) is incubated with a target molecule, and 
bound complexes are separated from unbound sequences (S2).  Bound 
aptamers are eluted (S3) and amplified by PCR (S4), forming a new library 
for further evolutionary selection.  Following multiple selection cycles, the 
optimal aptamer sequence(s) are determined by cloning and Sanger 
sequencing.  Reprinted with permission from Blind and Blank, Mol. Ther. 
Nucleic Acids, 2015.
25
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Figure 8-2:  Modified Cellular SELEX Protocol.  A random library of DNA molecules is 
transcribed to 2’-fluorine-modified RNA.  RNA is incubated in the apical 
chamber of a Transwell plate with Caco-2 monolayer for 1.5 h and 
transported sequences are isolated from unabsorbed sequences.  The 
absorbed aptamers are reverse transcribed to DNA and amplified by PCR, 
forming a new library for further evolutionary selection.  Following only 3 
selection cycles, the optimal aptamer sequences are determined using high 
throughput sequencing.  
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Figure 8-3:  Aptamer Absorption in Caco-2 Transwell Model.  Percent aptamer 
absorption was determined after each selection step for n = 4 parallel 
selection libraries using UV-Vis spectrometry.  Reported as average ± 
standard deviation.  
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Table 8-1:  Overview of MiSeq High Throughput Aptamer Sequencing Results. 
Library 
Total Sequence 
Reads (Millions)
 
Total Identified 
Aptamer Sequences 
(Millions) 
Unique Aptamer 
Sequences 
(Millions) 
Naïve Library 4.98 1.46 1.37 
Aptamer, #1 6.47 2.70 2.52 
Aptamer, #2 4.29 1.79 1.67 
Aptamer, #3 5.80 2.46 2.26 
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Table 8-2:  Top 10 Most Commonly Sequenced N20 Aptamer Sequences.  Sequences are 
named using the DNA sequence read on the MiSeq platform; the actual 
aptamer sequence is the RNA transcript of the listed sequence.  Number of 
sequence reads are listed as the total occurrences across all three sequenced 
aptamer libraries, the occurrences within individual libraries, and the 
occurrences in the naïve DNA library.  
DNA N20 Sequence 
Number of Sequences Observed 
Total, All 
Aptamers 
Aptamer, 
#1 
Aptamer, 
#2 
Aptamer, 
#3 
Naïve 
Library 
AGTATTACCTGAAAGATCGG 100 65 14 21 5 
TGACTAGTACATGACCACTT 80 36 17 27 12 
GTATTACCTGAAAGATCGGA 64 42 10 12 2 
TGTATTACCTGAAAGATCGG 59 39 10 10 2 
AGATCGGAAGAGCGTCGTGT 37 33 3 1 5 
GAGTCGTATTACCTGTTCAG 35 9 9 17 1 
ACGTATTACCTGAAAGATCG 33 16 6 11 0 
CTCGTATGCCGTCTTCTGCT 32 7 12 13 9 
GTTGTATTACCTGAAAGATC 26 15 5 6 0 
TCGTATTACCTGAATTCAGG 26 5 6 15 5 
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Table 8-3:  Selection Ratios of Sequenced Aptamers.  Sequences are named using the 
DNA sequence read on the MiSeq platform; the actual aptamer sequence is 
the RNA transcript of the listed sequence.  Selection ratio is defined as 
number of occurrences of aptamer in selected libraries divided by the 
number of occurrences expected based on the number of occurrences in the 
naïve library.  Selection ratio rank is numerical rank of sequence by 
selection ratio as compared to all observed sequences with a defined 
selection ratio. 
DNA N20 Sequence 
Number of Sequences Observed 
Total, All 
Aptamers 
Naïve 
Library 
Selection 
Ratio 
Selection Ratio 
Rank 
GAGTCGTATTACCTGTTCAG 35 1 10.53 1 
GTATTACCTGAAAGATCGGA 64 2 9.62 2 
TGTATTACCTGAAAGATCGG 59 2 8.87 3 
GAGTCGTATTACCTGAATTC 24 1 7.22 4 
AGTATTACCTGAAAGATCGG 100 5 6.01 5 
GCGTATTACCTGAAAGATCG 19 1 5.71 6 
AGATCGGAAGAGCGTCGTGT 37 5 2.23 22 
TGACTAGTACATGACCACTT 80 12 2.00 27 
TCGTATTACCTGAATTCAGG 26 5 1.56 37 
CTCGTATGCCGTCTTCTGCT 32 9 1.07 55 
ACGTATTACCTGAAAGATCG 33 0 Undefined N/A 
GTTGTATTACCTGAAAGATC 26 0 Undefined N/A 
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Chapter 9:  In Vivo Evaluation of Oral Protein Delivery Systems 
9.1 INTRODUCTION 
Significant improvement in high pI protein delivery capability has been 
demonstrated by using P(IA-co-NVP) hydrogels with a low ionic strength loading 
solution with high protein concentration.  However, these improvements have been 
demonstrated in idealized, in vitro conditions.  Because of the comparative complexity of 
the body, a system that appears to work well for delivering proteins in vitro may not 
actually work well in an in vivo setting. 
Numerous factors may affect the results seen in the in vitro tests:  the stomach and 
intestine have numerous proteins present that could inhibit therapeutic release due to 
adsorption or electrostatic interactions; the enzymes present in the small intestine could 
severely limit bioavailability by digesting the released drug; or, the level of absorption of 
proteins across the intestinal epithelium could differ significantly from what was 
observed in Caco-2 cultures. 
An excellent preclinical method of testing the efficacy of a drug delivery system 
is to use in vivo animal models.  An animal model provides the complex environments 
that the delivery vehicles will experience in a human, including enzymes, bacteria, 
intestinal mucosa, etc., that could cause large deviations from in vitro results.  As a result, 
in vivo results are often an unstated necessity before a medical product can begin clinical 
trials. 
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In vivo testing of pH-responsive hydrogel microparticles for oral protein delivery 
has previously been performed in rats using P(MAA-g-EG) hydrogel particles with 
encapsulated insulin.
1–6
  These studies indicated dose-dependent hypoglycemic effects 
upon administration of insulin-loaded hydrogel particles, with relative bioavailability 
ranging from 4.2 – 9.5% compared to subcutaneous injection of insulin.  All of these 
studies utilized a closed-loop rat model, wherein drug-loaded hydrogel microparticles 
were surgically inserted into a sutured section of the rat’s small intestine and blood 
samples were acquired to determine plasma concentrations of insulin and glucose.  The 
closed-loop model for testing intestinal drug perfusion was first described by Doluisio et 
al. in 1969,
7
 and has been used as one of the standard models of the small intestine ever 
since.
8–15
  Correlations to determine absorption rate constants and effective permeability 
coefficients are available for use with this model, enabling comparison of results between 
experiments. 
9.2 MATERIALS AND METHODS 
9.2.1 Drug Loading 
Two pH-responsive hydrogel formulations were used in this study.  The 
formulations made with molar monomer ratios of 1:2 P(IA-co-NVP) and 45:45:10 P(IA-
co-NVP-co-MMA) demonstrated the highest levels of salmon calcitonin delivery in the 
in vitro testing discussed in Chapter 5 and were therefore used in this experiment.  
Salmon calcitonin (Selleck Chemicals, Houston, TX) was dissolved in 1.5 mM PBS 
(0.01x) at a concentration of 0.5 mg/mL.  Purified and dried hydrogel microparticles, 
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sieved to 90-150 μm in size, were added to this solution at a concentration of 2.5 mg/mL.  
The solution’s pH was adjusted to pH 7.2, and the suspension was agitated on a rotary 
mixer for 24 h.  The solution was then acidified to pH 2.5 using 1 N HCl to collapse 
microparticles.  Microparticles were isolated by centrifugation and washed 2 times with 
0.01 N HCl (0.2 mL/mg hydrogel) via agitation followed by centrifugation.  Protein 
loading levels were determined by analysis of loading and wash supernatants using a 
MicroBCA assay (Thermo Scientific Pierce, Rockford, IL). 
Doses to be administered to the rats were pre-weighed and stored at 4 °C 
overnight prior to surgery.  Rats receiving P(IA-co-NVP) or P(IA-co-NVP-co-MMA) 
hydrogel microparticle-delivered salmon calcitonin received doses of 12000 IU/kg with 
respect to the total encapsulated protein.  Rats in the control group received subcutaneous 
injections of salmon calcitonin dissolved in sterile PBS buffer at doses of 600 IU/kg. 
9.2.2 Closed-loop Intestinal Rat Model2 
Adult, male, Sprague-Dawley rats (Charles River Laboratories, Wilmington, MA) 
with weights ranging from 328 g to 381 g were studied.  Twelve rats were used (n = 
4/group) for the study.  All rats had jugular catheters for blood draws during the studies.  
Rats were acclimatized to the research environment for at least 3 days with free access to 
water and solid food.  The rats were then placed on an all-liquid diet of TestDiet LD101 
(TestDiet, St. Louis, MO) for 2 days and fasted overnight immediately prior to surgery.  
The rats were induced and maintained under anesthesia throughout the duration of the 
                                                 
2 The surgical procedures described in this section were performed by Stephanie Steichen, Lindsey Sharpe, 
David Spencer, and Sarena Horava.  The author monitored anesthesia and assisted with blood draws. 
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experiment using isoflurane.  To maintain body temperature, the rats were placed in a 
supine position with body drapes on heated-water heating pads maintained at 37 °C. 
A closed-loop intestinal perfusion model was used in this study.  Experiments 
were performed in compliance with protocols approved by the Institutional Animal Care 
and Use Committee at The University of Texas at Austin.  An initial blood draw of 150 
μL was obtained via the jugular catheter to determine baseline calcitonin levels.  An 
abdominal mid-line incision was then made in each rat, and a 10 cm length of the ileum 
was isolated and clamped at both ends using silk sutures. 
Hydrogel microparticles with encapsulated salmon calcitonin (dosage and trial 
cohorts are described in section 9.2.1) were dispersed in 0.5 mL PBS (or 0.5 mL PBS for 
the subcutaneous control group) and injected into the closed-loop intestinal segment by 
syringe.  Rats in the subcutaneous control group received an injection of 0.5 mL PBS into 
the ileal loop as well as 0.1 mL of salmon calcitonin dissolved in PBS by subcutaneous 
injection under the animals’ neck scruff.  Blood samples (150 μL) were withdrawn from 
the jugular catheter at times of 5, 10, 15, 30, 60, 120, and 180 min following hydrogel 
administration and replaced with 150 μL of sterile PBS to maintain circulatory volume.  
Blood samples were immediately centrifuged at 2000 RCF for 15 min to isolate serum 
and frozen until analyzed by ELISA.   
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9.2.3 Blood Serum Analysis 
Blood serum was isolated by centrifugation and analyzed for salmon calcitonin 
concentration using a salmon calcitonin ELISA kit (Phoenix Pharmaceuticals, Inc., 
Burlingame, CA).  All samples were assayed in duplicate. 
Relative bioavailability was determined using the area under the curve (AUC) for 
the entire 3 h experiment as compared to the subcutaneous injection control group.  AUC 
was calculated for each rat using numeric integration by the trapezoid rule with 
concentrations as determined by ELISA.  Average AUC and standard deviation were 
determined for each group, and relative bioavailability of each group was determined 
using Equation 9-1, 
𝐹𝑟𝑒𝑙 = 100% ∙
𝐴𝑈𝐶ℎ𝑔 ∙ 𝐷𝑠𝑐
𝐴𝑈𝐶𝑠𝑐 ∙ 𝐷ℎ𝑔
 
Equation 9-1 
 
where Frel is the relative bioavailability as compared to subcutaneous injection [%], 
AUChg is the AUC calculated for a particular group receiving hydrogel administered sCT 
[ng-min/mL], AUCsc is the AUC calculated for the group receiving subcutaneous 
injection, Dsc is the subcutaneous dosage administered [IU/kg], and Dhg is the dosage 
administered to the particular group by hydrogel administration.  Data is presented as 
average ± standard deviation.  Comparison across groups was performed by analysis of 
variance (ANOVA), and significant differences were verified with a Student’s, unpaired, 
2-tailed, heteroscedastic t-test. 
 201 
9.3 RESULTS AND DISCUSSION 
A summary of rat weights prior to surgery and the administered doses is provided 
in Table 9-1.  All rats weighed between 328 and 381 g, and no rats displayed significant 
weight loss prior to surgery.  One of the rats to be included in the P(IA-co-NVP-co-
MMA) group had a faulty catheter that did not allow for blood draws, and was not 
included in the data analysis.  All other surgeries were successful. 
The dosage of salmon calcitonin administered to the control rats (600 IU/kg) was 
lower than that administered to the rats receiving hydrogel administration (12000 IU/kg).  
The study was designed with the expectation that relative protein bioavailability would be 
similar to that observed in previous in vivo studies using insulin, around 5%.
1–6
  To 
accommodate the reduced bioavailability observed with oral delivery compared to 
subcutaneous injection (owing to incomplete release and poor intestinal absorption), a 
20x multiple was built into the hydrogel doses so that expected serum protein 
concentrations would remain within the detectable range of the ELISA kit (0.3 – 100 
ng/mL).  This correction factor does not prevent accurate determination of relative 
bioavailability, as it is easily corrected by linear scaling, as seen in the calculation of 
relative bioavailability (Frel) in Equation 9-1.   
 Calcitonin was successfully encapsulated in both of the hydrogel formulations.  
The MicroBCA revealed a high loading level for both groups:  193.8 μg sCT/mg 
hydrogel in the P(IA-co-NVP) microparticles, and 112.8 μg sCT/mg hydrogel in the 
P(IA-co-NVP-co-MMA) microparticles.  The loading procedure was performed in a 
relatively large batch compared with the much smaller 1.5 mL batches used in the 
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loading and release experiments described in Chapter 5.  As a result, the pH of the 
loading solution was more precisely controlled, as larger amounts of acid or base were 
required to make small changes in the solution pH, which allowed for the improvements 
in the loading procedure described in Chapter 5 to be fully utilized for maximum effect.  
In addition, the high loading levels achieved using the same procedure in a larger batch 
show that the process is scalable and could easily be scaled up to full industrial 
production. 
Following the in vivo experiment, blood serum was analyzed by ELISA for 
salmon calcitonin concentration.  The blood serum sCT concentrations for the individual 
rats (graphed by group) are shown in Figure 9-1 (P(IA-co-NVP)), Figure 9-2 (P(IA-co-
NVP-co-MMA)), and Figure 9-3 (subcutaneous injection).  Although there are noticeable 
differences between rats within the study groups, certain trends can be identified.  The 
subcutaneous control group shows an early peak in sCT concentration in serum that 
rapidly declines back to the base level.  This result is expected since the drug is directly 
injected with little diffusion required to enter the bloodstream, therefore quickly entering 
circulation in essentially one large dose and declining quickly due to rapid clearance by 
the reticuloendothelial system.  In contrast, the two groups that were administered sCT by 
hydrogel microparticles in the intestine demonstrated a slower, but sustained increase in 
sCT concentration over time as compared to the rapid peak seen with the subcutaneous 
group.  Again, this result is expected.  The hydrogel administration pathway requires 
diffusive release from the hydrogel particles and transport across the intestinal epithelium 
before the protein reaches the bloodstream, which results in a slight lag time before the 
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concentration increases.  Fortunately, this lag time appears to be quite short, with 6 of 7 
rats experiencing a 91% increase in plasma sCT levels within 15 min.  Furthermore, the 
hydrogel microparticles act as a drug delivery depot demonstrating sustained release, as 
protein molecules must travel longer diffusive distances the closer they are to the center 
of the microparticle, resulting in proteins being released at different times over the course 
of the experiment, rather than in one single, bolus dose. 
The combined results are shown in Figure 9-4 and Table 9-2.  Due to the wide 
variations within test groups, the ANOVA analysis identified only one time point at 
which statistically significant differences (p < 0.05) between groups occurred.  Student’s 
t-test confirmed that at 15 min after drug administration, the group receiving 
subcutaneous administration of sCT had significantly higher sCT concentration in serum 
than both groups receiving sCT encapsulated in P(IA-co-NVP) (p = 0.022) and P(IA-co-
NVP-co-MMA) (p = 0.015).  At this early time point, the subcutaneous administration 
method yields higher sCT concentration due to the more rapid transport into the blood, 
resulting in an early, large peak in concentration that finds its maximum value at t = 15 
min.  At later times after drug administration, the drug begins to make it into the 
bloodstream after diffusing out of the microparticles as well, resulting in the hydrogel-
administered groups achieving similar sCT levels for the rest of the experiment. 
The calculated average AUC for each group is given in Table 9-2.  Although the 
subcutaneous group showed higher sCT serum concentration at early time points, the 
hydrogels achieved similar concentration levels within 30 min and for the remainder of 
the experiment.  As such, the AUCs are very similar between all groups.  The ANOVA 
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analysis confirms that there is no statistically significant difference among the study 
groups (p = 0.89); pairwise t-tests corroborated this result (p > 0.40).  This result 
indicates that the developed systems can provide a more convenient alternative to 
injection-based delivery of protein therapeutics. 
The relative bioavailability of sCT delivered by the hydrogels compared to 
subcutaneous injection is also shown in Table 9-2.  Although all groups received similar 
total amounts of sCT in the bloodstream with similar serum levels at nearly all time 
points, the relative bioavailability of sCT as administered by the hydrogels remains low at 
4.98 ± 3.23% for P(IA-co-NVP) administration and 4.23 ± 1.21% for P(IA-co-NVP-co-
MMA) administration.  These bioavailabilities are unfortunately low, indicating that the 
majority of salmon calcitonin administered to the rats is lost due to a combination of 
enzymatic degradation in the small intestine, incomplete release of protein from the 
microparticles, and incomplete absorption across the intestinal epithelium.  As a result, 
use of these systems in humans without further improvement would result in increased 
cost due to the need for larger doses of protein.  While such cost will be offset to some 
degree by eliminating the need for syringes and needles, easing manufacturing 
requirements, and obviating the need for healthcare professionals to administer the drugs, 
it is unlikely that such improvements will match the cost of producing 20x as much 
protein.  Thus, for the delivery systems studied in this experiment, financially feasible 
oral delivery may only be possible for therapeutic proteins that are inexpensive to 
produce. 
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Nevertheless, the results of this experiment are still positive.  The experiment 
shows that oral delivery of protein therapeutics exhibiting high isoelectric points is 
fundamentally feasible with the pH-responsive delivery systems developed herein.  
Furthermore, the bioavailability observed for salmon calcitonin in this experiment is of 
the same order of magnitude as that observed for insulin using P(MAA-g-EG) 
microparticles in previous in vivo experiments (4.2 - 9.5%),
1–6
 indicating that the 
improvements made in the pH-responsive material properties and the protein loading 
procedure described in Chapter 5 have largely overcome the challenges associated with 
the loading and release of the protein from the hydrogel.  If the electrostatic interactions 
that prevented sufficient protein release in previous studies
16
 still dominated over 
diffusive release of the protein, the bioavailability would be much lower than that 
observed for a low isoelectric point protein of similar size that demonstrated high levels 
of protein release in in vitro tests.  Fortunately, that is not the case. 
The results therefore indicate that the remaining obstacle to oral delivery of 
therapeutic proteins is likely intestinal absorption.  From studies of intestinal 
permeability, proteins are considered to be poorly absorbed compounds with only 0-20% 
absorption.
17,18
  Chemicals with reported Caco-2 permeabilities similar to that of salmon 
calcitonin (1.5 x 10
-7
/cm
2
)
19
 such as 1-deamino-8-D-arginine-vasopressin (1.3 x 10
-7
/cm
2
) 
or doxorubicin (1.6 x 10-7/cm
2
) show 1% and 5% absorption, respectively; therefore, the 
total absorption is expected to be within this range.
17,18
  The observed bioavailability 
being at the high end of the expected absorption range (4-5%) therefore indicates that the 
intestinal absorption accounts for the majority of the low bioavailability.  With 
 206 
subsequent improvements enhancing intestinal absorption, such as aptamer-targeted 
active transport or PEGylation as described in Chapters 7 and 8, this bioavailability can 
be dramatically enhanced to levels that would enable cost-effective delivery of protein 
therapeutics via the highly preferred oral route. 
 
Figure 9-1:  Closed-Loop Study—Blood Serum Concentration of Salmon Calcitonin in 
Rats Receiving Salmon Calcitonin Encapsulated in 1:2 P(IA-co-NVP) 
Microparticles.  Each data series represents a different test subject. 
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Figure 9-2:  Closed-Loop Study—Blood Serum Concentration of Salmon Calcitonin in 
Rats Receiving Salmon Calcitonin Encapsulated in 45:45:10 P(IA-co-NVP-
co-MMA) Microparticles.  Each data series represents a different test 
subject. 
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Figure 9-3:  Closed-Loop Study—Blood Serum Concentration of Salmon Calcitonin in 
Rats Receiving Salmon Calcitonin by Subcutaneous Injection.  Each data 
series represents a different test subject. 
  
0
1
2
3
4
5
6
7
8
9
10
0 50 100 150 200
sC
T 
C
o
n
ce
n
tr
at
io
n
 (
n
g/
m
L)
 
Time (min) 
 209 
 
Figure 9-4:  Closed-Loop Study Combined Data.  Each data series represents a different 
test group, receiving salmon calcitonin by:  1:2 P(IA-co-NVP) 
microparticles; 45:45:10 microparticles; or subcutaneous injection.  
Reported as average ± standard deviation. 
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Table 9-1:  Animal Dosing Summary.  Rat weights were recorded 12 h prior to surgery.  
Salmon calcitonin loading levels were determined by MicroBCA assay. 
Rat Test Group, Identifier 
Weight, 
Before 
Surgery (g) 
Dose Level 
(IU/kg) 
sCT Loading 
Level (μg/mg 
hydrogel) 
Dose 
Administered 
(mg hydrogel) 
P(IA-co-NVP), #1 328 
12000 193.8 
3.38 
P(IA-co-NVP), #2 363 3.75 
P(IA-co-NVP), #3 349 3.60 
P(IA-co-NVP), #4 363 3.75 
P(IA-co-NVP-co-MMA), #1 352 
12000 112.8 
6.24 
P(IA-co-NVP-co-MMA), #2
*
 333 5.90 
P(IA-co-NVP-co-MMA), #3 371 6.58 
P(IA-co-NVP-co-MMA), #4 381 6.76 
Subcutaneous, #1 330 
600 N/A 
33.0 μg sCT 
Subcutaneous, #2 332 33.2 μg sCT 
Subcutaneous, #3 337 33.7 μg sCT 
Subcutaneous, #4 370 37.0 μg sCT 
*
Rat had non-functioning catheter and was not used in studies.  
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Table 9-2:  In Vivo Study Combined Bioavailability Results.  All values are reported as 
average ± standard deviation.  Relative bioavailability is normalized to the 
subcutaneous absorption as 100% relative bioavailability.  AUC was 
determined by numerical integration of individual rats’ serum sCT 
concentration profiles. 
Test Group 
Total sCT Absorbed, AUC 
(ng-min/mL) 
Relative Bioavailability, Frel 
(%) 
P(IA-co-NVP) 740 ± 456 4.98 ± 3.23 
P(IA-co-NVP-co-MMA) 628 ± 128 4.23 ± 1.21 
Subcutaneous 743 ± 149 100 ± 28.3 
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Chapter 10:  Conclusions 
Therapeutic proteins are currently administered predominantly by injection, 
which significantly reduces patient quality of life due to the associated fear and pain, 
causing occasional and dangerous non-compliance with treatment.  The oral route would 
significantly improve patient quality of life by providing a more convenient 
administration pathway, but is difficult to use due to the proteolytic environment of the 
gastrointestinal tract and poor absorption across the epithelial cell lining of the small 
intestine. 
The overarching goal of this research was to overcome the multiple obstacles 
preventing the effective delivery of therapeutic proteins, particularly those expressing a 
high isoelectric point.  Many improvements toward this goal were accomplished using a 
combinatorial approach of redesign of hydrogels, optimization of hydrogel and drug 
loading parameters, bioconjugation strategies, and discovery of RNA aptamers as ligands 
to provide transcellular transport capability to enhance protein absorption across the 
small intestine. 
Hydrogels using itaconic acid as the pH-responsive unit rather than methacrylic 
acid, namely P(IA-co-NVP), P(IA-g-EG), and P(IA-co-NVP-co-MMA), were 
synthesized and evaluated.  Characterization of the hydrogels showed that the hydrogels 
were well tolerated by Caco-2 cells, showing no significant cytotoxicity or impact on cell 
proliferation even at high concentrations of 5 mg/mL.  Furthermore, itaconic acid-based 
hydrogels demonstrated significantly enhanced swelling properties at neutral pH 
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compared to the previously studied P(MAA-co-NVP) hydrogel.  All itaconic acid-based 
hydrogels tested demonstrated greater equilibrium swelling ratios—up to a 69% 
improvement—and vastly greater dynamic swelling ratios in time-limited experiments—
up to a 10-fold improvement—as compared to P(MAA-co-NVP), indicating a faster 
response and greater swelling, both of which should assist in protein delivery.  
Thermogravimetric analysis of hydrogels also showed that itaconic acid and methacrylic 
acid based hydrogels were very thermally stable up to temperatures well beyond what 
will be experienced in end use. 
Calculation of the average mesh sizes within these hydrogels using the best 
available models indicated very small mesh size at acidic pH, ranging from 0.4 – 1.3 nm, 
which is sufficiently small to prevent protein transport into or out of the mesh, providing 
strong protection of the encapsulated proteins.  At neutral pH, the mesh size was much 
larger, ranging from 3.7 to 28.0 nm—large enough for efficient diffusional release of 
most proteins.  Calculated mesh sizes in itaconic acid gels (7.1 – 28.0 nm) were 
significantly greater than the calculated mesh size in P(MAA-co-NVP) (3.7 nm), 
indicating improved molecular scale morphology for enhanced delivery. 
In in vitro loading and release studies, itaconic acid-based hydrogels also 
performed significantly better than methacrylic acid-based gels.  The P(IA-co-NVP) 
hydrogel formulation prepared using a 1:2 molar ratio of itaconic acid to N-
vinylpyrrolidone exhibited the greatest delivery levels of salmon calcitonin, achieving up 
to 12.4 μg sCT/mg hydrogel drug release within 3 h at neutral conditions—2.7 times 
more than P(MAA-g-EG) and 16.8 times more than P(MAA-co-NVP) achieved.  Charge 
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localization within the polymer backbone is believed to account for the improved 
delivery. 
The ionic strength of the loading solution was optimized for high isoelectric point 
exhibiting proteins.  Use of a low ionic strength solution for protein imbibition into the 
hydrogel yielded vast improvements in drug delivery potential of salmon calcitonin.  In 
one trial, 1:2 P(IA-co-NVP) microparticles loaded with sCT in a 1.50 mM PBS buffer 
loaded and released 83x more sCT per mass of hydrogel than microparticles loaded in a 
150 mM PBS buffer.  The vast improvement in protein delivery results from increased 
hydrogel swelling and more favorable electrostatic interactions between the polymer and 
therapeutic in a low ionic strength medium. 
The particle size of the microparticles was found to have little effect on drug 
delivery within the size ranges studied.  Microparticles ranging from 45-75 μm in size 
exhibited significantly greater percent release of encapsulated sCT compared to 
microparticles 90-150 μm in size.  However, the overall delivery potential was not 
significantly different between the two hydrogel size ranges.  Size effects may manifest at 
the smaller nano-scale, but were not observed at the micro-scale. 
Crosslinking density within the hydrogels was found to significantly affect oral 
protein delivery capability, and proved to offer a facile method for tuning the hydrogels 
to accommodate different protein sizes.  The small 3.4 kDa protein salmon calcitonin 
experienced the greatest delivery capability using hydrogels with 5 mol% crosslinker in 
the monomer feed.  On the other hand, the much larger monoclonal antibody, Rituxan 
(rituximab), experienced the greatest delivery levels using hydrogels with only 1 mol% 
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crosslinker in the monomer feed.  Crosslinking density provides a straightforward method 
of tuning the mesh size of the hydrogels without altering any of the more fundamental 
properties of the hydrogel affecting biocompatibility or pKa.  Larger proteins will benefit 
from low crosslinking density, yielding larger mesh sizes for increased diffusion out of 
the hydrogel, while smaller proteins benefit from higher crosslinking density, yielding 
better protection from proteolytic enzymes in the stomach. 
Hydrogels formed using enzymatically degradable peptide crosslinks exhibited 
high specificity for degradation in the small intestine and high delivery capability.  P(IA-
co-NVP) hydrogels with the MMRRRKK peptide crosslinker exhibited lower loading 
levels of salmon calcitonin than P(IA-co-NVP) hydrogels with the non-degradable 
TEGDMA crosslinker, but exhibited complete release of encapsulated protein upon 
degradation, giving greater overall delivery capability.  As such, these systems hold great 
promise for increasing the bioavailability of orally delivered proteins, although the 
relatively high cost of the peptide crosslinker may make such systems economically 
unviable. 
PEGylation of therapeutic proteins is a common technique for enhancing 
solubility and half-life in vivo.  To study the effect of PEGylation on oral protein 
delivery, salmon calcitonin was PEGylated and used in in vitro loading and release 
studies.  The presence of PEG did not significantly affect the loading level of sCT into 
1:2 P(IA-co-NVP) microparticles, but reduced the overall delivery level of the protein by 
40.6%.  Nevertheless, depending on the protein, the improvements in half-life from 
PEGylation could more than offset the loss in protein release, which would result in a 
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more effective therapeutic.  Furthermore, the increased size resulting from PEGylation 
could be readily accommodated by tuning the crosslinking density. 
PEGylation also proved to enhance the absorption of salmon calcitonin across a 
Caco-2 Transwell model of the intestinal epithelium.  Unmodified sCT exhibited 
apparent permeability on the order of 10
-9
 cm/s while sCT-PEG conjugates exhibited 
apparent permeability on the order of 10
-7 
cm/s—a two order of magnitude improvement 
that could offer intestinal absorption levels as high as 75%.  Microparticles of P(IA-co-
NVP) demonstrated insignificant effect on the intestinal absorption.  These results 
indicate that PEG exhibits some interaction with the tight junctions that significantly 
enhances protein absorption, thus strongly promoting the use of PEG as a conjugate, 
hydrogel monomer, or co-delivered excipient to help overcome the significant barrier of 
small intestinal absorption.  Some previous studies showed an improvement in perfusion 
in the presence of P(MAA-g-EG) microparticles, but attributed the improvement to Ca
2+
 
binding by the anionic hydrogels.  These results demonstrate that the PEG is responsible 
for the improvement through some interaction with the cells, while Ca
2+ 
chelation by the 
hydrogels plays a minor or negligible role. 
Limited absorption of proteins across the intestinal epithelium greatly impedes the 
ability to achieve high bioavailability by the oral route.  PEG proved to enhance the 
transport across the intestinal epithelium, but there may be more optimal molecules 
available.  A modified SELEX protocol was developed and used in order to 
systematically reveal aptamer sequences that could significantly promote intestinal 
perfusion.  The modified protocol utilized a Caco-2 Transwell model of the small 
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intestine as a selection step rather than isolated target molecules, necessitating the use of 
2’-fluorine modified nucleotides to resist degradation by nucleases in the cellular 
environment.  Using this model, optimal aptamers for enhancing intestinal absorption 
could be selected without knowing a priori the ideal transport receptors to target. 
The aptamer library demonstrated significant improvements in percent absorption 
of RNA from selection round to selection round (p < 0.05), indicating preferential 
selection of aptamers achieving high transport across the epithelium.  High throughput 
sequencing using an Illumina MiSeq revealed numerous sequences that were significantly 
upregulated.  RNA transcripts of the N20 DNA sequences 
GAGTCGTATTACCTGTTCAG, GTATTACCTGAAAGATCGGA, 
AGTATTACCTGAAAGATCGG, ACGTATTACCTGAAAGATCG, and 
GTTGTATTACCTGAAAGATC are especially promising, as these sequences’ 
transcripts achieved selection ratios of up to 10.53 (i.e., 10.53x the number of expected 
sequences were actually observed).  Further studies of these sequences’ RNA transcripts 
are necessary to fully test their intestinal transport enhancement capability.  Nevertheless, 
this experiment was successful as a discovery process by taking a library of 1.1 trillion 
possible candidate molecules and rapidly identifying a select 5-10 sequences that appear 
to exhibit enhanced intestinal transport ability. 
Finally, two of the hydrogels studied in this work were tested using in vivo 
closed-loop intestinal perfusion studies in rats.  The 1:2 P(IA-co-NVP) and P(IA-co-
NVP-co-MMA) hydrogels were loaded with salmon calcitonin in a low ionic strength 
buffer and injected into the small intestine of rats to compare to subcutaneous injection.  
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The hydrogels demonstrated 4.98% and 4.23% relative bioavailability as compared to the 
subcutaneous control.  These results demonstrate the ability of the hydrogels to achieve 
therapeutically relevant delivery levels via the oral route despite the complex challenges 
presented by the gastrointestinal environment.  However, the low absorption across the 
small intestine also highlights the need for methods to overcome the final barrier of 
absorption across the small intestinal epithelium.   
Using the improved design and procedure changes evaluated in this work, 
hydrogels can be readily tailored to accommodate the oral delivery of a wide variety of 
high isoelectric point-exhibiting therapeutic proteins.  High bioavailability can now be 
achieved up to the final barrier of crossing the small intestine, and progress toward 
overcoming this barrier has been made in this work through use of PEG conjugates and 
discovery of potential aptamers for enhancing protein absorption.  Once these strategies 
are fully explored, it is not unreasonable to believe that the oral delivery of therapeutic 
proteins will become a reality, leading to a more convenient and less invasive method of 
treatment for hundreds of millions of patients suffering debilitating diseases worldwide. 
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